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ABSTRACT 
Conjugated polymer nanoparticles (CPNs) possess important characteristics such 
as high fluorescence brightness, reasonable photostability, and non-toxicity. These 
properties allow the use of CPNs in fluorescence based cellular and biological 
applications including cellular labeling, imaging, biosensing, and single particle tracking. 
To realize the broad applications of CPNs, it is required that CPNs possess functionality 
to conjugate a recognition moiety and maintain colloidal stability in biological media. In 
the following dissertation, we have prepared functionalized CPNs by surface passivation 
with head group- functionalized poly (ethylene glycol) lipids and proteins. We studied 
the colloidal stability of CPNs in biological media and investigated their utility as cellular 
labels, fluid phase markers and detection reagent in immunoassay. 
Chapter 1 summarizes the general background information of CPNs including 
methods of preparation, physical properties, bioanalytical applications, and 
functionalization strategies. 
Chapter 2 contains a systematic study of a simple and rapid method to prepare 
extremely bright, functionalized, stable and biocompatible conjugated polymer 
nanoparticles incorporating functionalized polyethylene glycol (PEG) lipids by 
reprecipitation. The size of these nanoparticles, as determined by TEM, was 24±5 nm. 
These nanoparticles retain the fundamental spectroscopic properties of conjugated 
polymer nanoparticles prepared without PEG lipids, but demonstrate greater 
hydrophilicity and quantum yield compared to unmodified conjugated polymer 
nanoparticles. Nanoparticles were prepared with several PEG lipid functional end groups, 
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including biotin and carboxy moieties that can then be conjugated to biomolecules. We 
have demonstrated the availability of these end groups for functionalization using the 
interaction of biotin PEG lipid conjugated polymer nanoparticles with streptavidin. To 
demonstrate that nanoparticle functionalization could be used for targeted labeling of 
specific cellular proteins, biotinylated PEG lipid conjugated polymer nanoparticles were 
bound to biotinylated anti-CD 16/32 antibodies on J774A.1 cell surface receptors, using 
streptavidin as a linker. This work represents a method of preparation of bright and 
biocompatible CPNs by inclusion of functionalized PEG lipids. The functional end group 
on PEG lipid CPNs offers a link to conjugate CPNs to biomolecules. Hence, PEG-lipid 
CPNs are a viable technology for targeted labeling and imaging in biological systems.  
Chapter 3 constitutes the comparative study of sensitivity and limit of detection 
using PEG-lipid functionalized CPNs as a fluid phase marker in J774A.1 cells compared 
to cells loaded with carboxy-functionalized quantum dots (Q dots) or a dextran–linked 
small molecule organic dyes (Alexa fluor 488 dextran (AF488-dex)). Under typical 
conditions used for ex vivo biological imaging or flow cytometry, these CPNs were 175x 
brighter than Qdots and 1,400x brighter than AF488-dex. Evaluation of the minimum 
incubation concentration required for detection of nanoparticle fluorescence with a 
commercial flow cytometer indicated that the limit of detection for PEG lipid-PFBT 
CPNs was 19 pM( 86 ppb), substantially lower than values obtained for Q dots (980 pM) 
or AF488-dex (11.2 nM). Taken together, these data clearly indicate that CPNs can be 
used at very low labeling concentrations and are excellent fluid- phase markers with 
significantly greater fluorescence brightness than existing dyes or nanoparticles. 
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Chapter 4 studies the protein passivation of CPNs as a reliable approach to 
provide the colloidal stability of conjugated polymer nanoparticles in tissue culture media 
and buffer solutions. Unmodified CPNs aggregate under physiological salt conditions and 
are therefore unsuitable for biological applications such as imaging and sensing. We 
showed that when incubated in protein solutions (bovine albumin serum, lysozyme, or 
fetal bovine serum), bare CPNs rapidly acquire a stable protein coat that both increases 
CPN diameter and prevents aggregation at physiological ionic strength over pH range of 
4 - 8. The protein coat is highly stable; no change in hydrodynamic diameter is observed 
upon extended incubation following size exclusion chromatography into protein free 
saline solution. The results show that adsorption of protein on CPN surface does not alter 
fluorescence brightness. BSA-biotin modified CPNs show availability of protein corona 
for molecular recognition. Hence, we concluded that protein adsorption is a simple 
method to provide colloidal stability in physiological buffer and to modify CPNs for 
target selective cellular imaging and sensing. 
Finally, Chapter 5 reports the study of protein coating as a general method for 
providing functionality in CPNs. We have demonstrated that protein-A coated CPNs 
serve as scaffold for CPN linkage to IgG. Using anti-rabbit IgG linked CPNs as a 
detection reagent; we have detected rabbit IgG in solid phase immunoassay with antigen-
antibody binding constant of 5.5 ± 0.8 nM. Similarly, neutravidin coated CPNs that 
conjugated to biotin linked recognition moiety also serve as a direct detection reagent. 
Together, we conclude that protein A, neutravidin and immunoglobulin modified CPNs 
serve as direct detection reagent in solid phase based immunoassays. 
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Taken together, this study shows that head group functionalized phospholipids 
and a broad variety of proteins readily modify the surface of hydrophobic conjugated 
polymer nanoparticles. The resulting CPNs retain and improve fluorescence brightness. 
Hence, head group functionalized phospholipids and proteins act as linkers for 
biomolecules on the nanoparticle surface. Such CPNs are bright photon source for 
specific labeling, imaging, and sensing applications. 
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CHAPTER ONE 
 
INTRODUCTION 
 
 
 
Conjugated polymer nanoparticles (CPNs) have attracted attention as promising 
fluorescent nanoparticles because of their high fluorescence brightness. They are 
prepared by precipitation of hydrophobic fluorescent conjugated polymers that exhibit 
bright fluorescence as nanoparticles. These nanoparticles possess the brightest 
fluorescence per unit size of all characterized nanoparticles [1]. Unlike many other 
nanoparticles, these consist of relatively benign polymers; therefore, they do not have 
observable cytotoxicity [2-4]. Their high brightness, reasonable photostability, and no 
observable cytotoxicity consequently provide a motivation for studying conjugated 
polymer nanoparticles (CPNs) as a fluorescent label. These CPNs have found 
applications in fluorescence based experiments such as cellular labeling, imaging, single 
particle tracking, and biosensing [1, 3, 4, 6]. 
To realize the potential for biological applications of CPNs, it is required that they 
possess functionality on their surface and maintain colloidal stability in biological media. 
Presence of a functional group on the nanoparticle surface allows conjugation of 
recognition moiety which is necessary for specific detection and targeted labeling. 
However, the CPNs prepared from hydrophobic conjugated polymer by reprecipitation in 
water lack a functional group and tend to aggregate in high ionic strength salt solution [6, 
7].This limits the wide use of CPNs in biological applications. In this context, we have 
investigated approaches to functionalize the predominantly hydrophobic CPN surface and 
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also provide colloidal stability in biological media. Since the fluorescence properties of 
conjugated polymers arise from a delocalized π- electron system, chemical modification 
to introduce covalent functionality can destroy the delocalized electronic system causing 
potentially unintended changes in optical properties. Given the hydrophobic nature of 
CPNs, non-covalent interactions with biomolecules readily occur. Moreover, key 
interactions in molecular recognition processes involve non-covalent interactions. In this 
dissertation, we have modified and functionalized conjugated polymer nanoparticles 
(CPNs) by surface passivation with head group-functionalized poly (ethylene glycol) 
lipids and a variety of relevant proteins. We demonstrated that CPNs functionalized with 
a biotin end group PEG lipid can be utilized for targeted cell surface labeling and 
imaging. We studied the colloidal stability of surface modified CPNs in biological media 
and investigated their utility as fluid phase label in cellular imaging and flow cytometry 
experiments. In addition, we demonstrated that the CPNs decorated with a protein corona 
can be used as direct detection reagents in immunoassay. 
 
1.1 CONJUGATED POLYMER AS NANOPARTICLES 
Since the discovery of conducting polymers and the ability to control electrical 
conductivity by doping, conjugated polymers have been characterized and their 
properties investigated [8, 9]. They have widely been used as active materials in the light 
emitting diodes [10-12], photovoltaic devices [13-16], and thin film transistors [17, 18]. 
The preparation and properties of conjugated polymers, as well as its application in 
solution and thin films, have been extensively studied [13, 14, 19, 20]. However, by 
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comparison, there have been relatively few studies of conjugated polymers in the form of 
colloidal dispersion of nanoparticles. In particular, CPNs have been targets of 
investigation as fluorescent labels in biological applications [5]. 
 Beginning in the 1980s, Vincent et al reported colloids of conducting polymer 
nanoparticles produced by aqueous oxidative polymerization of acetylene [21] and 
polypyrole [22]. Since then, various approaches have been employed to access 
nanoparticle colloids in water. Principally, depending on molecular mass of starting 
materials, conjugated polymer nanoparticles can be synthesized by two different 
approaches. In the direct polymerization approach, nanoparticles are synthesized from 
low molecular weight monomers in a heterophase system. In addition, polymers entirely 
insoluble in any solvent can be converted into nanoparticles by this method. Vincent et al, 
also reported the preparation of polyacetylene particles by polymerizing acetylene in the 
presence of steric stabilizers [21]. Recently, this method has been adopted to access 
nanoparticles from a fluorescent semiconducting polymer [23-26]. The other common 
method utilizes a post polymerization approach. In this method, nanoparticles are 
prepared from high molecular weight polymers which have already been synthesized and 
purified. This type of nanoparticle synthesis relies on off-the-shelf commercially 
available conjugated polymers and does not require polymer synthesis expertise. The post 
polymerization approach is a relatively simple method and the preferred method of 
nanoparticles formation from fluorescent conjugated polymers by non-organic chemists. 
There are the general subcategories of the post-polymerization method which mainly 
include miniemulsion and reprecipitation. Typically, these methods of nanoparticle 
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preparation involve pre-synthesized conjugated polymer dissolved in organic solvent as a 
starting solution. Nanoparticle formation is carried out either by creating emulsified 
droplets in a water immiscible solvent and subsequent solvent removal (miniemulsion) or 
rapidly mixing polymer solutions during rapid dilution in an excess of solvent that is 
miscible with organic solvent most commonly water (reprecipitation). 
 
1.1.1 REPRECIPITATION 
The reprecipitation method involves mixing of a very dilute polymer solution 
dissolved in organic solvent, for example, tetrahydrofuran, into an excess of poor 
polymer solvent (water). This process is aided by sonication to assist the formation of 
nanoparticles. Mixing of the conjugated polymer dissolved in good solvent directly into 
poor solvent results in sudden alteration of solvent environment that induces precipitation 
of polymer. After precipitation into water, the organic solvent is evaporated at elevated 
temperature under vacuum resulting in nanoparticle dispersion in water. This preparation 
method can be used for wide variety of hydrophobic conjugated polymers that are soluble 
in water miscible organic solvents. 
Mashura et al used the reprecipitation method to prepare substituted-polythiophene 
particles by mixing a polymer solution in tetrahydrofuran (THF) into water. The resulting 
particle diameters range from 40-400 nm when measured by dynamic light scattering 
(DLS) [27]. This method was adopted and modified by McNeill et al to produce 
nanoparticles of smaller sizes from hydrophobic conjugated polymers [28-35]. In this 
procedure, a very dilute solution of conjugated polymer dissolved in organic solvent such 
 4 
as THF or DMSO is rapidly mixed in water during sonication. The sudden change from a 
good polymer solvent to a poor polymer solvent alters solubility of polymer causing 
polymer to precipitate into dispersion of nanoparticles. The polymer chain in nanoparticle 
adopts a collapsed conformation and forms spherical nanoparticles [36]. The mechanism 
of the colloidal stability of hydrophobic polymer particles in water with no surfactant is 
not clear; however, Clafton et al shows evidence of the presence of negatively charged 
surface defects on conjugated polymers during the formation of nanoparticles. Negative 
charge on the nanoparticle surface, as consequence, provides electrostatic stabilization to 
colloidal solution in water [37]. The average particle size prepared from this method 
ranges from 5-50 nm. The particle size is generally controlled by adjusting precursor 
polymer concentration and polymer composition. Compared to the miniemulsion 
technique, precipitation method generally yields smaller nanoparticles. In some cases, the 
small particle size corresponds to single polymer chain particles [36, 38].  
 
1.2 DEVELOPMENT OF FLUORESCENT CONJUGATED POLYMER 
NANOPARTICLES  
Fluorescence spectroscopic techniques in combination with improved 
fluorophores are an important tool for lowering the limit of detection in biological 
experiments. In particular, fluorophores sufficiently bright and with stable fluorescence 
allow investigation of biomolecular interactions at single molecule level which can 
provide spectacular details of biochemical processes [39]. In addition, the combination of 
fluorescence spectroscopy and imaging techniques enables researchers to make 
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measurements in multiple spatial and temporal dimensions. Traditional fluorophores in 
biological imaging and bioassays include small molecule fluorescent dyes such as 
fluorescein, rhodamine, and cyanine [40]. However, low absorptivity and poor 
photostability of conventional dyes limits the development of high sensitivity cellular 
imaging and in vitro assays especially at the single molecule level. Therefore, there is a 
need to develop fluorophores to maximize sensitivity and minimize limit of detection. 
Such nanoparticles include inorganic quantum dots (QDs) [41, 42], dye doped silica 
particles [43] and commercially available dye-loaded latex spheres. These nanoparticles 
offer numerous advantages over traditional organic dyes, including bright fluorescence 
and improved photostability. However, QDs, despite their superior optical properties with 
respect to organic fluorophore dyes, can suffer from problems of cytotoxicity due to 
leached metal from the nanocrystal core [44, 45] and the existence of dark dots [46]. 
Heavy metal leaching has been reduced by coating QDs with a variety of materials; 
however, such coatings can have their own associated cytotoxic effects [44, 47]. 
Fluorescent dye loaded polymer latex or silica nanoparticles also exhibit improved 
brightness and photostability than molecular dyes because of the large number of 
fluorophores per particle [48-50]. But, self-quenching of dye when loaded at high 
concentration ultimately limits the overall brightness of such particles [43]. 
In this context, the limitations of current fluorescent nanoparticles provide 
motivation for the development of other classes of nanoparticles with high photostability 
and bright fluorescence, but with reduced cytotoxicity. Great efforts have been invested 
to design and prepare nanoparticles that can overcome the limitations of existing 
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fluorophore and exhibit bright fluorescence, high photostability, and no cytotoxicity for 
biological applications. To that end, the development of CPNs is one promising strategy. 
CPNs are extraordinarily bright because of high absorption cross-sections and high 
radiative rates [29, 51]. The nanoparticles are composed of relatively benign constituent 
polymer material. As a result, there is low or no observed cytotoxicity [2]. These merits 
established CPNs as bright fluorescence probes for improving sensitivity and limit of 
detection in biological applications. 
For biological applications, the nanoparticles composed of conjugated polymers 
exist in many different forms. Nanoparticles prepared from hydrophobic conjugated 
polymer by reprecipitation method in water are the most common type [29-35, 52-57]. 
Water as a dispersion medium is preferred for most biological applications. This method 
generates nanoparticles with diameter in the range of 10-30 nm which can be adjusted by 
varying the polymer concentration in the stock solution in organic solvent [58]. 
Competition between inter chain aggregation and intra chain collapse during the 
nanoparticle formation process dictates the size of the nanoparticles. Preparation of 
particles from dilute stock solution reduces the possibility of inter chain aggregation that 
results smaller particles. The CPNs composed of hydrophobic polymers in water is 
thought to assume a collapsed spherical structure due to strong hydrophobic interaction 
and densely packed chromophores [59-61]. 
Not only hydrophobic conjugated polymers but also hydrophilic conjugated 
polymers and conjugated polyelectrolytes can be converted into nanoparticles [4, 62-66]. 
Poly (p-phenylene ethynylene), PPE polymer containing a hydrophilic amine and a PEG 
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linker in dimethylsulphoxide (DMSO) was mixed into saline solution to generate 
nanoparticles of much larger size (ca. 500 nm)[62]. The same group prepared 
nanoparticles of smaller size (ca. 97 nm) using similar hydrophilic polymers following 
method optimization and purification by sequential ultrafiltration. Polyelectrolytes are 
converted into nanoparticles by self-assembly and can have an average hydrodynamic 
particle size of about 80 nm [67, 68]. These CPNs consists of loosely aggregated polymer 
chains in comparison with hydrophobic CPNs which have a densely packed structure. 
Similarly, fluorescent amphiphilic polymers based on hydrophobic polyfluorene 
backbone containing hydrophilic PEGs on side chains form nanoparticles in water. Slow 
addition of water to a solution of polymer in THF results in micellar nanoparticles [69]. 
The size of particles prepared from amphiphilic polymers ranges from 10 nm to 100 nm 
[70-73]. Such nanoparticles have been used for cellular labeling and imaging 
applications. 
 
1.3 BIOLOGICAL APPLICATIONS OF CONJUGATED POLYMER 
NANOPARTICLES (CPNs) 
The useful photophysical features including high brightness, photostability, and 
low cytotoxicity is promising for a wide range of biological applications using CPNs. 
Generally, these nanoparticles find applications in biological studies such as: (a) labeling, 
imaging and tracking (b) sensing and assay readout, and (c) gene and drug delivery. All 
varieties of CPNs based on hydrophobic polymers, polyelectrolytes, or amphiphilic 
polymers have been employed for imaging and sensing applications. 
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For biological applications, biocompatibility of nanoparticles is an important 
concern. The utility of a given probe for biological applications in live cells is 
compromised if the probe causes cell death or other deleterious effects. Cytotoxicity of 
conjugated nanoparticles has been studied by several groups and all studies show very 
low or no cytotoxicity of CPNs. This observation is attributed to the benign nature of 
conjugated polymer which is the major constituent of nanoparticles. Fernando et al 
studied possible cytotoxicity and inflammatory responses of hydrophobic conjugated 
polymer nanoparticles (ca. 18 nm) in J774A.1 cells. Cell viability was assessed for (poly 
[(9,9-dioctylfluorenyl-2,7-diyl)-co-(1,4-benzo-{2,1’,3}-thiadiazole)], PFBT CPNs loaded 
macrophage cells with Cell Titer Blue, a dye which tracks cell viability and cell 
proliferation. The percentage of viable J774A.1 cells incubated with CPNs for 18 hours is 
indistinguishable from cells incubated without CPNs at all concentrations tested 
supporting the claim of the benign nature of CPNs. To evaluate the likelihood of a CPN 
induced inflammatory response; expression of the proinflammatory cytokines, tumor 
necrosis factor α (TNFα) and interlukin-1β (IL-1β) at the mRNA level were monitored in 
cells with and without nanoparticles. The results suggest that these CPNs have no 
inflammatory effects in this type of cells [2]. The same group studied cytotoxic effects of 
PEG-lipid incorporated CPNs by monitoring cell viability with Cell Titre Blue. They 
show that even at the CPN concentration 25 fold higher than the working concentration 
used for cell labeling; there is no discernible impact in cell viability [74]. Moon et al 
investigated the cytotoxic effects of nanoparticles prepared from hydrophilic poly (p-
phenylene ethynylene polymer derivatives in baby hamster kidney (BHK) cell lines [4]. 
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The cells incubated with ca. 97 nm particles and live cells were quantified at varying 
times using Cell Titre-Glo assay kit, which measures ATP to determine the number of 
viable cells. Results show that there is minimal inhibitory effect of nanoparticles in cell 
viability over a course of one week. Liu et al evaluated cytotoxicity of fluorescent 
conjugated polymer loaded poly (DL-lactide-co-glycolide), PGLA, nanoparticles larger 
size (ca.220 nm) in NIH/3T3 fibroblast cells. The metabolic viability assay of NIH/3T3 
cells incubated with poly [9,9-bis(2-(2-(2-methoxyethoxy)ethoxy)ethyl)fluorenyl-
divinylene], loaded nanoparticles at various PFV concentrations indicated the low 
cytotoxicity of these CPNs. They did not observe effects in metabolic activity even at 700 
nM PFV concentration for two days [75]. These results suggest that CPNs have low 
toxicity to the cells and suitable for cellular labeling and imaging for extended periods. 
 
1.3.1 CELLULAR LABELING 
Wu et al utilized multicolor conjugated polymer nanoparticles for cellular 
imaging in macrophage cells. These experiments involved the labeling of cells using bare 
hydrophobic conjugated polymer nanoparticles which were efficiently taken up by cells 
via endocytosis [1]. Fernando et al studied the mechanism of cellular uptake of non-
capsulated bare PFBT nanoparticles in macrophage cells using 18 nm diameter CPNs. 
The nanoparticles could be detected at extremely low loading concentration of 155 pM 
(270 ppb). Intracellular co-localization studies of CPNs and Texas red dextran indicated 
that cellular uptake took place through a macropinocytic mechanism. Again, CPNs and 
anti-LAMP-1 antibody staining indicated that the final destination of nanoparticles was 
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lysosomes following particles internalization via endocytosis [57]. Macropinocytosis is a 
nonspecific mechanism for taking up extracellular fluid which does not recognize and 
discriminate nanoparticle surface and charge delivering the fluid content to lysosome. 
This mechanism is useful in fluid phase labeling of endosomal and lysosomal organelles. 
In another study, PLGA nanoparticles loaded with conjugated polymer have been 
used for cellular labeling. When incubated with nanoparticles, MCF-7 breast cancer cells 
internalized these larger particles and were delivered into the cytoplasm [76]. The same 
group utilized folic acid conjugated particles to specifically target the folate receptor in 
cultured cancer cells. They reported the improved uptake of folic acid functionalized 
particles in MCF cancer cells than the non-functionalized ones by MCF cancer cells 
through folate receptor mediated endocytosis. Similarly, conjugated polyelectrolyte 
nanoparticles and amphiphilic conjugated polymer nanoparticles have also been 
demonstrated to be an effective cellular label [4, 73, 77-79]. Cellular uptake of 
nanoparticles was dependent on functional surface groups, the specific cell lines, and 
mainly occurred through both macropinocytosis and receptor mediated endocytosis. 
Endocytosis-based cellular labeling methods lack specificity for targeted labeling. 
The targeted labeling method generally involves antigen- antibody interactions and 
affinity of receptor-ligand system such as streptavidin- biotin. To develop CPN probes 
for immunofluorescent labeling, Chiu et al developed a bioconjugation method with 
carboxy functionalized CPNs. A carboxy functional group was introduced in CPNs by 
blending an amphiphilic polymer, containing carboxy end groups and subsequent linking 
of antibody or streptavidin based on standard conjugation chemistry [80]. Using this 
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probe, they labeled a specific cellular target, EpCAM, which is an epithelial cell surface 
marker present in circulating tumor cells. The results demonstrate the specific and 
effective labeling of targets. In addition, they compared the brightness of the CPNs 
labeled live MCF-7 cells against Q dot 565 labeled cells and Alexa 488 labeled cells 
using flow cytometry. Quantitative analyses of fluorescence intensity of these labeled 
cells shows that these CPN labeled cells were ca. 25 times brighter than that of Qdots 
labeled cells and ca. 18 times brighter than that of Alexa dye labeled cells. This indicates 
the potential of CPNs for cellular imaging and fluorescence based biological detection. 
The same group reported the smaller CPN of ca. 10 nm diameter bright orange 
fluorescence from the cyano substituted poly (p-phenylenevinylene) polymer. These 
probes were used in specific labeling of a cell surface marker and microtubule structures 
in HeLa cells by immunofluorescence [81]. 
 
1.3.2 IN VIVO IMAGING 
Fluorescence imaging has the potential for a wide variety of molecular 
diagnostics and therapeutic applications. Because of its high sensitivity, fluorescence 
based imaging techniques are being increasingly utilized in small animal research. 
However, photon limiting interferences such as scattering, absorption, and 
autofluorescence limits their ability to generate effective deep-tissue fluorescence 
imaging. To overcome these limitations, near infrared (NIR) fluorescence probes with 
fluorescence, an order of magnitude higher than that of currently used organic dyes, is 
desired. To that end, conjugated polymer nanoparticles hold the potential to overcome the 
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challenges because of their extreme fluorescence brightness. Kim et al used a cyano-
substituted derivative of poly (phenylenevinylene) to prepare nanoparticles that emit in 
the red to NIR region. They demonstrated the in vivo fluorescence mapping of sentinel 
node (SNL) in mouse model using nanoparticles of 60±14 nm in size[82]. Similarly, Chiu 
et al developed conjugated polymer nanoparticle of ca. 15 nm using a conjugated 
polymer blend with deep red emission (λ= 655nm). The probe was functionalized and 
conjugated to chlorotoxin which is a tumor specific peptide ligand for in vivo tumor 
targeting. Biophotonic imaging and quantitative analysis of bio-distribution demonstrates 
that these probes have the ability to target malignant brain tumors specifically [83]. 
 
1.3.3 SENSORS 
FRET (Fluorescence resonance energy transfer) based techniques allows the 
detection of receptor-ligand interactions and biomolecular conformational changes in 
response to binding [84-86] and provides the basis for FRET based sensing applications. 
Conjugated polymer electrolytes have been employed as sensitive FRET-based bio- and 
chemical sensors [68, 87, 88]. Wu and coworkers have developed a sensing system based 
on energy transfer between components doped inside hydrophobic polymer nanoparticles. 
The sensing moieties for specific analyte are incorporated into the hydrophobic 
nanoparticle. The intraparticle energy transfer from matrix polymer donor to the 
entrapped dye molecule results in emission that is sensitive to specific analyte or 
responsive to changes in the local environment.  
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An oxygen sensor was developed by doping a blue emitting conjugated polymer 
with a phosphorescent dye, platinum octaethylporphyrin (PtOEP), which is responsive to 
molecular oxygen [89]. This ratiometric single nanoparticle oxygen sensor exhibited 
energy transfer from conjugated polymer host to the dye molecule. As the oxygen content 
decreases, phosphorescence of the oxygen sensitive dye increases making it a useful 
ratiometric sensor to monitor cellular hypoxia. Based on the same strategy of 
incorporating fluorescent dyes, other conjugated polymer based sensors were developed. 
For example, a pH sensitive probe was developed by covalently linking hydrophilic 
fluorescein dye to conjugated polymer poly (p-phenylenevinylene) surface [90]. The 
energy transfer from polymer donor to fluorescein acceptor makes it ratiometric pH 
sensor. Intracellular pH was measured between 5.0 and pH 8.0 after delivering the probe 
into HeLa cells by endocytosis. Similarly, temperature sensitive conjugated polymer 
nanoparticles were developed by incorporating the temperature sensitive dye Rhodamine 
B (RhB) in the conjugated polymers PFBT and PFPV [91]. A hydrophobic polystyrene 
polymer linked covalently with hydrophilic Rhodamine B dye was mixed with 
conjugated polymers and converted into nanoparticles by precipitation. This ratiometric 
sensor where polymer matrix transfers energy to dye molecule shows a linear fluorescent 
response from 10⁰C to 70⁰C.  
The same group has extended the idea to develop ion sensors to detect 
biologically relevant ions such as Cu2+, Fe2+ based on fluorescence quenching by 
aggregation induced by these ions. The Cu2+ induced aggregation is reversible upon the 
addition of ethylenediaminetetracetic acid (EDTA) and fluorescence is recovered. Fe2+ 
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induced aggregation is not reversible and the fluorescence remains quenched. This 
differential in fluorescence allows the identification of copper and iron ions and the 
determination of specific species concentrations [92]. Harbron et al developed polymer 
nanoparticle sensors to detect mercury in aqueous solution by doping the molecular dye 
rhodamine spirolactam (RhB-SL), which is nonfluorescent and becomes fluorescent 
when exposed to mercury ions [93]. The fluorescent intensity ratio of the dye acceptor to 
PFBT donor allows the ratiometric sensing of mercury. These efforts indicate that CPNs 
show promise for chemical and biochemical sensing applications. 
 
1.4 RECENT FUNCTIONALIZATION STRATEGIES 
Hydrophobic conjugated polymer nanoparticles prepared by reprecipitation 
method in water lack functional surface properties. Functionality on nanoparticle surface 
allows conjugation to useful biomolecules required for specific labeling, targeted 
delivery, and sensitive detection. In addition, surface modified nanoparticles enhance 
solubility in water and improve colloidal stability to otherwise hydrophobic 
nanoparticles. Recently, various approaches have been employed to address this problem 
and several research groups are involved in developing effective functionalization 
methods. Initially, surface functionalization strategies of quantum dots were adopted to 
functionalize CPN surface. For example, encapsulation is a general strategy utilized in 
the functionalization of nanoparticles. Functionality in conjugated polymer nanoparticles 
has been introduced by encapsulating CPNs in functional materials such as silica [94], 
phospholipids [7, 95, 96] and PGLA polymers [76, 97].  
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Silica encapsulation has been widely used to functionalize nanoparticle surface 
[49, 98, 99]. This method has produced nanoparticles of 20-30 nm in diameter with few 
nanometers of silica that provides functionality for specific labeling of biomolecules. 
Utilizing the same strategy, Wu et al encapsulated the conjugated polymer nanoparticles 
of size 10-20 nm with 2-3 nm thick silica shell to incorporate functionality [94]. The 
silica encapsulation method can yield relatively small particle sizes, but the likelihood of 
hydrolysis of the silica shell causes leaching of encapsulated fluorophores in biological 
environments. In another approach to encapsulate hydrophobic conjugated polymer in 
phospholipid, Green et al adopted a strategy of encapsulation of quantum dots in 
phospholipid using the miniemulsion method [95,100]. The average diameter of the 
encapsulated nanoparticles in water ranges from 80 nm-100 nm. Incorporation of PEG-
lipid-COOH in nanoparticle during the encapsulation process results in carboxy 
functionalized nanoparticles that allowed conjugation of BSA. Employing the same 
strategy, both iron oxide nanoparticles and conjugated polymer were encapsulated inside 
phospholipid micelles [96]. To demonstrate their potential as a bimodal imaging probe, 
magnetic resonance imaging (MRI) was performed with the particle suspension. In 
another encapsulation approach, Li et al used PLGA with the aim to utilize the -COOH 
functional group of the matrix as a handle to conjugate biomolecules. The PLGA 
nanoparticles loaded with conjugated polymers prepared by the miniemulsion method 
have been used for targeted cellular labeling [76, 97]. The hydrodynamic diameter of 
PLGA particles loaded with conjugated polymer as measured with dynamic light 
scattering (DLS) are larger (243 – 272) nm. The relatively larger size for PLGA and 
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phopsoholipid encapsulated particles is the limiting factor in many cellular and 
subcellular targeting applications. Moreover, the low fluorophore loading concentration 
in the nanoparticles prepared by the encapsulation method prevents the formation of 
densely packed fluorophore polymer nanoparticles. This consequently decreases the per 
particle brightness of the nanoparticles. Therefore, an alternative approach to prepare 
nanoparticle with densely packed chromophore is desirable.  
CPNs prepared through the reprecipitation method are relatively small in size and 
contain a high volume fraction of conjugated polymer which results in high per unit size 
brightness. This is an important factor for cellular imaging applications. However, 
incorporation of a functional surface is crucial for bioconjugation and specific labeling of 
cellular targets. To that end, Chiu et al developed various strategies for introducing 
functional moieties in CPNs (Pdots) for bioconjugation [61,101-105]. The first strategy is 
based on intertwining and trapping amphiphilic polymer chains bearing functional groups 
inside CPNs during the nanoparticle formation process. Incorporation of a functional 
amphiphilic polymer modifies the nanoparticle surface offering a handle to link 
biomolecules to nanoparticles. Cellular target labeling is carried out based on specific 
biomolecular interactions such as antigen-antibody or biotin-streptavidin interactions. 
Functionalization by trapping functional polymers and subsequent bioconjugation 
strategy are applicable to any hydrophobic fluorescent conjugated polymer. For example, 
carboxy functional group was introduced in PFBT nanoparticle surface using an 
amphiphilic comblike polystyrene polymer, PS-PEG-COOH at various fractions [101]. 
Size measurement by TEM and DLS shows the average diameter of nanoparticle is 
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15 nm. Functionalized nanoparticles prepared from this strategy contain 80% effective 
fluorophores and 20% PS-PEG-COOH. Compared to encapsulation approaches where 
concentration of effective chromophore in nanoparticle is low, this strategy produces 
particles with high fluorophore density. The available carboxy functional group is utilized 
to conjugate biomolecules using standard conjugation chemistry such as carbodimide 
crosslinking. In another study to utilize click chemistry for cellular labeling, carboxy 
functionalized nanoparticles were prepared by coprecipitating the fluorescent PFBT 
polymer blend with a small amount of functional polymer, poly (styrene-co-maleic 
anhydride; PSMA)[102]. Utilizing carbodiimide conjugation chemistry, the carboxy 
functionalized Pdots were linked with amine group of a small molecule such as amino 
azides and amino alkynes. Biomolecules were labeled using copper (I) catalyzed click 
chemistry. These are examples of carboxy functionalization and subsequent 
bioconjugation of CPNs for cellular labeling experiments. 
However, incorporation of functional group by encapsulation and intertwining 
amphiphilic polymer with conjugated polymer by coprecipitation relies on non-covalent 
hydrophobic association. Disassociation of functional moiety as a result of swelling in 
high ionic strength solution or unfolding of polymer structure causes decrease in 
functional group carrier. So, in an another approach, Chiu et al employed a synthetic 
approach to introduce covalently linked functional group in polymer side chain before 
converting into nanoparticle [60]. Nanoparticles prepared from such polymer allow direct 
functionalization without the additional step of surface modification procedures. 
However, such direct functionalization requires modification of polymer side chains 
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demanding expertise in polymer synthesis. Also, the density of hydrophilic functional 
group plays an important role in the nanoparticle compactness, stability and fluorescence 
performance in solution [60]. They investigated the effect of varying hydrophilic side 
chains on the nature of nanoparticles formed and their optical performance. To study this 
effect of modification, the PFBT polymer with side chain COOH at molar fraction of 2%, 
14% and 50% were synthesized. As the density of –COOH side chains increased, the 
quantum yield of the respective nanoparticles decreased. This is the result of less compact 
nanoparticles with increasing hydrophilicity within the polymer chain. As a variant of the 
direct functionalization approach, the same group developed a method to synthesize 
PFBT polymer with imine group side chains and cross linked them with a functional 
polymer such as poly (isobutylene-alt-maleic anhydride) PIMA, which contains multiple 
reactive units. The functionalized polymer is converted into nanoparticles that bear 
carboxy functional groups on surface for further bioconjugation [61]. The particle size of 
the functionalized CNPs is ca. 10 nm which was successfully conjugated with 
streptavidin. Cancer cells were labeled with this probe and biological imaging was 
performed. 
 
1.5 INTERACTION OF PROTEINS WITH NANOPARTICLES 
Protein adsorption on the surface of colloidal particles occurs when they come in 
contact with protein solutions. Studies on protein and antibody adsorption on varieties of 
microparticles composed of glass [106], aluminosilicate[107], polyanhydride[108] and 
polystyrene latex particles[109] have shown that protein bound on the particle surface is 
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irreversible and adsorption depends on particle size, charge and hydrophobicity. 
Similarly, adsorption of proteins on the nanoparticle surface has also been studied for 
various types of nanoparticles that demonstrate irreversible protein binding on the surface 
[110-112]. Investigations into the pattern of protein adsorption on nanoparticles indicates 
that the protein corona composition changes as a function of nanoparticle type, size, 
surface properties and curvature of nanoparticles [113, 115-117]. The protein binding on 
nanoparticle surfaces includes an irreversibly bound inner layer called the hard corona 
and reversibly bound external layer called the soft corona [114]. Using the model system 
of adsorption of transferrin to sulfonate polystyrene nanoparticles and carboxyl-
polystyrene nanoparticles, Milani et al showed that a strongly bound first monolayer 
forms followed by weakly bound secondary layer around it which depends on molar ratio 
of protein to nanoparticles. The hard corona is stable and remains associated with 
nanoparticles even after removal of free protein. Varieties of proteins that are known to 
associate with nanomaterials have been studied by various researchers and have 
identified hard protein corona around nanoparticles [111]. Protein composition in the 
nanoparticle environment and protein concentrations also plays a role in the corona 
composition [118-121]. Generally, the thickness of protein corona increases with 
increasing hydrophobicity, charge density and curvature of nanoparticles [111]. 
Varieties of nanoparticles have been functionalized with biomolecules such as 
peptides, proteins, enzymes and nucleic acids to make the use of these nanoparticles. 
Generally, the association of biomolecules on the nanoparticle surface occurs by 
nonspecific chemisorption. Such nonspecific adsorption occurs by electrostatic attraction, 
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van der Waals forces or hydrogen bonding when nanoparticles are incubated with or 
comes in contact with the proteins and are irreversibly adsorbed [125-127]. For example, 
such adsorption processes not only provide colloidal stability but also introduces 
functionality for molecular recognition in quantum dots nanoparticles [122-124]. Proteins 
that come into intimate contact with the nanoparticle surface causes partial or complete 
denaturation [128] and the presence of protein on particle surface affects biological 
activity. For a series of nanoparticle types, including polystyrene, iron oxide and silica 
nanoparticles, cellular uptake and cytotoxicity is reduced by a protein 
coating[110,129,130] while other nanoparticles show increased uptake in the presence of 
protein corona[131]. These data indicate that the recognition surface presented to cells by 
the protein coat determines the efficiency of cellular uptake rather than the nanoparticle 
core characteristics [132]. 
In order to provide an inert, biocompatible and hydrophilic surface coating to 
nanoparticles, polyethylene glycol (PEG) has been used as a surfactant. PEG 
modification provides colloidal stability of nanoparticles in high ionic strength solution 
and in biological media [133,134]. Functional end group PEG molecules not only provide 
steric stabilization to nanoparticles but also provide functional groups to nanoparticle 
surface. Surface properties of encapsulated nanoparticles depend on the coating materials 
rather than material on the particle core [135-136]. Structural characterization of PEG 
lipid coated drug nanocarriers show that PEG lipids are firmly attached to the surfaces of 
nanoparticles [137]. Therefore, surface passivation of hydrophobic conjugated polymer 
nanoparticles by head-group functionalized PEG-lipids is a strategy to provide functional 
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biomolecular conjugation and colloidal stability. Similarly, the evidence of protein 
adsorption on varieties of nanoparticle surfaces and formation of irreversible hard 
coronas offers another method to provide functionality in CPNs for biological 
applications including immunoassay.  
In this dissertation, we demonstrated a simple method for passivation and 
functionalization of CPNs by incorporating head group modified PEG-Lipids and 
proteins. This method allows modification of otherwise hydrophobic surface and 
provides colloidal stability in biological media. In addition, incorporation of functional 
phospholipids and protein adsorption on the nanoparticle surface offer methods to 
provide the CPN surface with molecular recognition and targeting moieties. We have 
shown that surface modified particles designed to lack biological functionalities are taken 
up efficiently by macrophage cells via micropinocytosis. Fluorophore loaded cells 
showed that CPNs are brighter fluid phase markers compared to dextran-linked alexa 
fluor organic dye and carboxy functionalized quantum dots. We have also studied the 
protein and antibody adsorption on nanoparticles surface which shows that hard protein 
corona on nanoparticle surface makes it a direct detection reagent in immunoassay. 
Taken together, we conclude that the utility of such particles ranges from targeted cellular 
labeling, fluid phase markers, and direct detection reagents for biomolecular methods. 
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CHAPTER TWO 
 
INCORPORATING FUNCTIONALIZED POLYETHYLENE GLYCOL LIPIDS INTO 
REPRECIPITATED CONJUGATED POLYMER NANOPARTICLES FOR 
BIOCONJUGATION AND TARGETED LABELING OF CELLS 
 
2.1 INTRODUCTION 
 
The use of highly fluorescent nanoparticles as labels for cellular imaging and in 
vitro assays is an extremely promising approach to maximize sensitivity and minimize 
the limit of detection. Such nanoparticles include inorganic semiconductor quantum dots 
(QDs) [1, 2], dye-doped silica particles [3], and commercially available dye-loaded latex 
spheres. These nanoparticles offer numerous advantages over traditional organic dyes, 
including bright fluorescence and improved photostability. As a consequence, great 
efforts have been invested in preparation of highly fluorescent nanoparticles and their use 
in a wide variety of applications that include biosensing, live cell imaging, and 
intracellular dynamics [4, 6]. However, use of existing nanoparticles is not without 
disadvantages. For example, limited dye loading due to self-quenching and undesirable 
leakage of small dye molecules has been reported for dye-doped silica nanoparticles [3] 
and cytotoxicity due to leached metal from the nanocrystal core is a critical problem for 
use of QDs [7-9]. While heavy metal leaching has been reduced by coating QDs with a 
variety of materials, such coatings can have their own associated cytotoxic effects [7, 10], 
and may not completely ameliorate heavy metal leakage. 
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The limitations of current fluorescent nanoparticles provide impetus for the design 
of new nanoparticles with high photostability and bright fluorescence, but with greatly 
reduced cytotoxicity. One promising strategy is the development of conjugated polymer 
nanoparticles (CPNs).These nanoparticles are formed by collapse of highly fluorescent 
conjugated hydrophobic polymers to form nanoparticles with high absorption cross 
sections and high radiative rates [11, 12]. The result is extraordinarily bright fluorescent 
nanoparticles. Because these CPNs are composed of relatively benign constituents with 
intrinsic fluorescence, they have low cytotoxicity [13], and cannot leach dye or 
constituent materials. As a result, CPNs have established themselves as useful optical 
probes that can be used at extremely low concentrations. However, the extreme 
hydrophobicity of CPNs leads to aggregation at high concentrations, thus limiting the 
amount of CPNs that can be added to cells in culture. In addition, this category of 
nanoparticle has not previously been conjugated to useful biomolecules for targeted 
delivery to cells. 
One approach to reduce the hydrophobicity of CPNs would be to introduce 
hydrophilic functional group(s) to the conjugated polymer starting material(s). However, 
this approach could alter the structure of the polymer and affect both optical properties. 
Another strategy is to envelope the CPNs with hydrophilic component(s), which would 
alter the nanoparticle surface characteristics without changing polymer optical qualities 
[14, 15]. We were intrigued by reports that polyethylene glycol (PEG) with an attached 
phospholipid (PEG lipid) has been used to provide hydrophilicity to an otherwise 
hydrophobic nanosensor [16], to polymer coated quantum dots [17-20] and to 
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semiconductor polymer nanospheres formed by miniemulsion and also referred to as 
semiconductor polymer nanospheres [21-22]. We speculated that a similar strategy could 
be used with CPNs formed by reprecipitation. As PEG lipids are commercially available 
and PEG has been widely used in biological systems, surface modification of CPNs with 
functionalized PEG lipids is a viable method to create hydrophilic nanoparticles. 
Importantly, PEG lipids can be functionalized with a variety of end groups to incorporate 
a moiety for linking biomolecular recognition elements to the CPN surface. As a result, 
functionalized PEG lipids not only improve the hydrophilicity and biocompatibility of 
CPNs for live cell imaging, but also allow specific labeling of cellular targets. 
Here we report a general method that uses the straightforward reprecipitation 
method to prepare highly fluorescent CPNs that incorporate functionalized PEG lipids, 
using commercially available materials. The result is functionalized soluble nanoparticles 
of small size that are highly stable in aqueous solution over a large concentration range. 
The extremely bright fluorescence of these nanoparticles, coupled with functionality for 
targeted cellular imaging, gives them enormous potential for fluorescence based imaging 
and sensing, possibly including applications with single nanoparticle detection limits. 
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2.2 METHODS AND MATERIALS 
The polyfluorene conjugated polymers PFBT (poly[(9,9-dioctylfluorenyl-2, 7-diyl)-co-
(1,4-benzo-{2,1’,3}-thiadiazole)], MW 48,000, polydispersity 2.7), PFPV (poly[(9,9-
dioctyl-2,7-divinylenefluorenylene)-alt-co-{2-methoxy-5-(2-ehtylhexyloxy)-1,4-
phenylene}], MW 85,000, polydispersity 5.4), MEHPPV (poly[2-methoxy-5-(2-
ethylhexyloxy)-1,4-phenylenevinylene]-end capped with DMP, MW 565,000, 
polydispersity 5.1) and PFO (poly[(9,9-dioctylfluorenyl-2,7-diyl)]-end capped with 
DMP, MW 29,000, polydispersity 3.0) were purchased from American Dye source, Inc 
(Quebec, Canada). Mr 2000 PEG lipids with biotin end groups (1,2-dimyristoyl-sy-
glycerol-3-phosphoethanolamine-N-[biotinyl (polyethylene glycol)-2000];(ammonium 
salt)), and carboxy end groups (1,2-dimyristoyl-sy-glycerol-3-phosphoethanolamine-N-
[carboxy (polyethylene glycol)-2000];(ammonium salt)and 550,1000,and 2000 Mr PEG 
lipid with methoxy end group (1,2-dimyristoyl-sy-glycerol-3-phosphoethanolamine-N-
[methoxy (polyethylene glycol)-550, 1000, or 2000]) were purchased from Avanti Polar 
Lipids. THF (anhydrous HPLC grade) was obtained from Fisher Scientific. Biotin rat 
anti- mouse CD16/CD 32 antibody was purchased from BD Pharmingen. All chemicals 
and biological molecules were used without further purification. 
 
2.2.1 METHOD FOR PREPARATION OF NANOPARTICLES 
PFO, PFPV, PFBT, and MEH-PPV CPNs were prepared with biotin, carboxy, 
amine, and methoxy functionalized PEG lipids (550, 1000, or 2000 M r PEG). Stock 
solutions of conjugated polymers (1000 ppm) were dissolved in HPLC grade THF by 
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stirring overnight. Next, functionalized PEG lipids were dissolved in distilled-deionized 
H20 (ddH2O) at concentrations between 25 and 250 ppm. The conjugated polymer 
nanoparticles were than prepared by rapidly dispersing 1 ml of conjugated polymer 
solution (10-250 ppm) into 9 ml of the PEG lipid solution under continuous mild 
sonication (45% amplitude) with a microtip-equipped probe sonicator (Branson, 4C15) 
for two minutes. THF was evaporated under vacuum overnight at room temperature. 
Finally, the nanoparticles were filtered through a 0.2 um polyvinylidene fluoride (PVDF) 
syringe filter (National Scientific).  
 
2.2.2 NANOPARTICLE CHARACTERIZATION 
The nanoparticles were evaluated by transmission electron microscopy (TEM) 
and dynamic light scattering. A Hitachi H7600T TEM at 120 kV and a cryostage at liquid 
nitrogen temperatures were used for all TEM measurements. Samples were prepared by 
drop casting nanoparticle solutions onto Formvar/carbon grids. CPN diameter was 
measured with Image J. The measured particle diameters were fit to a Gaussian 
distribution using SigmaPlot (Systat). 
Dynamic light scattering was performed using a Malvern Zetasizer (ZS90) at 25 
ºC using distilled-deionized H2O (ddH2O) as dispersant. Prior to each DLS measurement, 
samples were briefly sonicated in a bath sonicator for 30 second to remove bubbles and 
minimize aggregates. The Z-average and polydispersity index were determined using 
cumulants analysis and manufacturer supplied software. Data were analyzed in terms of 
intensity weighted distributions. Three runs were performed for each sample, and the 
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mean and standard deviation of both the Z-average and polydispersity index were 
calculated. 
Fluorescence emission spectra of the CPNs were acquired using a photon 
counting spectrofluorometer (Photon Technology International; QM-4). The fluorescence 
emission of PFBT nanoparticles was measured from 480 nm to 700 nm in aqueous 
solution using 460 nm excitation. PFO nanoparticles were excited at 384 nm and 
emission measured from 395 to 700 nm. PFPV nanoparticles were excited at 458 nm and 
emission measured from 480 to 700 nm. MEH-PPV nanoparticles were excited at 498 nm 
and emission measured from 510 to 725 nm. Both excitation and emission 
monochromator slits were set to achieve a 4 nm band pass. Absorbance spectra were 
recorded using a Genesys 10UV Scanning spectrophotometer (Thermo) using a 1 cm 
quartz cuvette. Individual quantum yields were calculated using fluorescein in 0.1 M 
NaOH as a standard. High resolutions spectra of methoxy 2000 M r PEG lipid-PFBT and 
bare PFBT particles were acquired using a UV-2501PC (Shimaduzu) scanning 
spectrophotometer with 0.5 nm spectral resolution. 
Nanoparticle concentrations were estimated from the mass of conjugated polymer 
starting material diluted into aqueous solutions assuming complete polymer to 
nanoparticle conversion. Specifically, nanoparticle volumes were calculated from the 
particle diameter measured by TEM, assuming a spherical shape and converted to 
nanoparticle mass assuming a nanoparticle density of 1 g cm-3 ( actual density is between 
0.95 and 1.05 g cm-3); dividing the total mass of conjugated polymer used in the 
reprecipitation by the mass of a single nanoparticle then yielded the number of 
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nanoparticles formed, which was easily converted to moles of nanoparticles and molar 
concentration of the nanoparticle suspension. Concentration calculations do not take into 
account small reductions in yield that result from filtration and may therefore be a slight 
overestimate. UV measurements taken before and after filtration indicate that any loss 
from filtration, if any, is small, and demonstrate negligible formation of aggregates. 
 
2.2.3 CONCENTRATING PEG LIPID MODIFIED NANOPARTICLES 
Solutions containing dilute PEG lipid-CPNs were concentrated by ultrafiltration 
using a 30 kDa cutoff centrifugal concentrator with a regenerated cellulose filter 
(Millipore) according to manufacture protocols. Solutions were concentrated up to 625 
ppm. 
 
2.2.4 STREPTAVIDIN PULL-DOWN OF BIOTIN PEG LIPID-PFBT 
NANOPARTICLES 
PFBT nanoparticles (28ppm) prepared with biotin functionalized PEG lipid were 
incubated with magnetic streptavidin beads ( New England Biolabs) for 30 min in 
phosphate buffered saline (PBS; 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4). The magnetic beads were removed from solutions using a strong permanent 
magnet and washed 5x in PBS to remove any unbound CPNs. The magnetic beads were 
then incubated overnight with 0.2 mg ml-1 free biotin to dissociate the CPNs from the 
magnetic beads. The magnetic beads were then removed from solution using a strong 
permanent magnet. The fluorescence from the remaining biotinylated nanoparticles was 
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measured at 460 nm excitation while scanning the fluorescence emission from 480 nm to 
700 nm. The slits for both the excitation and emission monochromators were set to 
achieve a 2 nm band pass.  
 
2.2.5 IMAGING OF BIOTINYLATED NANOPARTICLES LOCALIZED ON 
STREPTAVIDIN COATED COVER GLASS  
For single particle fluorescence imaging, cover glasses were cleaned with 
concentrated sulfuric acid, washed with water and dried air. Clean cover glasses then 
coated with 1% poly-l-lysine, washed with water to remove excess poly-L-lysine, 
incubated with 1 mg ml-1 streptavidin for 30 minutes, and carefully washed with Ringer’s 
buffer 3x (RB; 155 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 2mM NaH2PO4, 
10 mM glucose, 10 mM HEPES, pH 7.2). Dilute solutions ( 5 pM/25 ppb) of CPNs 
(carboxy PEG lipid-PFBT and biotin PEG lipid-PFBT) were incubated with the 
streptavidin-modified cover glass by inverting the cover glass over a drop of dilute CPNs 
on parafilm. Cover glasses were incubated with PEG lipid-CPNs for half an hour, washed 
carefully 3x with RB buffer, and air dried before taking images. Fluorescence imagine 
was performed by inverted epifluorescence microscope (Olympus IX71, 60x/1.45 N.A. 
objective using Xe arc lamp excitation, 495/10 nm excitation filter, and 510 nm long pass 
emission filter). 
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2.2.6 TARGETING OF PEG LIPID-PFBT NANOPARTICLES TO CELL SURFACE 
RECEPTORS 
J774A.1 macrophage cells were plated onto 35 mm glass bottom microscope 
dishes in DMEM (Dulbecco’s Modified Eagle’s Medium) containing 10% fetal bovine 
serum, 1% penicillin-streptomycin and 1% glutamate and incubated in humidified 
environment overnight (5% CO2, 37 ºC). Adherent cells were washed with RB 3x, fixed 
with 4% paraformaldehyde for 10 minutes at 37 ºC and blocked with 1% bovine serum 
albumin (BSA) for 1 hour at room temperature, washed again, and treated with 1:1000 
dilution of biotin rat anti-mouse CD16/CD32 antibodies (BD Pharmingen) for 2 hours. 
Cells were washed 3x with RB to remove unbound antibodies before incubating with 1µg 
ml-1 streptavidin for 30 minutes, again at room temperature. After streptavidin incubation, 
cells were washed 3x with RB, then incubated with PEG lipid-CPNs (biotin 2000 Mr 
PEG lipid-PFBT or carboxy 2000 Mr PEG lipid-PFBT; 5 pM/25 ppb) for 30 minutes, 
followed by an additional three washes with RB. Images were acquired with an inverted 
microscope [Olympus IX71, Xe arc lamp for excitation and filters and beam splitters 
(495/10 for excitation and 510 LP for emission) from Chroma, Ocra-ER CCD 
(Hamamatus)]. The acquired images were analyzed using Slidebook 5.0. 
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2.3 RESULTS AND DISCUSSION 
 
2.3.1 PREPARATION OF PEG LIPID-MODIFEID CONJUGATED POLYMER 
NANOPARTICLES 
CPNs form in response to rapid dilution of conjugated polymer solutions into 
water; the hydrophobic polymer molecules collapse in aqueous solution to create 
nanoparticles with very high intrinsic fluorescence. To prepare CPNs which incorporate 
PEG lipid into the nanoparticle structure, conjugated polymer solutions in THF were 
diluted into aqueous solutions containing PEG lipid, during brief mild sonication to aid 
mixing, as described in detail in the experimental section. The PEG lipid molecules used 
here contain two C14 lipid chains linked to the PEG through a phosphate moiety and 
provide a bidentate hydrophobic group for interaction with conjugated polymer. The 
functional end group is located at the opposite end of the PEG chain. 
PEG lipid-CPNs were prepared using PFBT and a series of PEG lipids (PEG Mr = 
2000, 1000, 550) with either carboxy, biotin, or methoxy end groups (Table 1). Our intent 
was to demonstrate that functionalized PEG lipid-CPNs can be prepared with a range of 
PEG sizes and moieties for bioconjugation, using a common strategy. Different end 
groups provide different moieties for conjugation to biomolecules; carboxy end groups 
allow for covalent linkage using established chemistry, and biotin end group can be used 
to bind streptavidin or streptavidin-linked molecules with high affinity. We have also 
prepared PEG lipid-CPNs using other conjugated polymers, including PFO, PFPV, and 
MEH-PPV. These additional NPs behave similarly to PEG lipid-PFBT nanoparticles, 
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with variation in size and spectral properties that most likely reflect the differences 
between their respective conjugated polymer starting materials. 
 
Table 1 TEM size of PFBT nanoparticles prepared with different varieties of PEG 
lipids 
 
Nanoparticle Diameter (mean ± FWHM)/nm 
 
Methoxy 550 Mr PEG lipid-PFBT 26±5 
Methoxy 1000 Mr PEG lipid-PFBT 26±4 
Methoxy 2000 Mr PEG lipid-PFBT 24±5 
Biotin 2000 Mr PEG lipid-PFBT 21±5 
Carboxy 2000 Mr PEG lipid-PFBT 24±5 
  
 
The size of PFBT nanoparticles formed in the presence of PEG lipid was 
characterized by both TEM and DLS. Representative TEM data and size distribution are 
shown in Fig. 1; TEM diameter obtained for PEG lipid- PFBT nanoparticles with 
different functional end group are listed in Table 1. Mean PEG lipid-PFBT particle size is 
ca. 24 nm, and is insensitive to changes in PEG lipid end groups and PEG Mr tested. DLS 
diameters for PEG lipid-PFBT NPs are 20-30 nm larger than those measured by TEM. 
Unlike TEM measurements, DLS size measurements reflect the hydrodynamic diameter 
and are expected to be somewhat higher than those measured by TEM, particularly for 
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PEG coated nanoparticles, since extension of long PEG groups into solution will be 
accompanied by significant solvation not present under TEM conditions. Differences 
between TEM and DLS measurements observed here are similar to those reported for 
PEG coated semiconducting polymer nanospheres [22]. However, absolute size values 
obtained by DLS measurements are accurate only for monodisperse particles; measured 
sizes can be inflated by the presence of even small amounts of aggregate. For this reason, 
we use DLS size measurements here as a tool for comparison of relative size and do not 
interpret DLS data in terms of absolute size. 
 
 
Fig.1 Representative TEM images and size distribution for PEG lipid-PFBT 
nanoparticles. (A) TEM image of methoxy 2000 Mr PEG lipid-PFBT nanoparticles. 
Images are acquired at 120 kV on a cryostage at liquid nitrogen temperature and are 
shown at 120,000 magnifications. Scale bar is 500 nm. (B) Histogram of size distribution 
and fit to a Gaussian function for the methoxy 2000 Mr PEG lipid-PFBT nanoparticles 
showing the average diameter to be 24±5 nm (mean±FWHM). 
 
A B
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Using DLS, we also measured the ζ potential of the PEG lipid-PFBT NPs. These 
data provide initial evidence for PEG lipid incorporation into these CPNs. Since ζ 
potential of PEG lipid CPNs reflects the charge of all constituent materials in NP, 
incorporation of different functionalized PEG lipid into the CPN will result in ζ potentials 
that reflect the charge of the different end groups, in addition to the phospholipid and 
constituent conjugated polymer. PFBT nanoparticles prepared with carboxy PEG lipid 
have negative ζ potential (- 38±1 mV), reflecting the negative charge on charged end 
group as well as the phospholipid, while biotin and methoxy PEG lipid-CPNs have 
smaller negative ζ potentials (-9±1 mV and -6±1 mV, respectively) that reflect the neutral 
end group as well as the negative charge on the phospholipid. 
Additional evidence for incorporation of PEG lipid into these CPNs comes from 
their observed properties, which are different than those of the corresponding unmodified 
CPNs. For example, PEG lipid-CPNs will pass through a size exclusion column in buffer 
(e.g. 30 cm G-25 sephadex packed column, commonly used in separations for 
bioconjugation methods) with high recovery, while unmodified particles show strong 
nonspecific binding to the stationary phase. Similarly, CPNs prepared with PEG lipid can 
be filtered through hydrophobic membrane filters in buffer (e. g. 0.2 micron PVDF 
syringe filters) without difficulty; absorbance measurements of PEG lipid-CPNs before 
and after filtration are indistinguishable, consistent with no significant binding to the 
hydrophobic filter. In contrast, CPNs prepared without PEG lipid and diluted in buffer 
bind to the filter in small but visible quantities in our hands, either as a result of their 
higher hydrophobicity, possible instability in the presence of buffer salts, or the presence 
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of aggregates. Most notably, we observe that PEG lipid-PFBT CPNs have higher 
quantum yield than the corresponding unmodified CPNs (Table 2). For example, 
methoxy 550 Mr PEG lipid-PFBT nanoparticles have a quantum yield of 19 ± 1%, 
compared to the value of 12 ± 1% we measure for unmodified particles prepared using 
the same conjugated polymer and conditions. On average, PEG-lipid-PFBT nanoparticles 
have nearly a 50 % increase in quantum yield relative to unmodified nanoparticles. 
Together, these observations are consistent with incorporation of PEG lipid into the 
CPNs, with resulting increases in hydrophilicity and fluorescent brightness. 
 
Table 2. Quantum yields for PFBT CPNs (fluorescein in 0.1 M NaOH as reference) 
 
 
Nanoparticle Quantum yield 
 
Methoxy 550 Mr PEG lipid-PFBT 19±1% 
Biotin 2000 Mr PEG lipid-PFBT 17±1% 
Carboxy 2000 Mr PEG lipid-PFBT 18±1% 
PFBT (unmodified) 12±1% 
________________________________________________________________________ 
We hypothesize that PEG lipid-CPNs form via a process analogous to that 
proposed for unmodified CPNs formed via reprecipitation. When the conjugation 
polymer is diluted, nano-particles experience a sudden change in the microenvironment 
of solvent, leading to collapse of the hydrophobic polymer chain into nanoparticles. We 
propose that in the presence of PEG lipid, the aliphatic side chains on the polymer 
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backbone interact with the hydrophobic PEG lipid tail and are incorporated into the 
nanoparticles during chain collapse; the bidentate lipid tail inserts into the CPN core and 
is retained there by hydrophobic interactions, while the hydrophilic PEG group protrudes 
out into the aqueous solution. Hence, the CPN surface is modified with hydrophilic 
functionalized PEG that helps prevent aggregation, improves biocompatibility, and 
provides end groups that can be used for conjugation and labeling. A similar structure has 
been proposed for polymer-encapsulated quantum dot nanoparticles coated with PEG 
lipid [17, 18]. 
Our hypothesis of insertion of the lipid tail into the polymer chain during collapse 
is consistent with the observed higher quantum yield of the PEG lipid-CPNs relative to 
unmodified particles. It is known that conjugated polymer fluorescence is quenched by 
interactions between polymer fluorophores [23]. For example, polymer aggregation 
lowers the quantum yields of conjugated polymer in aqueous or hydrophilic solutions. 
Similarly, unmodified CPNs have substantially lower quantum yields than their 
constituent conjugated polymer precursors, presumably due to interactions between 
polymer segments after chain collapse [24]. As a result, the increase in quantum yield for 
PEG lipid-CPNs relative to unmodified CPNs can be rationalized on the basis of changes 
in the relative interactions of the polymer chain(s) in the CPNs caused by insertion of the 
lipid tail in the nanoparticle core; the lipid tails may create greater spacing between 
individual conjugated polymer fluorophores that contributes to reduced intrachain 
quenching and correspondingly larger quantum yields than those observed for 
unmodified CPNs. In this case, the absorbance maxima of PEG lipid CPNs should also be 
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decreased relative to unmodified particles, since decreased interaction of polymer 
fluorophores is accompanied by blue shifts in the absorbance spectrum [25]. Indeed a 
comparison of high resolution absorption spectra of methoxy 2000 Mr PEG lipid-CPNs 
and the corresponding particles prepared without PEG lipid demonstrates a decrease in 
absorbance maximum of 2.4 nm for PEG lipid CPNs (data not shown), consistent with 
disruption of interaction between conjugated polymer fluorophores by lipid insertion into 
the core. 
We cannot rule out the possibility that PEG lipid-CPNs prepared here form by 
micelle entrapment of conjugated polymer nanoparticles, as proposed for PEG-capped 
polymer coated QDs [20] and semiconducting polymer nanospheres [21]. A study of 
micelle formation for 2000 Mr PEG lipid reports a critical micellar concentration (CMC) 
value that is approximately micromolar, and a measured micelle size of ca. 17 nm [26]. 
The PEG lipid concentrations used in our experiments. (17-83 µM) are therefore above 
the CMC, and micelles may be present in solution prior to addition of conjugated 
polymer. However, the thermodynamic stability of PEG lipid micelles of such small size 
is predicted to be low [27, 28], and our CPNs are not prepared under conditions that favor 
micelle formation. We carried out control experiments to investigate the presence of lipid 
micelles in our nanoparticle preparations; no measurable light scattering was observed in 
PEG lipid solutions at concentrations up to 83 µM (data not shown), indicating that 
micelle, if present, were not observable. Since the reported PEG lipid micelle size is 
comparable to or smaller than the reported diameter for unmodified CPNs (e. g. 10 to 30 
nm for PFBT [12]), it is unlikely that partitioning of independently precipitated CPNs 
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into preformed PEG lipid micelles could occur. If CPNs present inside are larger than 
predicted micelles, there must be intimate association of the lipid tails with the CPN 
structure sufficient to produce the observed increased quantum yield and blue shift in 
absorbance maximum. In this case, the final PEG lipid-CPN structure would be 
indistinguishable from that resulting from the proposed coprecipitation mechanism. 
 
2.3.2 OPTIMIZATION OF PEG LIPID-CPN PREPARATION 
To determine preparation conditions that result in maximal incorporation of CPNs 
with PEG lipid, experiments were carried out that altered the concentration of PEG lipid 
in solution. Initial nanoparticles preparations used 50 µg ml-1 PEG lipids. However, PEG 
lipid-CPNs were also prepared using 25 µg ml-1, 100 µg ml-1, 150 µg ml-1, and 200 µg 
ml-1 PEG lipid. No significant change in apparent hydrodynamic size of the resulting 
nanoparticles was observed by DLS relative to that for nanoparticles prepared in the 
original 50 µg ml-1 PEG lipid concentration. When nanoparticles were prepared in 
reduced concentrations of PEG lipid (less than 20 µg ml-1), a portion of the nanoparticle 
preparation bound to the membrane filter, reflecting increased hydrophobicity that 
presumably results from inadequate incorporation of PEG lipid into CPNs. These 
analyses suggest that maximum incorporation of the PEG lipids tested here is achieved 
for preparations that use a 50 µg ml-1 PEG lipid solution, and increased PEG lipid 
concentrations have no effect. 
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Table 3: Apparent hydrodynamic (DLS) size for carboxy 2000 Mr PEG lipid- PFBT 
CPNs prepared with a range of starting PEG lipid concentrations. 
 
 
PEG lipid  Diameter (DLS)/nm  Polydispersity  
 
25 µg ml-1  52    0.25 
50 µg ml-1  54    0.22 
100 µg ml-1  52    0.23 
150 µg ml-1  58    0.22 
200 µg ml-1  56    0.19 
________________________________________________________________________ 
Table 4: Apparent hydrodynamic sizes for carboxy 2000 Mr PEG lipid-PFBT CPNs 
prepared from a range of starting conjugated polymer concentrations. 
 
[PFBT]ini [PFBT]fin Dilution Diameter Polydispersity 
 factor  (DLS)/nm Index (PDI) 
 
1000 ppm 1 ppm  1000  86   0.35 
500 ppm 50 ppm 10  62   0.15 
250 ppm 25 ppm 10  59   0.15 
200 ppm 20 ppm 10  59   0.17 
150 ppm 15 ppm 10  58   0.19 
100 ppm 10 ppm 10  58   0.19 
50 ppm 5 ppm  10  58   0.19 
10 ppm 1 ppm  10  58   0.22 
________________________________________________________________________ 
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To see the dependence of PEG lipid-CPN size on initial polymer concentration, 
PEG lipid-PBFT nanoparticle solutions were prepared from initial conjugated polymer 
concentrations of 10-250 ppm in THF via a ten-fold dilution to final concentrations 
ranging from 1 to 25 ppm. The size of the resulting nanoparticles was evaluated by DLS. 
At these starting concentrations of conjugated polymer (10 to 250 ppm), the apartment 
hydrodynamic diameter of the PEG lipid-PFBT nanoparticles is independent of the 
starting concentration, and the only outcome of increased starting polymer concentration 
is increased nanoparticle concentration. However, at higher polymer concentrations, 
apparent particle size increases. Ten-fold dilutions of polymer concentrations above 500 
ppm resulted in larger observed particle size by DLS. It has been observed that the size of 
unmodified CPNs also varies with starting polymer concentration [12], although no 
systematic study of this dependence has been reported.  
 
2.3.3 FLUORESCENCE PROPERTIES OF PEG LIPID-CPNs 
We evaluated the spectroscopic properties of PEG lipid-CPNs. Notably, the 
absorption and emission maxima of PEG lipid-CPNs (Fig. S1) are close to those of 
particles prepared in the absence of PEG lipid for PFBT, PFO, PFPV, and MEH-PPV 
PEG lipid nanoparticles [12, 24, 29]. Like unmodified CPNs the emission maxima of 
nanoparticles in aqueous solution are slightly red shifted compared to precursor 
conjugated polymer dissolved in organic solvent (THF), while the overall shape of the 
emission profile is maintained. This phenomenon has been attributed to a change in the 
spatial environment of the polymer fluorophores caused by folding to create the 
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nanoparticle [24, 29]. As noted above, PEG lipid-CPNs are somewhat less red-shifted 
than bare particles (by 2.4 nm), presumably as a result of lipid insertion into the folded 
core. Similar to unmodified CPNs, PEG lipid-CPNs show good photostability (Fig. S2). 
PEG lipid-PFBT nanoparticles show the best photostability in our experiments of 
unmodified CPNs [12]. Together; these data indicate that apart from increases in 
quantum yield, incorporation of PEG lipid does not substantially alter the spectroscopic 
behavior of CPNs. 
 
Fig: S1 Absorbance and fluorescence spectra of PEG-Lipid CPNs. (A) Normalized 
absorption spectra for biotin PEG lipid PFO (solid line), PFPV (dashed line), PFBT 
(dotted dashed line), and MEH-PPV (dotted line) nanoparticles; (B) Normalized 
fluorescence emission spectra for biotin PEG lipid PFO (solid line), PFPV (dashed line), 
PFBT (dotted dashed line), and MEH-PPV (dotted line) nanopartilcles. Fluorescence 
emission spectra were acquired using excitation maxima (λex(PFO) = 384 nm, λex(PFPV) 
= 458 nm, λex(PFBT) = 460 nm, λex(MEH-PPV) = 498 nm). 
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Fig: S2 Photostability of biotin PEG-lipid CPNs. Biotin 2000 Mr PEG-Lipid CPNs 
were continuously illuminated with 250µW excitation light source (λex(PFO) = 384 nm; 
λex(PFPV) = 458 nm λex(PFBT) = 460 nm λex(MEH-PPV) = 498 nm) for 2 hours. 
Fluorescence emission was monitored (λem (PFO) =435 nm; λem(PFPV) =518 nm; 
λem(PFBT) = 535 nm; λem(MEH-PPV) =590 nm. Spectra correspond for PFBT, PFO, 
MEH-PPV and PFPV from top to bottom.  
 
2.3.4 STABILITY OF PEG LIPID-CPNs IN SOLUTION  
Over time or at high concentrations, hydrophobic particles will tend to form small 
aggregates as a mechanism for water exclusion from hydrophobic surfaces, and 
minimization of aggregation is desirable to increase nanoparticles shelf life. Since 
incorporation of a PEG lipid into CPNs result in increased surface hydrophilicity, our 
expectation was that once formed, these PEG lipid-CPNs would be highly stable in 
solution. We have observed no signs of aggregation in any of the PEG lipid CPN 
solutions described here. However, to more thoroughly assess stability over time, the 
apparent diameter of CPNs in a 28 ppm solution of carboxy PEG lipid-PFBT 
nanoparticles was measured by DSL at intervals over 60 days (Fig. 2). No significant 
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variation in apparent hydrodynamic size was observed, indicating that observable 
aggregation did not occur, and that these PEG lipid-CPNs are stable for long periods of 
time in solutions. The resistance of these PEG lipid-CPNs to aggregation may reflect the 
surface charge contributed by the PEG lipid and end groups, steric effects of PEG 
interactions, and the increased hydrophilicity of the PEG. 
 
 
Fig.2 Apparent hydrodynamic size of biotin PEG lipid-PFBT nanoparticles as a 
function of time. Hydrodynamic size was monitored by DLS over 60 days. All 
measurements were in triplicate. Error bars are the standard deviation and are enclosed 
within the data symbol. Note that x-axis is not linear. 
 
 
2.3.5 STABILITY OF PEG LIPID-CPNs TO CONCENTRATION  
Our standard protocol (10-fold dilution of 250 ppm conjugated polymer into 50 
ppm PEG lipid) yields 28 ppm CPNs of reproducible size after evaporation of the THF. 
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However, higher concentrations could be advantageous for specific applications, 
including chromatographic separations during bioconjugation and live cell experiments 
requiring dilution of CPN stock into media. As a result, we investigated the stability of 
PEG lipid nanoparticles to being concentrated by ultrafiltration with a centrifugal 
concentrator. In these experiments, a 28 ppm solution of carboxy PEG lipid-PFBT 
nanoparticles solutions was concentrated to a final concentration of 625 ppm. Portions of 
this concentrated solution were rediluted 25 ppm before analysis by DLS. The resulting 
apparent hydrodynamic size (60±2 nm) was indistinguishable from the size of original 
solutions (59±2), indicating that no aggregation occurred as a consequence of 
concentration. No binding of CPN solutions to the concentrator filters could be observed. 
While we have not concentrated PEG lipid-CPNs above 625 ppm, we expect that even 
higher concentrations of these particles are achievable. In contrast, unmodified CPNs 
cannot be concentrated by ultrafiltration due to nonspecific binding to ultrafiltration 
membranes, and are currently concentrated by dilution in glycerol followed by vacuum 
evaporation [30] to yield CPN solutions of nanoparticles in glycerol, with an upper 
concentration limit of about 200 ppm. Solutions concentrated via this method are not 
useful for cell studies, as glycerol is a potent osmolyte. The amenability of PEG lipid 
CPNs to concentration via ultrafiltration will allow their more widespread use in 
biological system that require increased CPN concentration, or that require 
concentrations not achievable for unmodified CPNs. 
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2.3.6 BIOCONJUGATION OF PEG LIPID-CPNs  
Conjugation of nanoparticles to specific biomolecules such as antibodies or other 
biomarkers is highly desired for specific labeling of biomolecules on or within the cell. 
The PEG lipid end groups incorporated into these CPNs contain inherent functionality for 
molecular recognition and/or covalent linkage. To demonstrate that these end groups are 
in a steric and conformational arrangement that allows bioconjugation, we carried out a 
series of experiments in PFBT PEG lipid-CPNs with biotin end groups were used to bind 
streptavidin. In the first set of experiments, biotin modified CPNs were incubated with 
magnetic streptavidin beads. After pulling out the beads from solution and washing to 
remove unbound nanoparticles, bound nanoparticles were removed by competition with 
free biotin and the magnetic beads removed with a strong permanent magnet. As shown 
in Fig.3, the resulting supernatant contains significant nanoparticle fluorescence (solid 
line), indicative of biotin-functionalized PEG lipid-CPNs binding to the streptavidin 
beads. In contrast, no nanoparticle fluorescence was observed in the supernatant from 
magnetic beads incubated with carboxy-PEG lipid-CPNs (Fig.3, dashed line), which lack 
the biotin functionality necessary for binding to the beads. These results demonstrate both 
successful incorporation of biotin PEG lipid end group for molecular recognition and/or 
covalent linkage.  
In additional experiments, a streptavidin coated cover glass was incubated with a 
very dilute solution of nanoparticles modified with biotin PEG lipid, rinsed to remove 
non-binding particles, and then air-dried. As shown in the Fig. 4, significant numbers of 
near diffraction-limited spots of nanoparticle fluorescence can be observed (Fig.4A), 
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indicating biotin-functionalized PEG lipid CPNs binding to streptavidin on the glass 
surface. Spots with a range of brightness are observed, with brighter spots probably 
reflecting multiple nanoparticles bound to streptavidin clusters and/or nanoparticles 
clusters formed during drying. In contrast, very little nanoparticle fluorescence is 
observed in the control plates incubated with PEG lipid-CPNs with carboxy end groups 
(Fig.4 C). Together, these data indicate binding of biotin PEG lipid-CPNs to the 
streptavidin coated glass. 
 
 
Fig 3: Fluorescence emission spectra of biotinylated PEG lipid PFBT nanoparticle 
pull down with streptavidin magnetic beads. Streptavidin coated magnetic beads were 
incubated with biotinylated 2000 Mr PEG lipid PFBT nanoparticles, washed to remove 
unbound CPNs, and then incubated with free biotin to release bound nanoparticles. 
Magnetic beads were removed with a strong magnet, and the fluorescence of supernatant 
was recorded (solid line; λex= 460 nm). Control experiments using carboxy 2000 Mr PEG 
lipid-PFBT nanoparticles do not bind streptavidin magnetic beads, as shown by the 
emission spectrum of the control supernatant (dashed line). 
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Fig. 4 Single nanoparticle fluorescence and intensity distributions from biotinylated 
PEG lipid-PFBT nanoparticles bound to streptavidin coated cover glass. (A) 
Representative fluorescence image of streptavidin-coated cover glass incubated with 
biotinylated 2000 Mr PEG-lipid-PFBT nanoparticles (λex= 495 nm; λem= 510 nm long 
pass filter). Scale bar = 10 µm. (B) Histogram of biotinylated 2000 Mr PEG-lipid-PFBT 
nanoparticle fluorescence intensities obtained from the image; a threshold mask was 
applied to all objects. (C) Fluorescence image of streptavidin-coated glass slide incubated 
with carboxy 2000 Mr PEG lipid-PFBT nanoparticles, as a control for nonspecific 
binding to slide and (D) histogram of the 2000 Mr PEG lipid-PFBT nanoparticle 
fluorescence intensities obtained from the image. Exposure times were identical for (A) 
and (C). The diffraction limit of the microscope was 225 nm. 
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Surprisingly, careful examination of the CPN signal observed in these cover glass 
experiments suggests possible observation of single nanoparticles. The diffraction limit 
of our microscope is 225 nm. Hence, we cannot distinguish the signal from individual 
nanoparticles if they are a distance of less than 225 nm apart. However, variations in the 
intensity of individual sites of PFBT fluorescence can be used to indicate varying 
numbers of CPNs in individual diffraction-limited spots. We estimate that a signal from a 
single nanoparticle of diameter 25-50 nm (TEM vs. DLS diameter) could occupy one to 
four pixels in these images, depending on whether the nanoparticle was located in the 
center or periphery of individual pixels. We examined the intensity of all image objects 
occupying four or fewer pixels. As shown in the Fig. 4B, the intensity distribution of the 
near diffraction-limited regions shows a narrow distribution of biotin PEG lipid-CPN 
spots of approximately constant intensity (Fig. 4B), consistent with measurement of 
single particles. We cannot distinguish between single particles and small aggregates of 
consistent size under these conditions. However, given the lack of aggregation evident in 
the TEM data for these 2000 Mr PEG lipid-PFBT Nps (Fig.1), the observed size stability 
of these nanoparticles in solutions over time (Fig.2) and the precedent for nonaggregation 
of PEG coated particles in previously published systems [19, 31], formation of aggregates 
is not expected here. A substantive conclusion of single particle imaging under these 
conditions requires additional experimentation. However, the possibility of single 
particles imaging data obtained here with a standard camera and arc lamp excitation 
highlights the extreme brightness of these PEG lipid-CPNs and their potential utility for 
single particle imaging in biological systems. 
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2.3.7 TARGETING OF BIOCONJUGATED PEG LIPID CPN TO CD/32 RECEPTORS 
ON CELL SURFACE  
The properties of PEG lipid-CPNs such as their high extinction coefficient, bright 
fluorescence, photostability, and functionalization indicate significant potential for 
targeted single particle imaging and tracking in living cells. Here we demonstrate 
targeted localization of functionalized nanoparticles to individual CD16/32 receptors on 
the surface of mouse macrophage J774A.1 cells. In these experiments, a commercially 
available biotin-linked rat anti-CD16/32 antibody was bound to CD16/32 on the cell 
surface, and then labeled with biotin-functionalized PEG lipid PFBT nanoparticles, using 
streptavidin as a linker in a sandwich format. 
The result was Ab-conjugated nanoparticles that specifically labeled antibody-
tagged receptors on the cell surface. Fig.5 shows the differential interference contrast and 
fluorescence images taken of labeled cells. Localized nanoparticle fluorescence is 
observed on the periphery of the cell, as is typical for membrane localization. Control 
experiments performed either without streptavidin or using carboxy modified 
nanoparticles instead of biotinylated nanoparticles showed no fluorescence (data not 
shown), indicating that observed binding of biotinylated PEG lipid-PFBT Nps does not 
represent nonspecific adsorption to the cell membrane. Together, these data demonstrate 
that PEG lipid-CPNs can target specific tagged proteins on the cell surface. To our 
knowledge, these results represent the first report of targeted delivery of CPNs to 
individual sites on the cell surface. 
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 Fig.5 Biotinylated PEG lipid-PFBT nanoparticles targeted to cell surface receptors. 
(A) Differential Interference Image (DIC) of fixed J774 A.1 cells; (B) fluorescence image 
of fixed J774 A.1 cells labeled with biotinylated PFBT nanoparticles. Scale bar is 25µm. 
J774 A1 macrophage cells which express CD 16/32 (Fc receptor) were paraformaldehyde 
fixed and incubated with biotinylated anti-CD 16/32 antibody. After washing the cell 
with RB, the cells were next incubated with streptavidin, washed, and labeled with 
biotinylated PEG lipid-PFBT nanoparticles. Images were obtained with 495 nm 
excitation, using a 510 nm long pass emission filter. 
 
 
 
 
2.4 CONCLUSION 
Incorporating functionalized PEG lipids into CPN is a simple method for 
preparing extremely bright biocompatible nanoparticles with enhances properties suitable 
for fluorescence imaging applications. The PEG lipids impart improved hydrophilicity 
and quantum yield, and straightforward conjugation to biomolecules for targeted 
delivery. We have demonstrated the utility of bioconjugation via PEG lipid bioton end 
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groups. The resulting data demonstrate that functional end groups on PEG lipid-CPNs 
provide a platform to conjugate nanoparticles to molecules of biological importance. 
Hence, PEG lipid- CPNs are a viable technology for a wide range of labeling and 
imaging applications in living biological systems. 
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CHAPTER THREE 
 
THE RELATIVE BRIGHTNESS OF PEG LIPID-CONJUGATED POLYMER 
NANOPARTICLES AS FLUID PHASE MARKERS IN LIVE CELLS 
 
3.1 INTRODUCTION 
Analyses of cellular functions routinely employ fluorescence-based techniques 
such as fluorescence microscopy and flow cytometry. For example, confocal and wide 
field imaging techniques are used to visualize cell and organelle structure, while flow 
cytometry takes advantage of fluorescently labeled cells to analyze, sort, and classify 
populations of cells for a variety of applications. However, the success of both 
fluorescence imaging and flow cytometry depends on the availability of bright photo-
stable fluorescent probes. Small molecule dye labels such as fluorescein or Texas red 
have been widely used, particularly as labels for endocytic compartments in live cells [1]. 
However, these organic fluorophores tend to photo-bleach rapidly [2] and are removed 
from the cellular environment via efflux pathways such as organic anion transporters [3] 
unless tethered to larger polymer molecules such as dextrans. Further, these fluorophores 
do not have sufficient fluorescent signal for straight forward single molecule imaging [4]. 
Fluorescent nanoparticles are a better photon source for biological applications 
due to their improved brightness, photo-stability, and lower susceptibility to transport out 
of the cell compared to small molecule labels [2, 5-7]. In addition, the nanoparticle 
surface can be coated with specific external shell materials like polyethylene glycol 
(PEG) lipid[8-11], amphiphilic block copolymer [9], or silica [12] to increase 
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nanoparticle solubility and stability in aqueous environments and provide functional 
groups for targeting to cell surface specific receptors and active delivery to specific 
cellular locations [11, 13, 14]. However, some nanoparticles result in cellular toxicity, 
which can arise from either core nanoparticle or the external shell composition [15-17]. 
Cytotoxicity is most noted for semiconductor quantum dots, due to the possibility of 
leaching heavy metal ions such as highly toxic Cd+2 from the nanoparticle core. 
Highly fluorescent organic dye polymers, such as PFPV (poly[{9,9-dioctyl-2,7-
divinylenefluorenylene}-alt-co-{2-methoxy-5-(2-ethylhexyloxy)-1,4-phenylene}], MEH-
PPV(poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene], PDHF (poly(9,9-
dihexylfluorenyl-2,7-diyl) and PFBT (poly[(9,9-dioctylfluorenyl-2,7-diyl)-co-(1,4-benzo-
{2,1,3}-thiadazole)]) have been used to synthesize extremely bright conjugated polymer 
nanoparticles by a simple reprecipitation method [11, 18]. According to this method, 
when rapidly diluted from an organic solvent phase into aqueous solution, hydrophobic 
polymer molecules fold to exclude water from their surfaces, creating nanoparticles with 
concentrated intrinsic fluorescence, and extremely high absorption cross sections in vitro. 
For example, unmodified PFBT nanoparticles have a reported extinction coefficient of 5 
x 107 M-1cm-1, a value ca. 100-fold greater than quantum dot nanoparticles of similar size 
and 1000-fold greater than typical small molecule dyes [12]. In addition, nanoparticle 
excitation and emission can be tailored by mixing two different polymers, or doping with 
specific dyes [19, 20]. These physical and photophysical properties make reprecipitated 
conjugated polymer nanoparticles ideal tools for imaging in biological systems, including 
single particle tracking [21], multicolor applications [22] and biological sensor 
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development [23, 24]. Conjugated polymer nanoparticles can also be prepared via 
miniemulsion [25-27] although with somewhat lower yield and typically much larger 
observed nanoparticle diameters. As a part of efforts to tether conjugated polymer 
nanoparticles to recognition molecules for cellular targeting, we have prepared 
reprecipitated conjugated polymer nanoparticles in the presence of amphiphilic 
functionalized PEG lipid, to create conjugated polymer nanoparticles encapsulated with 
functionalized PEG [11]. These new functionalized PEG lipid-coated conjugated polymer 
nanoparticles possess improved properties relative to uncoated conjugated polymer 
nanoparticles, including resistance to aggregation, greater solubility in aqueous solution, 
and increased quantum yield [11]. It has been demonstrated that uncoated CPNs contain 
potentially non-reproducible surface chemical defects resulting from surface polymer 
oxidation that occurs during preparation [28], and surface coating by PEG may 
ameliorate this effect. 
Because of the extremely high fluorescent brightness of conjugated polymer 
nanoparticles in vitro, it has been suggested that these nanoparticles are attractive 
candidates for use as cellular labels in biological imaging. Indeed, a series of manuscripts 
have shown that conjugated polymer nanoparticles are efficiently taken up into cells [29-
34]. We have reported that uncoated conjugated polymer nanoparticles can be 
successfully used as endocytic markers [29]. However, figures of merit typically used to 
describe conjugated polymer nanoparticles’ brightness, including extinction coefficient, 
quantum yield, and fluorescence cross-sectional area, are obtained outside the cell, and 
do not necessarily translate directly into brightness inside the cell. For example, 
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fluorophore signal may change or show diminished brightness inside cells, as has been 
reported for several organic dyes [35, 36]. In addition, fluorophores may be taken up into 
cells with a range of uptake efficiencies, leading to variations in relative intracellular 
signal(s) that reflect differences in intracellular concentration rather than the brightness of 
individual fluorophores. As a result, direct intracellular comparison of different 
fluorophores under biological conditions is required to appropriately assess relative 
brightness for biological imaging. In this manuscript, we compare PEG lipid-coated 
conjugated polymer nanoparticles to commercially available Qdots and small molecule 
organic dyes with respect to spectral properties, mode and rate of cellular uptake, final 
destination in the macrophage cell line J774A.1, and relative brightness inside the cell. 
The resulting data indicates that these PEG lipid-coated conjugated polymer 
nanoparticles are exceptional candidates for biological labeling applications, including 
both cellular imaging and flow cytometry.  
 
3.2 MATERIALS AND METHODS 
3.2.1 REAGENTS 
 
The conjugated polymer PFBT (Mr = 48,000; polydispersity = 2.7) was purchased 
from American Dye source (Quebec, Canada). Methoxy 2000 Mr polyethylene glycol 
lipid was purchased from Avanti Polar Lipids. The J774A.1 mouse macrophage cell line 
was purchased from American Type Culture Collections. Texas red dextran (TR-dex) (Mr 
= 10,000), AF488-dex (Mr = 10,000), and carboxy Qdots 525 were purchased from 
Invitrogen. Allophycocyanin (APC) labeled lysosome-Associated Membrane Protein 1 
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(LAMP-1) monoclonal antibody was purchased from Southern Biotech. All other 
chemicals used were purchased from Sigma-Aldrich, Fisher Scientific, or VWR. 
 
3.2.2 PREPARATION AND CHARACTERIZATION OF CPNs 
The method of preparation of PEG lipid-PFBT nanoparticles is described in detail 
elsewhere [11]. Briefly, one ml of PFBT (250 ppm) dissolved in HPLC grade 
tetrahydrofuran (THF) was diluted rapidly into 9 ml distilled-deionized H2O containing 
50 ppm methoxy-capped 2000 Mr PEG lipid under mild sonication to facilitate fast 
mixing. THF was removed from the suspension under vacuum evaporation, and filtered 
through a 220 nm PVDF syringe filter. A very dilute solution (ca. 100 pM) of the 
resulting nanoparticles was spread on formvar copper grids by drop casting. The size of 
the nanoparticles was measured using a Hitachi H7600 transmission electron microscope 
(TEM) at 120 kV on a cryostage cooled with liquid nitrogen. The diameter of the CPNs 
was measured with Image J. The determined particle diameters were fit in to a Gaussian 
distribution using Sigma Plot (Systat). Hydrodynamic size of the nanoparticles was 
measured by dynamic light scattering (DLS) using a Malvern Zetasizer (ZS90) at 25°C as 
previously described [11]. Nanoparticle concentration was estimated from the mass of 
conjugated polymer diluted into aqueous solution and the TEM size, assuming complete 
polymer to nanoparticle conversion, as previously described [29].  
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3.2.3 FLUORESCENT INTENSITY MEASUREMENTS OF FLUORPHORES (AF488-
DEX, QDOTs, AND CPNs) 
Fluorescence emission spectra of AF488-dex, Qdots, and CPNs were acquired 
using a photon counting spectrofluorometer (Photon Technology International; QM-4). In 
order to achieve measurable fluorescence intensity, a 500-µM stock solution of AF488-
dex was diluted to 112 nM; an 8 µM Qdot stock was diluted to 22.4 nM, and 6 nM CPN 
stock was diluted to 0.6 nM in water. The emission spectra of the diluted solutions were 
measured from 495 nm to 650 nm using 488 nm excitation, (4 nm bandpass) for all of the 
three fluorophores. Fluorescence emission of each of the fluorophores was also recorded 
under similar conditions but using the corresponding excitation maximum for each 
fluorophore (494 nm for AF488-dex, 400 nm for Qdots and 460 nm for CPNs). 
 
3.2.4 CELL CULTURE 
Mouse macrophage-like J774A.1 cells were grown in Dulbecco’s Modified 
Eagles Medium (DMEM; Mediatech) supplemented with 10% heat inactivated Fetal 
Bovine Serum (FBS; Hyclone), L –glutamine (2 mM), penicillin (100 units/mL) and 
streptomycin (100 µg/mL), in a humidified incubator with 5% CO2 at 37oC. The viability 
of the cells was 97% or more with each passage, as determined by Trypan blue exclusion 
assay. 
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3.2.5 FLUORESCENCE MICROSCOPY OF FLUOROPHORE UPTAKE 
J774A.1 cells were grown in optical bottom culture plates until about 70% 
confluent, at which time the cells were incubated with either 0.6 nM (2.7 ppm) CPNs, 
22.4 nM Qdots, and 112 nM AF488-dex overnight (16 h) in DMEM + 10% FBS at 37°C 
and 5% CO2. For co-localization experiments, 200 nM TR-dex was also added together 
with each fluorophore. Following incubation, cells were washed three times with 
Ringer’s Buffer (RB; 10 mM HEPES, 155 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM 
MgCl2, 2 mM NaH2PO4, 10 mM glucose, pH 7.2-7.4), and incubated without 
extracellular fluorophore under culture conditions (chased) for ≥4 hours prior to imaging. 
Under these chase conditions, sufficient time has elapsed that all endocytic cargo is 
assumed to be delivered to terminal vacuoles [1], which for fluid phase uptake in 
macrophage cells is the lysosome [37],[1]. Fluorescence imaging was performed on an 
inverted epifluorescence microscope (Olympus IX71) with xenon arc lamp excitation and 
a 60X/1.45NA objective. CPNs, Qdots and AF488-dex were viewed with 494 nm 
excitation (20 nm bandpass) and 531 nm emission (22 nm bandpass) while TR-dex was 
viewed with excitation wavelength 575 nm (25 nm bandpass) and emission at 624 nm (40 
nm bandpass). 
 
3.2.6 FLOW CYTOMETRIC STUDIES OF FLUOROPHORE UPTAKE 
J774A.1 cells grown in 35 mm culture dishes were incubated with Qdots, AF488-
dex, and CPNs separately in DMEM containing 10% heat inactivated FBS. For time 
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course studies, cells were incubated with fluorophore for each of 1, 2, 4 and 8 h, with 0.6 
nM (2.7 ppm) CPNs, and with Qdots (22.4 nM) and AF488-dex (112 nM) concentrations 
that were 37-fold and 186-fold higher, respectively. At individual time points, cell plates 
were chilled on ice and the cells were detached from the surface by pipetting. Detached 
cells were pelleted, and washed 3X with RB before suspension in RB. Fluorescence from 
10,000 cells was measured by flow cytometer (BD FACScan) at an excitation wavelength 
of 488 nm with the emission in the green channel. The data from FACScan were 
analyzed using FlowJo software (Treestar). In the dose dependent studies, cells were 
incubated with each fluorophore for 8 hours over the concentration range(s) of 22 to 600 
pM (CPNs), 1.4 to 22.4 nM (Qdots), or 4.5 to 112 nM (AF488-dex). Cells were prepared 
for flow cytometer analysis as for the time course studies. 
 
3.2.7 IMMUNOCYTOCHEMICAL ANALYSIS 
J774A.1 cells grown in glass bottom culture dishes were incubated with 
fluorophores at 37°C for 16 hours in a 5% CO2 incubator. Cells were washed 3x with RB, 
and then chased for 4 hours in DMEM culture medium. The cells were fixed with 4% 
paraformaldehyde in RB at 37o C for 10 minutes, and washed 3x again with RB before 
blocking with blocking buffer (RB containing 1.5% BSA, 0.3% Triton-X solution) for 2 
hours at 4oC. The cells were next incubated with the LAMP-1 specific antibody labeled 
with Allophycocyanin (APC) (200-fold dilution of 0.1 mg/ml stock solution) for 16 hours 
in RB containing 1.0% BSA and 0.3 % Triton-X at 4oC. The cells were washed with 
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blocking buffer 3x 15 minutes each at room temperature. Fluorescence imaging was 
performed by inverted epifluorescence microscope (Olympus IX71) with xenon arc lamp 
as excitation source and a 60X/1.45NA objective. The fluorescence of each of CPNs, 
Qdots, and AF488-dex were observed with 494 nm excitation (20 nm bandpass) and 
emission of 531 nm (22 nm bandpass); Allophycocyanin fluorescence of the antibody 
was observed with 575 nm excitation (25 nm bandpass) and emission of 624 nm (40 nm 
bandpass). 
 
3.2.8 BLOCKING NANOPARTICLE UPTAKE USING INHIBITORS OF 
MACROPINOCYTOSIS 
Known inhibitors of macropinocytosis were used to help elucidate the mechanism 
of cellular uptake of CPNs, as described in Fernando et al. [29]. Briefly, J774A.1 cells 
were plated in 35 mm tissue culture plates and grown to ~70% confluence. The cells were 
preincubated with methyl-β-cyclodextrin (2.5 mg/mL final concentration), wortmannin 
(100 ng/ml final concentration), and LY294002 (20 µg/ml final concentration) in culture 
medium for 30 min, followed by incubation of cells with 0.60 nM (2.7 ppm) CPNs for 
1.5 – 2 hours, also in media. Methyl-β-cyclodextrin and wortmannin are insoluble in 
media and require dilution in DMSO; cells treated with these inhibitors were therefore 
exposed to small amounts of DMSO. An additional vehicle control was performed in 
which cells were exposed to equivalent amounts of DMSO in the absence of inhibitors 
prior to incubation with CPNs. Cell processing, flow cytometry measurements and data 
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analysis were carried out as described above. Statistical analysis of the mean fluorescence 
for each treatment compared to the untreated and vehicle controls was done using 
ANOVA in SigmaPlot. We have previously demonstrated that under these conditions, 
there is less than 10% cytotoxicity from the inhibitor alone [29], indicating that observed 
decreases in CPN uptake in the presence of individual inhibitors do not reflect inhibitor 
cytotoxicity. 
 
3.2.9 CYTOTOXICITY STUDIES 
The Cell Titer Blue assay was used to assess cytotoxicity of CPNs. J774A.1 cells 
were plated at 10K/well in a black 96-well plates in DMEM + 10% FBS at 37°C and 5% 
CO2 and incubated with CPNs in culture medium for 16-18 hours at concentrations 
ranging from 0 ppm (control) to 67.5 ppm (15 nM). The background fluorescence from 
the CPNs at λex = 546 and λem = 585 nm was recorded using a Genios top reading 
fluorescence plate reader (Tecan). Cell Titer Blue reagent was then added to all according 
to manufacturer’s instructions, incubated with the cells for an additional 2 hours, and then 
the fluorescence in each well was remeasured. Individual well background fluorescence 
was subtracted from the total fluorescence to determine Cell Titer Blue fluorescence and 
then converted to percentage viability versus the untreated control wells. Statistical 
analysis of cell viability versus the untreated control was done using ANOVA in 
SigmaPlot followed by Bonferroni comparison; P-values less than 0.05 were used to 
conclude a significant difference between samples and controls. 
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3.3 RESULTS AND DISCUSSION 
In this study, we explore the suitability of methoxy-functionalized PEG lipid-
coated conjugated polymer nanoparticles for application as intracellular probes for 
cellular imaging and flow cytometry. We compare the advantages these nanoparticles 
offer over commercially available fluorophores such as Qdots and Alexa fluor dextran for 
ex vivo cell labeling in J774A.1 cells. Our goal was to determine the relative brightness of 
the CPNs to Qdots and organic dyes when loaded into cells, their respective uptake 
efficiency and mechanism of cell entry, and their final intracellular localization. We also 
evaluate the cytotoxicity of PEG lipid-CPNs. 
In these studies, we use CPNs as a representative PEG lipid conjugated polymer 
nanoparticle. These nanoparticles were synthesized from commercially available 
methoxy-functionalized PEG lipid and PFBT by reprecipitation, as previously described 
[11]. Based on spectral behavior and functional end group reactivity, the resulting 
nanoparticle structure is presumed to have a fluorescent PFBT-lipid core, surrounded by 
a corona of PEG molecules that results in high solution stability and increased quantum 
yield relative to bare PFBT particles [11]. A Similar behavior was observed for PEG lipid 
coated conjugated polymer nanoparticles prepared with other functional end groups (e.g. 
carboxy, biotin) that allow for conjugation to biorecognition molecules [11]. 
Transmission electron microscope characterization of the CPNs used here indicates that 
the particles are approximately spherical in shape with a mean particle diameter of 24±5 
nm, as shown in Figure 1a and 1b. Dynamic light scattering (DLS) analysis of this 
preparation gave a DLS diameter of 59 ± 2 nm, with a moderate polydispersity index of 
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0.14 ±0.03. The observed size difference between TEM and DLS measurements is 
consistent with 20 to 30 nm differences previously reported for PEG-coated conjugated 
polymer nanoparticles prepared by miniemulsion [34] and presumably reflects substantial 
hydration of the PEG surface. Some additional inflation of measured hydrodynamic 
radius by small amounts of high molecular weight particles is possible in this moderately 
polydisperse sample, although we have seen no evidence of the existence of aggregates. 
The measured size for this preparation is identical to our previous preparation [11], 
indicating that this method produces nanoparticles of highly reproducible size. The 
choice of methoxy as functional end group is arbitrary here, as we have seen no impact of 
the functional group in PEG lipid molecule on nanoparticle spectral behavior [11] or 
cellular uptake. 
 
 
Fig. 1 TEM characterization and size distribution of CPNs.  (a) Typical TEM image 
of CPNs. (b) Histogram of measured CPN diameter from TEM image analysis using 
Image J software. Histogram fit to Gaussian.  Mean diameter = 24 ± 5 nm. Scale bar = 
500 nm. 
 
ba
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Nanoparticle uptake can change as a function of particle size and surface 
characteristics [15, 38-41], as alteration of nanoparticle surface or size can lead to 
differential interaction with cell surface receptors that can facilitate uptake. Hence, direct 
comparisons of nanoparticle uptake are only relevant for nanoparticles with similar size 
and surface characteristics. To directly compare the behavior and uptake of these CPNs, 
we chose a representative commercially available Qdot with an amphiphilic coating and 
approximately equivalent size. In this case, the semiconductor CdSe or CdTe core with a 
Zn sulfide shell was coated with a carboxy-functionalized (proprietary) amphiphilic 
polymer layer. The result was a ca. 20 nm quantum dot with a hydrophilic surface. A 
range of commercially available fluorescent dyes are available for comparison to the 
CPNs; we chose to use AF488-dex, since it is among the brightest of the available 
organic dyes at the wavelength typically used for biological imaging and flow cytometry. 
As a result, signal performance of AF488-dex relative to CPNs represents a “best case” 
behavior for organic dyes. 
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 Fig.2: In vitro comparison of the fluorescence intensity of CPNs, Qdots, and AF488-
dex.  Fluorescence emission spectra of 0.6 nM CPNs (solid), 22.4 nM Qdots (dashed) and 
112 nM AF488-dex (dotted) obtained using (a) excitation wavelength of 488 nm and (b) 
at the optimal excitation wavelength of each fluorophore (494 nm for AF488-dex, 400 
nm for Qdots and 460 nm for CPNs; excitation bandpass = 4 nm). All spectra were 
acquired using a steady state spectrofluorometer (emission bandpass = 4 nm). 
 
Biological imaging and analysis is typically carried out with 488 nm excitation, 
using a 488 nm argon-ion laser. In particular, commercially available flow cytometry 
instruments widely used to detect cell labeling are equipped with 488 nm excitation. We 
compared the spectral behavior of CPNs to Qdots and AF488 under these conditions. 
Figure 2A shows a comparison of the fluorescence intensities of the three fluorophores at 
an excitation wavelength of 488 nm. In this case, CPNs are so much brighter than either 
Qdots or organic dyes that they cannot be compared at equivalent concentrations; 
concentrations that allow adequate AF488 signal result in overloaded detection for CPNs. 
Spectra shown in Figure 2 were obtained with 0.6 nM (2.8 ppm) CPNs, while Qdots and 
AF488-dex concentrations were 37 and 186 fold higher, respectively. The spectra 
a b
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demonstrate that CPNs have a wide emission spectrum (λ max= 540 nm) compared to 
Qdots and AF488-dex. Based on the integrated fluorescence intensity under the spectra, 
we estimate that the measured signal intensity for CPNs would be 160 times brighter than 
Qdots and 600 times brighter than AF488 under these conditions when corrected for the 
differences in concentration of the different fluorophores. We note that these 
measurements were not obtained at the excitation maximum for either CPNs λmax = 460 
nm) or Qdots (λmax = 400 nM). When the fluorescence intensity was compared using the 
respective absorption maxima of each fluorophore (Fig. 2B), CPNs have still higher 
relative signal; CPNs are ca. 37-fold brighter than Qdots and 510-fold brighter than 
AF488-dextran under ideal excitation conditions. We have seen no impact of functional 
end group on PEG lipid coated conjugated polymer nanoparticle spectra or quantum 
yields; hence, data obtained for CPNs also reflect that for PEG lipid-coated PFBT 
nanoparticles with other PEG lipid end groups [11]. We note that single molecule 
brightness comparisons have been made between Qdot 565, IgG-AF488 and polystyrene 
PEG PFBT NP prepared using an alternate protocol [42]; the relative brightness of this 
alternative type of PFBT CPN was reported to be somewhat lower than we observe here. 
 
3.3.1 RELATIVE FLUOROPHORE UPTAKE AND INTRACELLULAR 
BRIGHTNESS 
We compared the efficiency and mechanism of CPNs uptake into J774A.1 
macrophage cells with that for commercial Qdots and AF488-dex dyes under equivalent 
conditions. Our goal was to determine the relative brightness of the CPNs versus Qdots 
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and organic dyes in vivo, and to evaluate their respective mechanism of cell entry and 
final intracellular location(s). 
First, to determine the time course of fluorophore uptake and to quantify the 
resulting intracellular signal, cells were incubated with each of CPNs, Qdots, and AF488-
dex over time periods up to eight hours. The intracellular fluorescence of each loaded cell 
was determined by flow cytometry (Fig.3). As for in vitro experiments, cells were 
incubated in higher concentrations of Qdots and AF488-dex in order to place the signal 
from these fluorophores on the same scale as the CPN signal. As shown in Fig. 3, we 
were able to observe good CPN signal with an hour-long incubation at a concentration of 
0.6 nM (2.7 ppm) whereas 37-fold and 186-fold higher concentrations of Qdots and 
AF488-dex took ca. 2 and 4 hours respectively to get a discernable fluorescent intensity. 
This difference in time to achieve measureable intracellular fluorescence reflects 
differences in fluorophore brightness, and does not necessarily imply a difference in the 
uptake mechanism. After 8-hour incubation, the observed intracellular CPNs 
fluorescence was ca. 175-fold and 1400-fold greater than Qdots and AF488-dex 
fluorescence intensities when corrected for the differences in fluorophore concentration 
bathing the cell. We note that this correction for differences in extracellular fluorophore 
concentration assumes equivalent uptake efficiency; apparent intracellular brightness 
could be inflated or diminished by differences in relative uptake efficiencies for the 
different fluorophores. Regardless of assumptions, these observations indicate that CPNs 
are efficiently taken up into this cell type, and have remarkably bright intracellular 
fluorescence. 
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 Fig. 3. Time course of fluorophore uptake by cells. J774A.1 cells were pulsed with 
AF488-dex (black; 112 nM), Qdots (light grey; 22.4 nM), or CPNs (dark grey; 0.6 nM) 
for the indicated times, and cell-associated fluorescence was analyzed by flow cytometry.  
Error bars represent the standard deviation of the mean fluorescence at 488 nm excitation 
for at least 3 independent measurements of 10,000 cells. 
 
 
To examine the relationship between extracellular fluorophore concentration and 
intracellular fluorescence for CPNs, Qdots, and AF488-dex, J774A.1 cells were 
incubated for 8 hours with each of the three fluorophores over a range of concentrations; 
as for previous experiments, concentrations of Qdots and AF488-dex were 37-fold and 
186-fold higher than that used for CPNs. The resulting cell-associated fluorescence under 
each condition was quantified by flow cytometry. As shown in Fig. 4, cellular uptake of 
each fluorophore resulted in dose-dependent cellular fluorescence detectable by flow 
cytometry. These data indicate that extremely low concentrations of the CPN label can be 
detected in live cells using a standard flow cytometer equipped with a <15 mW argon ion 
laser. Depending on the sensitivity of the individual cytometer, even lower concentrations 
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of CPNs could be detectable. The higher intracellular signal of CPNs compared to Qdots 
and AF488-dex is highlighted by their relative detection limits under these conditions. 
While the observed detection limit for CPNs was 19 pM (86 ppb), corresponding 
detection limits for Qdots and AF488-dex were 980 pM and 11.2 nM, respectively. 
 
Fig.4. Dose dependent uptake of CPNs, Qdots, and AF488-dex in J774A.1 
macrophage-like cells.  Individual graphs represent uptake of (a) AF488-dex; (b) Qdots; 
and (c) CPNs. Cells were pulsed with different concentrations of fluorophore for 8 hours, 
washed, and analyzed for cell-associated fluorescence by flow cytometry.  Data reflects 
the mean fluorescence at 488 nm excitation for at least 3 independent measurements of 
10,000 cells.  Normalized fluorescence intensity at each dosage reflects the ratio of mean 
fluorescence intensity value at that dosage to mean fluorescent intensity value of the 
highest dosage. 
 
CPN concentrations used in this study are low. CPNs form in response to dilution 
from an organic phase to an aqueous phase, resulting in a stock solution with low CPN 
concentrations. It should be noted that we have further diluted this low concentration into 
media for cell studies. However, given the extremely bright fluorescence of these 
particles, these very low loading concentrations are more than adequate, and we have 
investigated cell loading over the range of concentrations likely to be used. Also, we have 
previously demonstrated that the high solution stability of PEG lipid-coated conjugated 
a b c
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polymer nanoparticles allows these particles to be concentrated via ultra-filtration [11]. 
Hence, if higher concentrations were required for specific experiments, such as toxicity 
studies, these low concentration stock solutions could be concentrated to allow treatment 
of cells with dramatically more concentrated CPN solutions.  
 
3.3.2 FLUOROPHORE UPTAKE MECHANISMS 
Application of different fluorophores as labels for cellular imaging or flow 
cytometry requires that their final intracellular location be established. For example, 
dextran-coupled dyes have been widely used as intracellular labels, an application that 
takes advantage of their known fluid-phase uptake and trafficking to lysosomes [1]. To 
investigate the uptake and cellular trafficking of CPNs, and to compare it to that for 
Qdots and AF488-dex, a series of experiment were performed in J774A.1 macrophage 
cells. 
In the first set of experiments, cells were incubated in fluorophore solutions 
overnight in the presence of TR-dex, washed to remove any extracellular fluorophore, 
and then incubated under culture conditions (chased) for at least an additional 4 h prior to 
imaging. Since dextran-labeled dyes can be present in a variety of endosome types (e.g. 
early endosomes, late endosomes, late-endosome-lysosomal fusion compartments, 
lysosomes) depending on the timescale of the experiment following initial uptake [37], a 
long chase was necessary to allow sufficient time for all endocytic cargo to be delivered 
to terminal vacuole(s), which for fluid-phase uptake in macrophage cells is the lysosome 
[37]. A 2 h chase is generally assumed to be sufficient for complete lysosomal delivery 
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[1], and macropinosomes have been shown to deliver fluid-phase cargo to lysosomes in 
less than 20 minutes [37]. Hence, a 4 hours chase, as chosen here, is more than sufficient 
to allow all fluorophore to be delivered to lysosomes. In addition, use of a long pulse and 
chase helped minimize cell-to-cell variation frequently observed when using shorter 
experimental time scales. Fig.5 demonstrates that under these conditions, each 
fluorophore was taken into the cell, resulting in a vesicular staining pattern of 
intracellular fluorescence consistent with fluorophore localization in intracellular 
organelles (green), rather than dispersed uniformly throughout the cytosol. A comparison 
of the cellular localization of each of the fluorophores (Fig. 5; green) demonstrates that 
the pattern of TR-dex fluorescence (red) mirrors (i.e. merges with) that for each of CPNs, 
Qdots, and AF488-dex in these experiments. Dextran coupled dyes are known to be taken 
up by host cells via fluid phase pinocytosis (usually macropinocytosis) and are trafficked 
along the cell’s endocytic pathway, finally accumulating in lysosomes [1]. Hence, co-
localization of TR-dex and the respective fluorophores in these experiments indicates 
trafficking to the lysosome, and suggests simultaneous uptake via a single endocytic 
mechanism. These data suggest that each of these fluorophores enter the cell via a fluid-
phase endocytic mechanism, and are ultimately located in membrane-bound organelles, 
presumably lysosomes, located in the perinuclear region of the cells. We point out that 
under the conditions of these experiments, cells could not phagocytose extracellular 
material (cells were grown in complement-free media to preclude complement-mediated 
phagocytosis and nanoparticles were not opsonized, to prevent Fc-receptor mediated 
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phagocytosis). Hence, fluorophores entering the cell through endocytic mechanism(s) in 
these experiments must do so through fluid-phase endocytosis, rather than phagocytosis. 
 
Fig. 5.  Fluorophore co-localization with TR-dex.  J774A.1 cells in individual glass 
bottom culture dishes were pulsed overnight with fluorophores in the presence of TR-dex 
and chased for ≥4 h prior to imaging. Green images reflect CPN, Qdot, and AF488-dex 
fluorescence; red images reflect TR-dex fluorescence; in the merged image, yellow color 
indicates co-localization.  Because of the differences in relative brightness, the different 
fluorophores were loaded into cells at different concentrations (CPNs = 0.6 nM; Qdots = 
22.4 nM; AF488-dex = 112 nM).  Scale bars = 10 µm. 
 
Additional support for fluid-phase endocytosis as the mechanism of fluorophore 
entry under these conditions was provided by uptake experiments performed on ice. In 
these experiments, cells were bathed in the different fluorophores and incubated on ice. 
At low temperatures, cells cannot take in extracellular material by energy-dependent 
endocytic mechanisms, and any CPN fluorescence associated with cells under these 
conditions must result from either CPN binding to the cell surface or via energy 
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independent uptake mechanisms such as diffusion through the cell membrane. After 
washing cells with ice-cold buffer, the relative intracellular fluorescence was evaluated 
by flow cytometry (Fig. 3). For each of the fluorophores, very little cell-associated 
fluorescence can be observed under these conditions. This observation is consistent with 
uptake by an energy-dependent mechanism (i.e. endocytosis), and rules out simple 
diffusion as the mode of fluorophore uptake since some diffusion could still occur at low 
temperature. In addition, the lack of interaction with the cell surface indicates that uptake 
does not occur through receptor-mediated endocytosis, which is initiated by interactions 
with receptors on the cell surface. However, while the fluorescent intensity of the CPN 
and AF488-dex samples incubated on ice were a very small percentage of the 
corresponding value at 37oC (0.2% and 2%, respectively), a somewhat higher value was 
observed with Qdots (13% of the value at 37◦C). This observation suggests that there may 
be small amounts of either binding to the cell membrane or energy-independent cellular 
uptake, such as diffusion through cellular membranes, for these Qdots. 
Flow cytometry experiments cannot distinguish between intracellular 
fluorescence and fluorescence resulting from fluorophore adsorption to the cell surface. 
Hence, the low measured CPN fluorescence observed by flow cytometry at low 
temperature indicates that there is very little physical adsorption (or receptor binding) of 
CPNs to the cell surface. A PEG coating is believed to reduce interaction with the cell 
surface for other nanoparticles, including Qdots [9, 43]. Consequently, the observation of 
little or no association of CPNs with the cells at low temperature is not unexpected. 
Similarly, dextran-coupled dyes do not typically interact with cell surfaces [44], 
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consistent with the low AF488-dex fluorescence also associated with cells at low 
temperature. In contrast, the Qdots fluorescence associated with cells at low temperature 
may reflect adsorption of the proprietary amphiphilic coating to the cell surface, as well 
possible energy-independent uptake mechanism(s) such as diffusion through the cell 
membrane or receptor-mediated endocytosis. 
A subsequent set of experiments were designed to further confirm that CPNs, like 
other fluid-phase markers, are ultimately delivered to lysosomes. LAMP-1 or CD107a is 
a protein that is trafficked to the membranes of late endosomes during endosomal 
maturation, and is retained in the lysosomal membrane [45]. Late endosomes mature to 
lysosomes or fuse with and/or deliver their contents to lysosomes [37], and the presence 
and contents of these vacuoles are closely linked [46]. Hence, while LAMP-1 cannot be 
used to identify lysosomes in the absence of late endosomes, it is commonly used to 
identify the presence of lysosome or lysosome-like late endosomes. To demonstrate that 
CPNs are finally localized to lysosomes in macrophage cells, immunocytochemical 
analysis was carried out using a Cy5-labeled anti-LAMP-1 antibody. In these 
experiments, a pulse-chase experiment was performed in which cells were incubated with 
fluorophore to allow uptake, washed, and incubated without extracellular fluorophore for 
≥ 4 hours, more than sufficient time to allow delivery of endocytic cargo to lysosomes. 
Cells were then fixed and stained with anti-LAMP-1 antibody. As shown in Fig.6, CPN 
fluorescence (green) is present in large compartmentalized LAMP-1 immunostained 
organelles (red) near the nucleus; the fluorophore signal co-localizes with anti-LAMP-1 
antibody (merge). Similar results were obtained for Qdots, and AF488-dex. Together, 
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these data confirm that each fluorophore is taken up by these cells via solution phase 
endocytosis and is ultimately trafficked to LAMP-1-containing lysosomes.  
 
Fig. 6. Co-localization of fluorophores with LAMP-1.  J774A.1 cells were pulsed with 
CPNs (0.6 nM); Qdots (22.4 nM); or AF488-dex (112 nM), followed by a ≥4 hour chase.  
Cells were then paraformaldehyde fixed, detergent permeabilized, and stained with an 
anti-LAMP 1 allophycocyanin (APC) -conjugated antibody. Green images reflect CPN, 
Qdot, and AF488-dex fluorescence; red images reflect APC fluorescence; in the merged 
image, yellow color indicates co-localization of fluorophores and LAMP 1.  Scale bars = 
10 µm. 
 
We have previously demonstrated that uptake of uncoated PFBT nanoparticles in 
J774A.1 macrophage cells takes place via macropinocytosis. For these bare particles, 
uptake was inhibited in the presence of chemical compounds that interfere with 
individual aspects of macropinocytosis (i.e wortmannin, cyclodextrin, and LY294002), 
while compounds known to inhibit other uptake mechanisms had no effect [29]. We 
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performed a similar analysis with these PEG lipid PFBT particles. To establish that CPNs 
are taken up by macropinocytosis, we evaluated the sensitivity of uptake to wortmannin 
and LY294002, which block the action of phosphoinositide 3-kinase (PI3K) [47]. Since 
PI3K is required for spontaneous cell surface ruffling that is an integral part of 
macropinocytosis [47], inhibition of uptake in the presence of wortmannin and 
LY294002 indicates that nanoparticles enter the cell through macropinocytosis. As 
shown in Fig. 7, both wortmannin and LY294002 result in significant inhibition of CPN 
uptake. An additional inhibitor, methyl-β-cyclodextrin, which inhibits cholesterol 
formation, also significantly reduces CPN uptake. Since cholesterol is involved in cell-
surface ruffling, inhibition by cholesterol is also consistent with CPN uptake via 
macropinocytosis. Together, these data indicate that like uncoated CPNs, PEG-coated 
CPNs are taken into macrophage cells via macropinocytosis. Since macropinocytosis is a 
nonspecific uptake mechanism that does not require interaction with cell surface 
receptors [48], this characterization also indicates that interaction of CPNs with the cell 
surface is not required for uptake, consistent with the lack of CPN interaction with cell 
membrane observed at low temperature. 
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 Fig.7. Disruption of CPN uptake by macropinocytosis inhibitors. J774A.1 cells 
treated with β- methyl cyclodextrin, wortmannin, and LY 294002 were incubated with 
identical concentrations of CPNs, and cellular uptake was evaluated by flow cytometry. 
Data is presented as a percentage uptake relative to cells not treated with inhibitors; CPN 
uptake into cells in media in the absence of inhibitors (positive control) represents 100% 
uptake, and cellular fluorescence in the absence of both inhibitors and CPNs (negative 
control) represents 0% uptake. β- methyl cyclodextrin and LY 294002 are insoluble in 
media and were delivered to the cells in DMSO.  The vehicle control reflects experiments 
in which equivalent volumes of DMSO were delivered to cells in the absence of 
inhibitors prior to incubation with CPNs in media.  Data reflects the mean cell-associated 
fluorescence at 488 nm excitation for at least 3 independent measurements of 10,000 
cells. Error bars are standard deviations. 
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3.3.3 EVALUATION OF NANOPARTILCE TOXICITY 
The utility of a given probe for biological imaging or analysis is compromised if 
the probe causes cell death or other deleterious effects. Hence, we evaluated the 
cytotoxicity of CPNs in cells over the concentration range likely to be used in cell 
imaging. First, cells were incubated with increasing amounts of CPNs for 16-18 h and the 
percentage of live cells was determined using the Cell Titer Blue Assay (Fig 8). 
 
Fig. 8. Cytotoxicity of CPNs. Cells were incubated with the indicated concentrations of 
nanoparticles for 16-18 hours, and viability analyzed using the Cell Titer Blue Assay. 
Percent viability is relative to cells incubated without CPNs.  The standard deviation is 
shown based on the average of the wells used for each concentration. All nanoparticle 
concentrations resulted in P-values > 0.05 when compared with untreated control 
samples. 
Notably, the percentage of live J774.A1 cells in CPN treated wells were similar to 
the controls (i.e. cells that had not been exposed to CPNs) at every CPN concentration 
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tested (P>0.05). These data indicate that CPNs have no discernable impact on cell 
viability over this concentration range. In addition, CPN loaded cells were examined 
under DIC illumination (600 x) using an epifluorescence microscope; we observed no 
detached cells or membrane blebbing that would reflect cell damage, even at the highest 
concentrations evaluated (67.5 ppm). Hence, these data indicate that these CPNs are not 
toxic to the macrophage cell line at the highest tested concentration. We note that the 
highest concentration evaluated for toxicity is ca. 25 fold higher than the working 
concentration needed for cell labeling.  
 
3.3.4 DISCUSSION  
We have prepared small (24 nm) conjugated polymer nanoparticles via 
reprecipitation in the presence of methoxy PEG lipid. This method results in highly stable 
nanoparticles with extremely bright fluorescence, and different preparations consistently 
yield particles of equivalent size [11]. Nanoparticles of similar composition but larger 
size can also be prepared by miniemulsion [10, 34]. Reported outstanding figures of merit 
for CPNs suggest their application as labels for cellular imaging and analysis [31, 32, 42]. 
However, intracellular conjugated polymer nanoparticles brightness had not been 
evaluated with respect to competing labels. In this study, we compared the performance 
of CPNs with widely used commercially available fluorophores to analyze suitability for 
biological applications, including brightness under spectral condition likely to be used for 
both biological imaging and flow cytometry. These comparisons use 488- or 494-nm 
 92 
excitation, rather than the relative absorption maxima of either CPNs or Qdots, since 
these excitation wavelengths are commonly used for flow cytometry and imaging 
applications using argon ion lasers. In vitro comparison of fluorophore intensity in a 
steady state spectrofluorometer at an excitation wavelength of 488 nm indicates that 
when corrected for concentration differences; measured signal intensity for CPNs is ca. 
160 times brighter than the Qdots and 600 times brighter than AF488 at this wavelength. 
However, the relative brightness of CPNs is much higher inside cells. We performed 
experiments in which cells were loaded with fluorophore by incubation with defined 
concentrations of fluorophore, and the fluorescence associated with those cells was 
evaluated by flow cytometry. Assuming equivalent cellular uptake and after correction 
for differences in fluorophore concentration, we estimate that the intracellular 
fluorescence signal of CPNs is 175 times brighter than the corresponding Qdots signal 
and 1400 times brighter than AF488-dex under these conditions. We note that neither 
CPNs nor Qdots are excited on resonance for these experiments, leading to somewhat 
reduced brightness for each of these fluorophores. However, the wavelengths chosen 
reflect conditions typically used for biological imaging and flow cytometry, and 
measured brightness obtained under these conditions is the appropriate comparison for 
these cell-based applications.  
Flow cytometry experiments, as used here to assess intracellular signal, cannot 
distinguish between intracellular signal and signal resulting from fluorophore adsorption 
to the cell surface, and our reports of relative intracellular brightness assume that 
fluorophore signal measured by flow cytometry reflects intracellular fluorescence. This 
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assumption is supported by experiments in which the different fluorophores were 
incubated with cells on ice, and the resulting cell-associated fluorescence was measured 
by flow cytometry. Very little resulting fluorescence was associated with cells under 
these conditions. Since low temperatures would necessarily inhibit active uptake but not 
interaction with the cell surface, the observed negligible fluorescence under these 
conditions suggests that any contribution from fluorophore interaction with the cell 
surface is small. We point out that Qdots show the largest amount of uptake and/or cell 
surface adsorption when incubated on ice and it is therefore probable that some quantity 
of Qdots are associated with the cell surface and/or taken into the cell by mechanism(s) 
not available to CPNs or dextran-coupled dyes. 
Analysis of the mechanism of CPN uptake indicates that these particles are taken 
up by J774A.1 macrophage cells via fluid phase endocytosis. Co-localization of 
intracellular CPNs with TR-dex and inhibition of uptake in the presence of wortmannin, 
LY294002, and β methyl cyclodextrin give evidence that the mode of endocytosis is 
macropinocytosis, similar to our previous observations of uncoated PFBT nanoparticles 
uptake in macrophage cells [29]. In contrast to the majority of endocytic uptake 
mechanisms, macropinocytosis does not require interaction with the cell surface to 
initiate uptake [48]; instead, extracellular material is taken into the cell via spontaneous 
actin-mediated ruffles that nonspecifically enclose extracellular solution. Since it has 
been observed that PEG coating of nanoparticles can inhibit interaction with cell surface 
receptors responsible for other fluid-phase uptake mechanisms [9, 43], entry of CPNs via 
this nonspecific fluid phase uptake mechanism is perhaps not surprising. While 
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macrophage cells have particularly high levels of constitutive macropinocytosis, many 
cell types can take in extracellular material by this mechanism [49], and would therefore 
be amenable to labeling with CPNs, with the modification of somewhat longer incubation 
time. For example, we have observed efficient conjugated polymer nanoparticle uptake 
into non-macrophage Chinese hamster ovary (CHO) cells (unpublished data).  
Co-localization of CPN fluorescence with TR-dex and labeled anti-LAMP-1 
antibodies indicates that following macropinocytic uptake, these nanoparticles are 
trafficked from endosomes to lysosomes. In this respect, these nanoparticles behave 
similarly to the range of dextran-conjugated organic dyes such as Lucifer Yellow dextran, 
TR-dex, and FITC-dextran that are commonly used as fluid phase markers. Such 
fluorophores have been widely utilized as specific labels of endocytic compartments for 
analysis of cell function and endocytosis [1]. We suggest that the high brightness of these 
PEG-lipid CPNs, combined with their easy synthesis, resistance to aggregation, and 
photo-stability, makes them highly attractive substitutes for historically used fluid phase 
markers. For example, we have shown here that these characteristics allow them to be 
used as intracellular markers for flow cytometry. 
We have previously demonstrated that functionalized PEG lipid-coated CPNs can 
be conjugated to biorecognition molecules and targeted to specific cell-surface receptors 
[11]. Howes et al have demonstrated coupling of larger PEG lipid coated conjugated 
polymer nanoparticles to BSA, as proof of principle that the PEG lipid functional group 
can be used to couple nanoparticles to proteins for targeted delivery [34]. Depending on 
the biorecognition molecule used and the choice of receptor to be targeted, such 
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conjugation to specific biologically relevant molecules could initiate cellular uptake via 
receptor-mediated endocytic mechanisms, with subsequent delivery to individual cellular 
locations that could include the nucleus, cytosol, or individual organelles [50, 51]. In this 
case, targeted delivery with minimal competition from macropinocytic delivery would be 
made possible simply by using a cell line with low levels of constitutive 
macropinocytosis. In cell line with higher rates of macropinocytosis, targeted delivery 
could be facilitated by experimental conditions that minimize nonspecific endocytosis; 
targeted CPNs could be incubated with cells on ice and washed to remove CPNs not 
bound to cell surface receptors prior to incubation at physiological temperatures to allow 
endocytic uptake. 
Notably, evaluations of possible CPN cytotoxicity show no impact of 
nanoparticles on cell viability or structure at all tested concentrations. Similar low 
cytotoxicity was observed for unmodified PFBT nanoparticles [29] and other conjugated 
polymer nanoparticles [31], indicating that the benign behavior of these nanoparticles 
may reflect the characteristics of the conjugated polymer core, rather than simple 
shielding by PEG. While loading concentrations tested for cell damage were low, they 
are well above concentrations likely to be used for cell studies, given the extreme 
fluorescent brightness of this label.  
 
3.4 CONCLUSION 
A dogma of fluorescence labeling in cellular biology is that the amount of 
fluorophore probe added to the cells is sufficiently small so as to not perturb cell 
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function. Depending on the concentration, even routinely used probes can impact the 
system being measured (e.g. FITC- dextran is used to measure intralysosomal pH, but is 
also a weak acid that could potentially act as a buffer). Hence, the lower probe 
concentration required for a given application, the less likely the probe is to alter the 
system under observation, and extremely fluorescent probes suitable for use at low 
concentrations are very desirable. Data presented here clearly indicates that the extreme 
brightness of the CPNs allows use of very low labeling concentrations inside the cell. 
When combined with their low cytotoxicity, these evaluations clearly demonstrate the 
high utility of conjugated polymer nanoparticles as labels for both biological imaging and 
flow cytometry. 
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CHAPTER FOUR 
 
PROTEIN CORONAS IMPROVE COLLOIDAL STABILITY OF CONJUGATED 
POLYMER NANOPARTICLES IN BIOLOGICAL MEDIA AND ALLOW 
BIOCONJUGATION 
 
4.1 INTRODUCTION 
 
Conjugated polymer nanoparticles (CPNs) are formed by precipitation of highly 
fluorescent conjugated polymers [1,2]. CPNs largely retain the extremely bright 
fluorescence of their polymer component(s) found in other applications, such as thin 
films [3, 4], and as a consequence, have perhaps the brightest fluorescence per unit size 
of any characterized nanoparticle [5]. In addition, unlike many other nanoparticles that 
have detrimental effects on cellular function or morphology [6], CPNs have no observed 
cellular cytotoxicity [7, 9]. Their facile preparation, extreme brightness, easy uptake, and 
specific lysosomal delivery makes CPNs attractive fluid phase labels for range biological 
applications, including cellular imaging and flow cytometry experiments.  
We have previously characterized cellular uptake of unmodified CPNs [7] and 
PEG-lipid functionalized CPNs [10] into macrophage cells, and carried out systematic 
comparisons of the intracellular brightness of CPNs and competing fluid-phase markers 
[10]. These studies demonstrate that CPNs are efficiently taken up into cells, and that 
their intracellular brightness is orders of magnitude brighter than competing fluid-phase 
markers, including quantum dots. Similar high relative intracellular brightness figures 
have been reported by other researchers [11]. Using cellular images and specific labeling 
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of lysosomal membranes, we have demonstrated that both bare and PEG-lipid coated 
CPNs are taken into macrophage cells via endocytosis, and are ultimately delivered to 
lysosomes. However, one aspect of our cellular uptake experiments was puzzling. Given 
the relative hydrophobicity of bare particles, we expected partitioning of bare 
nanoparticles into cellular membranes, or at the very least, substantial localization of 
CPNs on extracellular membranes that would be visualized as membrane localized 
fluorescence. However, cellular images showed no interaction of unmodified particles 
with the cell surface. Moreover, cellular inhibitor studies indicated that CPN uptake 
occurred via macropinocytosis, a mechanism that does not require binding at the cell 
surface [7]. In addition, while bare (unmodified) CPNs aggregate and precipitate under 
physiological salt conditions [12, 13], reflecting their high surface hydrophobicity, we 
observed no precipitation in our uptake experiments, which were carried out in serum 
solutions at physiological salt concentrations. The incongruity of these results with the 
expected hydrophobicity of unmodified CPNs led us to question whether the surface 
hydrophobicity of these CPNs was indeed as high as predicted in media or serum-
containing solutions. We reasoned that CPNs in serum could be interacting with serum 
proteins. In this case, protein adsorption to otherwise unmodified CPNs would alter the 
CPN surface that was presented to the cells, and block interaction of a highly 
hydrophobic CPN surface with the hydrophobic cell membrane, as well as ameliorate 
aggregation. Hence, to understand CPN behavior under biological conditions, it is 
necessary to know whether unmodified CPNs in serum or media acquire a protein coat.  
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Interactions of proteins with the nanoparticle surface are well established for a 
variety of nanoparticle types [14, 15]. A recent review lists at least twenty nanoparticle 
types with demonstrated protein binding in solution [16]. Protein association includes a 
transient external layer (soft corona) and a long-lived inner layer (hard corona) that 
remains associated with nanoparticles after removal from protein solution(s) [17]. A 
series of researchers have isolated and identified the hard corona proteins interacting with 
individual nanoparticle types in serum or other biological fluids (recently reviewed in 
[15]). These investigations indicate that, for the nanoparticles studied, protein corona 
composition changes as a function of the nanoparticle type and size, reflecting changes in 
nanoparticle curvature, charge, or functional group orientation [18-20].Corona 
composition is also somewhat sensitive to protein solution concentration and composition 
[21-24].  
Notably, the presence or absence of the protein corona can affect nanoparticle 
biological activity. For a series of nanoparticle types, including polystyrene, iron oxide, 
and silica nanoparticles, cellular uptake and cytotoxicity is reduced by a protein coating 
[14, 25, 26]. Other nanoparticles can show increased uptake in the presence of a protein 
corona [27]. These data indicate that the recognition surface presented to cells in protein 
solutions reflects the protein coat, rather than the nanoparticle core characteristics [28]; 
the protein coat is the likely determinant of cellular uptake and/or efficiency, as well as of 
intracellular targeting. However, despite the importance of a potential protein corona on 
for biological applications of CPNs, no investigation of protein interaction with CPNs has 
been reported.  
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To test the interaction of CPNs with proteins in solution, we undertook a 
systematic study of the stability of unmodified PFBT CPNs under biological conditions 
in the presence and absence of added protein(s), including those found in serum. We 
demonstrate that under the conditions of high ionic strength used in physiologically 
relevant buffers and media, PFBT CPNs rapidly aggregate. However, when protein is 
included in the solution, bare particles acquire a stable protein coat. The resulting protein-
coated particles have dramatically improved characteristics under biological conditions. 
Protein-coated CPNs do not aggregate, are stable over a wide pH range, and are taken 
into cells with greatly increased efficiency compared to either uncoated or PEGylated 
CPNs. These data demonstrate that protein adsorption is a facile and rapid method to 
modify otherwise hydrophobic CPNs surfaces, and will occur spontaneously in protein 
containing solutions, including serum. In addition, we demonstrate that adsorbed protein 
is available for molecular recognition. Protein adsorption thus both improves colloidal 
stability and offers a simple method to modify CPN surfaces with molecular recognition 
or targeting moieties.  
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4.2 MATERIALS AND METHODS 
All chemicals and reagents used were commercially available. Polyfluorene 
conjugated polymer PFBT (poly[9,9-dioctylfluorenyl-2,7-diyl)- co-(1,4-benzo-{2,1’,3}-
thiadiazole)], (Mw 48,000, polydispersity 2.7) (American Dye Source), HPLC grade 
Tetrahydrofuran, THF (Fischer chemicals), Bovine albumin serum (BSA) fraction 
V,(Omnipur), lysozyme (EMD), FBS (fetal bovine serum), Sulfo-NHS-biotin (Thermo 
Scientific) and streptavidin- magnetic beads (New England BioLabs) and FITC (Acros 
chemicals) were used without further purification. All water used was Barnstead 
Nanopure deionized water (18.2 MΩ) that had been further filtered through 20 nm PVDF 
filter (Whatman). 
 
4.2.1 NANOPARTICLE PREPARATION AND PROTEIN ADSORPTION 
Protein-modified PFBT CPNs were prepared by two different methods. In the first 
method, unmodified (bare) PFBT nanoparticles were prepared by reprecipitation, and 
then the resulting nanoparticles were incubated with protein in a separate step to allow 
protein adsorption to the CPN surface. Briefly, 1000 ppm PFBT polymer stock solution 
was diluted in tetrahydrofuran (THF) to make a 250 ppm solution that was rapidly diluted 
1:10 in water (10-20 mL total volume) under continuous sonication with a micro-tip 
equipped sonicator (Branson; 45% power, corresponding to 67.5 W). Sonication was 
continued after dilution, to make a total of 2 minutes sonication. Following CPN 
formation, THF was removed by vacuum evaporation, and volume lost after evaporation 
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was replaced by addition of water. The nanoparticle suspension was finally filtered 
through a 220 nm PVDF membrane syringe filter. The resulting 25 ppm nanoparticle 
suspension was used for subsequent protein adsorption experiments. The nanoparticle 
molar concentration of 25 ppm PFBT was calculated to be 3±1 nM based on the mass of 
the conjugated polymer diluted in water during reprecipitation and the size of the CPN 
core as measured by TEM (Fig. S1). To allow interaction of protein with the bare PFBT 
CPN surface, bare nanoparticles were incubated with protein solution(s). Briefly, BSA 
was added directly to nanoparticles in water at different protein: CPN molar ratios; 
ranging from 33 to 250. Other proteins including biotinylated BSA (BSA-biotin), or 
lysozyme were added directly to nanoparticles in water at protein: CPN molar ration of 
83. Alternatively, to investigate interaction of total serum proteins with CPNs, 3±1 nM 
CPNs were incubated with 1% fetal bovine serum (FBS). After 1 hour of incubation with 
proteins, 2.5 ml of CPN-protein was mixed with 2.5 ml of 2x PBS ( PBS:140mM NaCl, 
2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 at pH 7.2). 
In the second (alternative) method, PFBT polymer in THF was diluted directly 
into water containing BSA, to create protein-modified PFBT CPNs in a single step. 
Briefly, BSA was mixed in 9 ml water, to make solutions with BSA, concentrations 
ranging from 100 nM to 750 nM when total volume is 10 ml. 250 ppm PFBT in 1 mL 
THF was diluted directly into each solution under continuous sonication, as described 
above, to create protein modified PFBT CPNs in a single step. THF was then removed in 
vacuum evaporation and lost solution mass was compensated by water addition. 
Similarly, 1 ml of 250 ppm PFBT in THF was dispersed directly in 9 ml of 1x PBS 
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containing BSA in the concentration range from 100 nM to 750 nM. THF from the CPN 
suspension was removed by vacuum evaporation; volume lost was compensated with 
PBS, and finally filtered through 220 nm PVDF syringe filter.  
PEG-Lipid incorporated PFBT CPNs were prepared by dispersing 1 ml of PFBT 
in THF into 9 ml of water containing 40 ppm PEG-Lipid methoxy2000, as previously 
described [9]. During experiments to test for possible protein association with PEG-Lipid 
CPNs, 5.5 nM nanoparticles were incubated with 250 nM (final concentration) BSA in 
PBS for at least two hours prior to DLS measurement. 
 
4.2.2 NANOPARTILCE SIZE AND ZETA POTENTIAL MEASUREMENT 
The hydrodynamic size of the CPNs were measured and monitored by Photon 
Correlation Spectroscopy (PCS), also called Dynamic Light Scattering (DLS), using a 
Malvern Zetasizer (ZS90). DLS experiments were performed in the backscattering mode 
(scattering angle of 173º) at 25ºC using distilled deionized water (refractive index 1.33) 
or PBS as dispersant wherever relevant. Refractive index of PFBT in THF at 25 ppm was 
1.40 as measured using an Abbe refractometer. Prior to each measurement, CPN 
suspension were sonicated for 20 seconds in a bath sonicator to remove bubbles and 
minimize possible transitory/unstable aggregates. The Z-average mean hydrodynamic 
size and polydispersity index were determined and analyzed in terms of intensity 
weighted distributions using Cumulant analysis. Measurements were performed on each 
of three independent preparations; the mean and standard deviation were calculated from 
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measurement of three measurements each in duplicate. Zeta potential of CPNs were 
measured by Malvern Zetasizer(ZS90) using 10 mM TRIS buffer at pH 8.0 as dispersant. 
 
4.2.3 NANOPARTICLE STABILITY STUDIES 
To test the stability of bare PFBT CPNs in phosphate buffered saline (PBS), 1 ml 
of 25 ppm PFBT CPN in water was mixed 1 ml of 2X PBS. A similar experiment was 
performed in which equivalent amounts of CPN were added to 1 mL of 2X PBS 
containing 500 nM BSA, to make a 250 nM BSA solution in PBS. To test the pH-
dependence of CPN stability, CPNs were diluted into pH calibration buffer (130 mM 
KCl, 15 mM HEPES and 15mM MES) at different pH (4 to 8). Each test solution was 
photographed under UV illumination by 365 nm handheld UV illuminator and CPN size 
was monitored by DLS (Malvern Zetasizer nano ZS) and fluorescence intensity measured 
by using steady state spectrafluorometer (Photon Technology International, PTI 
Quantmaster). The Emission spectra was collected using 460 nm excitation (2 nm band 
pass) and emission was scanned from (480-650) nm (1 nm step; 2 nm band pass).  
The long term solution stability of the protein-modified particles stored in PBS at 
4°C was monitored by DLS size measurement over a period of two weeks. CPN solutions 
were warmed to room temperature (25ºC) prior to measurement, and DLS measurements 
were performed as described above.  
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4.2.4 OPTICAL PROPERTIES MEASUREMENT 
Fluorescence spectra were acquired using steady state spectrofluorometer (Photon 
Technology International, PTI Quantmaster). The Emission spectra of CPNs were 
collected using 460 nm excitation (2 nm band pass) and emission were scanned from 
(480-650) nm (1 nm step; 2 nm band pass). Absorption spectra were measured using high 
resolution UV-vis spectrophotometer (UV-2501PC, Shimadzu). Quantum yield of CPNs 
was measured against fluorescein in 0.1M NaOH as standard using standard methods. 
 
4.2.5 BIOTINYLATION OF BSA 
Bovine albumin serum protein was biotinylated using Sulfo-NHS biotin following 
the manufacturer recommended protocol. Briefly, 60 µL of 10 mM biotin reagent 
solution was added in 1 ml of 2mg/ml BSA protein solution in PBS. The incubation 
reaction was carried out at room temperature for 30 minutes and excess biotin removed 
by size exclusion chromatography (Sephadex G50). 
 
4.2.6 SIZE EXCLUSION CHROMATOGRAPHY 
Excess protein in the solution was removed by size exclusion used to separate 
chromatography using a Sephacryl S-200 resin filled column with either water or PBS as 
eluent at flow rate of 1ml/min. Resulting CPNs in water or buffer were concentrated by 
centrifugal concentrator (Fisher Scientific AccuSpin1R).  
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4.2.7 MAGNETIC BEAD PULLDOWN 
BSA-biotin coated PFBT nanoparticles (50 µL of 0.12 nM (1ppm) suspended in 
PBS buffer was added to streptavidin magnetic beads that had been extensively washed 
with Ringer’s Buffer (RB: 155mm NaCl, 5 mM KCl, 2 mM CaCl2,1 mM MgCl2, 2 mM 
NaH2PO4, 10 mM glucose, 10 mM HEPES, pH 7.2-7.4). A mixture of magnetic beads 
and BSA- biotin coated CPNs were incubated together for 30 minutes at room 
temperature, before separation of magnetic beads under magnetic field. Separated beads 
were washed 5 x with RB to remove (any) unbound CPNs, then resuspended in RB to 
make a total of 150µL. 100 µL of this solution was diluted to 2500 µL in buffer and 
placed in a cuvette; the fluorescence emission spectra of PFBT CPNs captured by the 
magnetic beads were acquired using a photon counting spectrofluorometer. The 
fluorescence emission were collected from (480-650) nm using 460 nm excitation. Both 
excitation and emission monochromatic slits were set to achieve a 4 nm band pass. BSA-
coated CPNs and PEG-Lipid methoxy 2000 incorporated CPNs were used as a negative 
control in this experiment. 
 
4.2.8 CELL CULTURE 
The J774 A.1 mouse macrophage like cells were grown in tissue culture flask 
using Dulbecco’s Modified Eagle Medium (DMEM; Mediatech) supplemented with 10% 
heat inactivated fetal bovine serum (FBS; Hyclone), penicillin (100 units/mL), 
streptomycin (100µg/mL), and L- glutamine (2 mM) in a humidified incubator with 5% 
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CO2 at 37ºC until reaching to 70-80% confluence, then plated on glass bottom Petri 
dishes. 
 
4.2.9 NANOPARTICLE UPTAKE 
Cells were grown onto 35 mm tissue culture dishes. The cell culture medium was 
then replaced with serum free DMEM to remove serum proteins. BSA coated CPNs, 
lysozyme coated CPNs, bare CPNs, or PEG-lipid coated CPNs were added to dishes to a 
final concentration of 2 ppm/ ca. 0.24 nM and incubated for two hours to allow cell 
uptake (pulse), before DMEM in the extracellular solution was replaced with warm 
(37ºC) RB (without CPNs) and incubated for a further two hours (chase) before analysis 
of uptake. As a control, a similar experiment was performed on ice. In this case, BSA 
modified CPNs were incubated with J774 A.1 cells on ice for two hours (pulse), after 
which the DMEM was replaced with ice cold Ringer’s buffer and incubated for another 
two hours (chase). Following the 2 h chase, J774 A.1 cells were rinsed 3X with warm 
(37º C) RB, then suspended in ice cold RB by gentle pipetting. Cell-associated 
fluorescence was analyzed using a BD Accuri C6 flowcytometer, using. 488 nm laser 
excitation and green fluorescence channel (FL1) for signal collection. 10,000 cells were 
analyzed for each measurement, and each sample was measured in triplicate. Data were 
analyzed using FlowJo software (Treestar), and uncertainty determined from the mean 
fluorescence of triplicate measurement for each sample. 
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4.3 RESULTS AND DISCUSSION 
Protein adsorption prevents aggregation of otherwise unmodified PFBT 
nanoparticles at physiological salt concentration. We have prepared PFBT nanoparticles 
using the reprecipitation method [29], in which conjugated polymer in a small volume of 
THF are rapidly diluted into water under sonication. Under these conditions, the PFBT 
polymer chains rapidly fold to minimize hydrophobic surface area in contact with water, 
creating nanoparticles. After preparation and evaporative removal of THF, the resulting 
“bare” (unmodified) CPNs had a hydrodynamic diameter of 55± 2 nm, as measured by 
intensity averaged cumulant analysis.  
We believe that conversion of DLS intensities into nanoparticle hydrodynamic 
diameter using cumulant averaging (Z-averaging), as reported here, is the appropriate 
method for measurement hydrodynamic diameter, since it is rigorously supported by light 
scattering theoretical models. DLS diameters for nanoparticles are sometimes calculated 
from number averaged, rather than intensity averaged, scattering data. Unfortunately, 
transformation of light scattering into hydrodynamic diameter using number averaging is 
not supported by theoretical mathematical models. In addition, number averaging 
requires assumptions about refractive index that are rarely reported and if reported, are 
difficult to validate. For size comparison with reports of other CPNs measured via DLS 
number averaging, we have included hydrodynamic radii obtained from both cumulant 
intensity Z-averaging and number averaging (assumed polymer refractive index of 1.40, 
measured for soluble PFBT in THF) for these PFBT CPNs. As shown in Table 1, the 
number averaged hydrodynamic diameter is more than 20 nm smaller than that obtained 
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by cumulant intensity averaging, a result suggesting that use of number averaged DLS 
hydrodynamic diameter can lead to systematic underestimates of true hydrodynamic size. 
For example, we have observed that number averaged analysis lead to estimates of 
nanoparticle size that are 20-30 nm smaller than obtained by cumulant averaging (Table 
S1). Other size determination methods can also underestimate nanoparticle size. For 
example, we have previously reported that the PEG-Lipid PFBT CPN diameter is 24 ± 5 
nm when dried and measured by TEM, while the same nanoparticles in suspension had a 
measured hydrodynamic size of 52 ± 1 nm when measured by intensity averaged 
scattering data [7] and 31 nm diameter when analyzed via number averaged light 
scattering. We assume that smaller sizes reported by TEM relative to DLS reflect CPN 
shrinkage that occurs upon drying. AFM measurements also yield small apparent CPN 
sizes; PFBT CPNs prepared under conditions identical to those used here have reported 
AFM particle heights that vary from 14 nm [30]or 18 nm [31] to 25 nm [32], all 
significantly smaller than measured by DLS intensity averaging. Very small particle 
heights obtained by AFM presumably reflect shrinkage during CPN drying, similar to 
that occurring during TEM, as well as compression of relatively soft CPNs by the 
microscopy tip during measurement. Based on a comparison of light scattering data for 
these and previously synthesized reprecipitated PFBT CPNs [7], we believe the bare 
PFBT CPNs described here to be sized consistently with the actual size of previously 
reported unmodified PFBT CPNs, despite apparent disparities between reported 
diameters.  
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We observed the DLS size of these bare PFBT particles in water over a period of 
2 weeks, at a concentration of 10 ppm/1.2 nM. We observed no apparent change in 
hydrodynamic size (Figure S4), indicating that progressive aggregation does not occur in 
water in the absence of physiological salt concentrations. Similar results have been 
observed for other CPNs [12]. Given the high hydrophobicity of bare CPNs, formation of 
a long-lived nanoparticle suspension in water as observed here is somewhat unexpected 
[1]. Since removal of hydrophobic surface area from contact with water is sufficient to 
drive CPN formation, removal of additional hydrophobic surface area via CPN-CPN 
interactions (i.e. progressive aggregation) could also be expected to occur. However, it 
has been speculated that oxidation defects in individual conjugated polymer molecule 
starting materials could provide enough polarity to promote CPN solubility [1]. In 
addition, a recent study has demonstrated that oxidation defects are introduced into CPNs 
during vacuum removal of THF after CPN formation by reprecipitation [33], which 
would provide additional surface polarity. Local charges induced by chemical defects 
may thus be sufficient to explain both stability in water and the negative zeta potentials 
typically reported for unmodified CPNs [34].  
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Table 1. Comparison of size of PFBT CPNs measured by DLS, TEM and AFM. DLS 
size were measured in water for unmodified PFBT CPNs and PEGlipidmethoxy2000-PFBT 
CPNs; TEM size and AFM data were obtained as described in relevant reference. 
 
 
To compare stability of the PFBT CPNs in water to stability under physiological 
conditions, we exchanged the CPNs into PBS, a buffer solution commonly used to 
approximate physiological conditions, and monitored CPN stability and aggregation over 
time. In this case, aggregation of CPN solutions can be monitored by tracking 
fluorescence intensity over time, since aggregation-induced precipitation and subsequent 
sedimentation reduces the concentration of fluorescent materials in the detection window 
of a cuvette. As shown in Figure 1A, the fluorescence associated with bare PFBT CPNs 
falls dramatically in PBS over a period of hours; loss of fluorescence is essentially 
complete after 12 hours. These results demonstrate that unmodified PFBT nanoparticles 
are not stable under conditions of physiological ionic strength, as has been observed 
 
 
 
Unmodified PFBT 
CPN 
 
PEGlipidmethoxy2000-PFBT 
CPNs 
 
DLS Z-average (nm) 
 
55±2 
 
58±1 
 
Polydispersity Index 
 
0.16 
 
0.14 
 
DLS number average (nm) 
 
32±1 
 
33±1 
 
TEM size (nm) 
 
N/D 
 
24±5b 
 
AFM size (nm) 
 
18±5a 
 
N/D 
 
(a) Fernando L. et al Biomacromolecules, 2010, 11, 2675-2682. 
(b) Kandel et al Nanoscale, 2011, 3, 1037-1045. 
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previously [12]. Unlike unmodified nanoparticles in water, unmodified CPNs in PBS 
aggregate and then precipitate. Hydrophobic aggregation of CPNs in solution mirrors 
commonly observed decreases in the solubility of hydrophobic small molecules and 
hydrophobic particles with increasing salt concentration [35]. Presumably, as the polarity 
of the solvent increases in the presence of higher salt concentrations, the hydrophobic 
driving force for aggregation also increases. At physiological salt, any local CPN surface 
polarity caused by chemical defects may be insufficient to counteract the increased 
hydrophobic driving force, resulting in enclosure of CPN surface area in aggregates. 
 
Fig.1. CPN fluorescence in PBS. (A) Unmodified CPNs incubated in PBS; (B) 
Unmodified CPNs incubated in PBS containing 250 nM BSA. Reductions in fluorescence 
intensity reflect aggregation and precipitation out of the detection window. Inset shows 
the image of CPNs directly after dilution into PBS and after 12 hours, confirming that 
loss of fluorescence reflects CPN precipitation. Error bars represent the standard 
deviation of mean fluorescence. 
 
Protein adsorption forms a hard corona that prevents CPN aggregation. We have 
previously prepared PFBT CPNs with a surface coating of PEG by inclusion of PEG 
A B
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Lipid into the nanoparticle during conjugated polymer preparation. This methodology 
results in a high colloidal stability under physiological conditions [8]. Presumably, the 
resistance to hydrophobic aggregation we observed for PEGylated particles reflects 
shielding of the hydrophobic PFBT surface from the aqueous phase by a layer of PEG. In 
principle, any amphipathic polymer could perform a similar function. We asked whether 
proteins, which contain a mixture of polar and nonpolar regions, could also be used as a 
stable surface coating for CPNs. To test whether protein adsorption to CPNs improves 
colloidal stability under physiological conditions, we incubated prepared bare PFBT 
nanoparticles in solutions of bovine serum albumin (BSA) in PBS. BSA is the most 
abundant blood plasma proteins in mammals and is used extensively to reduce 
nonspecific binding via adsorption to hydrophobic surfaces in biological applications 
such as ELISA [36]. Like other proteins, BSA is a zwitterinoic polymer, whose 
hydrophobic amino acid side chains could be expected to interact with hydrophobic 
CPNs while its hydrophilic amino acid and carboxyl groups could interact with water and 
aqueous solution components. We added both BSA and physiological salt to suspensions 
of unmodified CPNs, and tracked the stability of CPN fluorescence over time. As shown 
in Figure 1B, the fluorescence intensity of CPNs in BSA-containing PBS is stable over at 
least 12 hours, indicating that under these conditions, the CPNs do not precipitate. This 
behavior is in sharp contrast to identical nanoparticles in PBS in the absence of BSA, 
which show profoundly decreased fluorescence at 12 hours as a result of aggregation and 
precipitation over the same time period. 
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We hypothesized that stability improvements in the presence of BSA reflected 
coating of hydrophobic nanoparticle surfaces via adsorption of hydrophobic regions on 
the protein. The resulting protein corona would presumably both stabilize the 
hydrophobic surface and acts as a barrier that occludes the hydrophobic CPN surface, 
with corresponding minimization of CPN-CPN interaction and resulting aggregation. To 
confirm our hypothesis of protein adsorption to the CPN surface, we compared the DLS 
size of CPNs before and after incubation with BSA. While bare PFBT nanoparticles have 
a DLS size of 55 ± 2 nm, CPNs incubated with BSA have a DLS size of 76 ± 2 nm, an 
increase of ca. 40%. Hydrodynamic diameter obtained via DLS is the average diameter 
of all dispersed objects, reflecting the average of the observed scattered light signal 
intensities. As a result, the calculated cumulant Z-averaged hydrodynamic size could be 
skewed by a bimodal (or multimodal) distribution of scattering that reflects contributions 
from small amounts of large particulates such as protein or CPN aggregates. Since larger 
particles (such as aggregates) have larger signal intensities, the presence of even small 
amounts of aggregate can result in substantially increased average nanoparticle size; it is 
correspondingly possible that the observed larger hydrodynamic diameter observed in 
BSA solutions could reflect the presence aggregates rather than size increases caused by 
a shell of adsorbed protein. However, this potential systematic error would be evidenced 
by a bimodal DLS trace; we observed a mono-modal light scattering distribution under 
the conditions of these experiments, indicating the absence of high MW aggregates 
(Figure S5A). In addition, DLS measurements of BSA solutions in the absence of CPN 
could detect no significant light scattering contribution from BSA at concentrations used 
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in the CPN incubations (data not shown). Hence, the ca. 20 nm observed increase in CPN 
hydrodynamic size following incubation of unmodified PFBT CPNs in BSA reflects 
increases in the size of individual CPNs caused by protein adsorption on the CPN 
surface. We note that the dimensions of fully folded BSA has been estimated at ca. 7 nm 
diameter [37], while fully or partially unfolded BSA would be somewhat larger. 
Assuming a BSA monolayer on the CPN surface, the 20 nm size increase observed for 
BSA-adsorbed CPNs thus implies that some BSA unfolding could occur to promote 
interaction of BSA hydrophobic regions with the CPN surface, consistent with previous 
reports of conformational changes in proteins adsorbed to other nanoparticle types [26, 
38-40]. However, modeling of native BSA gives dimensions of 4 by 4 by 9 nm [41]; BSA 
interactions with CPNs exclusively along its short (4 nm) axis would give a BSA 
thickness virtually indistinguishable from the observed 20 nM size increase. 
To compare the protein adsorption between bare and PEG-Lipid coated CPNs, we 
also incubated PEG Lipid-coated PFBT CPNs with BSA solutions. Since PEG is 
routinely used as a surface coating to ameliorate protein adsorption, we expected no 
significant interaction of PEG Lipid-coated CPNs with BSA. Indeed, the PEG Lipid-
coated CPNs demonstrated no appreciable interaction with protein; PEG-Lipid-CPNs did 
not increase in size when incubated with BSA. PEG-Lipid coated PFBT CPNs had a DLS 
size of 58 nm in both PBS and BSA solutions, and was unchanged when monitored over 
7 days (Figure S6).  
To confirm that BSA adsorption to bare PFBT nanoparticles is primarily 
promoted by hydrophobic, rather than electrostatic, interaction(s), we observed both the 
 119 
size and colloidal stability of PFBT CPNs in BSA solutions over the physiological pH 
range (from pH 4-8). Since BSA has a pI of 4.7, this pH range samples both protonated 
and unprotonated forms of the protein, with corresponding changes in net charge. If 
electrostatic interaction had the largest driving role in protein adsorption to the CPN 
surface, then the change in BSA charge with pH would significantly impact BSA 
interaction with the PFBT CPNs, and a change in the DLS size and/or colloidal stability 
between pH 4 and6 would be observed. However, the size of BSA-adsorbed PFBT CPNs 
is largely independent of solution pH (Figure 2A), and no PFBT precipitation is observed 
in BSA-containing solutions at each of pH 4-8 (Figure 2B).  
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 Fig. 2. BSA- CPN stability in high ionic strength buffer over the physiological pH 
range. (A) DLS hydrodynamic size in pH calibration buffers from 4-8; error bars 
represent standard deviation. (B) Images of CPN solutions at different pH values show no 
precipitation. BSA-CPNs were prepared by overnight incubation of unmodified PFBT 
CPNs in pH calibration buffer containing 250 nM BSA and measured without removal of 
excess BSA. Slightly larger hydrodynamic diameters observed here relative to particles in 
PBS or water may reflect the higher total ionic strength of pH calibration buffers relative 
to PBS, since protein conformation and hydrodynamic diameter ae sensitive to ionic 
strength. 
 
Together, these data indicate that adsorption of protein to CPN surfaces likely 
does not have a large electrostatic component, consistent with interactions driven 
primarily by the hydrophobic effect. Similar insensitivity to charge has been observed for 
BSA interaction with polymers on the surface of Au nanoparticles [42]. However, we 
cannot rule out some degree of electrostatic interaction with BSA; negative charges on 
the CPN surface caused by local chemical defects [33] could contribute to electrostatic 
5 6 7 8pH 4
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interaction with BSA, similar to what has been observed for electrostatic interaction of 
CPNs with positively charged polyelectrolyte copolymers in solution [43]. 
PFBT nanoparticles can be modified with a range of proteins. To test whether 
adsorption to the CPN surface reflects a specific interaction of BSA with PFBT, rather 
than a general hydrophobic adsorption phenomenon, we examined adsorption of 
additional proteins to bare PFBT particles. As part of these experiments, aliquots of 
unmodified PFBT nanoparticles were incubated in 250 nM solutions of BSA or 
lysozyme, or in 1% fetal bovine serum (which contains a mixture of serum proteins). The 
relative hydrodynamic sizes were measured to detect protein adsorption. These data show 
that adsorption to hydrophobic CPNs is not specific to BSA. As shown in Figure 3A, the 
hydrodynamic size of PFBT CPNs increased substantially following incubation in each 
protein solution. Further, the zeta potential of protein-coated particles is significantly less 
negative than bare particles (Figure 3B), presumably reflecting occlusion of surface 
negative charges from oxidative defects [33]. CPN zeta potential is less negative for 
lysozyme-coated particles than for those coated with BSA, consistent with the calculated 
charges of the respective proteins (lysozyme pI = 11.35; BSA pI = 4.7). Together, these 
alterations in CPN size and zeta potential of after incubation in proteins solutions indicate 
that a variety of proteins adsorb to the hydrophobic surface of CPNs, with resulting 
alteration of CPN properties.  
 122 
 Fig.3. Stable protein- coated CPNs can be prepared using different proteins. (A) 
hydrodynamic size of 3 nM CPNs incubated with 250 nM BSA, 1% Fetal bovine serum 
(FBS) or 250 nM lysozyme in PBS for 1 day (black bar), 3 days (light gray bar), or 7 
days ( dark gray bar). Error bars represent standard deviation. Prior to addition of 
proteins, bare CPNs had a DLS size of 55 nm. One way ANOVA analysis indicates that 
there is no significant difference in size in BSA (P= 0.412), FBS (P= 0.269), or lysozyme 
nanoparticle size over (P= 0.427) within group at various days, but statistically 
significant difference among treatment groups (P<0.001). (B) Zeta potential measurement 
of protein coated and bare CPNs in Tris buffer at pH 8.0. Error bars represents standard 
deviation of three independent measurements. 
 
 
 
Notably, as shown in Figure 3A, the size of the CPNs incubated in different 
proteins/protein mixtures was not identical. The size difference between lysozyme-coated 
and BSA-coated CPNs could reflect differences in the efficiency of the two proteins’ 
interaction with the nanoparticle surface, as the accessibility and size of hydrophobic 
regions can vary between proteins. However, the size difference between lysozyme and 
BSA-coated CPNs likely also contributes to differences in CPN hydrodynamic diameter. 
BSA         FBS          Lysozyme
A B
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BSA is somewhat larger than lysosome (BSA MW 66,500 kDa and modeled native 
dimensions of 4 by 4 by 9 nm vs. lysozyme MW 14,300 and modeled native dimensions 
of 3 x 3 x 4.5 nm [41]), and BSA-coated CPNs may therefore be expected to have a 
somewhat thicker protein coating than lysozyme-coated particles, consistent with our 
observation. In contrast, CPNs incubated in FBS have size closer to BSA-coated CPNs. 
FBS contains a mixture of proteins, including a high concentration of BSA, and studies of 
the hard corona composition of a variety of nanoparticle types in serum show that BSA 
consistently binds nanoparticle surfaces. As a result, BSA could be a primary contributor 
to the protein corona in FBS solution(s). However, protein corona(s) in complex protein 
in serum typically contain a large number of different adsorbed proteins [15]), and it is 
likely that BSA is not the only component of the CPN corona in FBS solutions.  
We note that CPN size increases are on the large end of what would be expected 
from a monolayer of native protein. However, interaction with nanoparticles often 
induces some degree of protein unfolding [40], which could allow extended protein 
conformations. Indeed, since hydrophobic regions in folded proteins are disproportionally 
located in the protein interior, it is plausible to assume that hydrophobic adsorption to 
CPN surfaces would be accompanied by local unfolding of protein structure to allow 
interaction of interior hydrophobic regions with CPNs. 
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Table 2. Hydrodynamic size of PFBT-BSA CPNs prepared by incubating BSA with 
CPNs after CPN formation. BSA was added in the mentioned ratio of BSA to CPN and 
incubated overnight before size of particles was measured by DLS. 
 
BSA adsorption to CPN surfaces presumably reflects both the affinity of the 
protein for the CPN surface and the concentration of protein in solution. In the absence of 
sufficient protein in solution, the CPN surface could be inadequately covered, and CPN 
aggregation could still occur. To determine the amount of solution BSA required to 
completely coat CPN surface, various molar ratios of protein/ CPN were tested. Molar 
ratios (protein/CPN) less than ca. 50 resulted in aggregation under physiological salt 
Molar 
concentrations 
BSA:CPN 
(nM) 
Molar ratio 
BSA:CPN 
Hydrodynamic 
diameter of PFBT 
CPNs in BSA/water 
(nm) 
PDI Hydrodynamic 
diameter of PFBT 
CPNs in BSA/PBS 
(nm) 
PDI 
750:3 250 (bimodal trace)   (bimodal trace)   
500:3 166 (bimodal trace)   (bimodal trace)   
375:3 125 77±2 0.19 78±2 0.18 
250:3 83 76±2 0.17 76±1 0.16 
200:3 66 68±3 0.15 78±1 0.18 
150:3 50 65±2 0.16 (multimodal trace)   
100:3 33 60±2 0.19 (multimodal trace)   
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conditions, as evidenced by increased DLS size and polydispersity induces in PBS. 
(Table 2). In this case, aggregation at low BSA concentrations presumably reflects an 
incomplete protein coating that is not sufficient to prevent all aggregation. We conclude 
that as long as the protein/CPN molar ratio in the incubating solution was above ca. 80, 
the PFBT CPNs were coated with a complete “corona” of BSA. For BSA solutions, 
molar ratios more than ca. 170 resulted in a small bimodal peak in DLS (Figure S3), 
which could reflect aggregation caused by BSA dimerization at high concentration. 
 
Fig.4 Protein coated CPNs retain their protein coat after removal of solution-phase 
proteins. (A) DLS size of BSA-coated CPNs in the presence of solution phase BSA (left 
hand side; black bars) or after size exclusion chromatography for removal of solution 
phase BSA (right hand side; gray bars). (B) DLS size of lysozyme-coated CPNs in the 
presence of solution phase lysozyme solutions (left hand side; black bars) or after size 
exclusion chromatography to remove solution phase lysozyme (right hand side; gray 
bars). Prior to size exclusion, protein-coated NPs were prepared by incubation of 3 nM 
bare (55 nm) CPNs with 250 nM protein. All protein coated CPNs were suspended and 
stored in PBS. One way ANOVA analysis indicates that there is no significant difference 
in mean size before and after size exclusion for either BSA coated particles (P=0.064) or 
lysozyme coated particles (P= 0.412). 
A B
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Protein adsorption to CPN surfaces is not reversible under normal incubation 
conditions. So-called “hard corona” proteins remain associated with nanoparticles 
following removal from protein solutions, while weaker affinity “soft corona” proteins 
dissociate as a function of low protein concentration, and are not retained under 
conditions of dilution or washing [17]. To determine whether the adsorbed proteins 
coating PFBT CPNs reflects a long-lived coating surrounding the nanoparticle, similar to 
the “hard corona” characterized for other nanoparticle types, we used size exclusion 
chromatography to separate BSA-coated and lysozyme-coated CPNs from excess protein 
in solution. We did not separate FBS protein-coated CPNs from excess proteins in 
solution, as large variation in protein sizes in this complex solution made the separation 
impractical. A comparison of the DLS size of protein-coated CPNs before and after size 
exclusion into PBS (Figure 4) shows no change in hydrodynamic diameter after removal 
of solution-phase protein for both BSA-coated and lysozyme-coated CPNs. Moreover, 
the constant size and resistance to precipitation in PBS persisted over the period of 
observation (7 days). These data indicate that the protein-PFBT interaction does not 
dissociate even under conditions of prolonged incubation in the absence of excess 
protein. Both BSA and lysozyme association with PFBT CPNs is therefore sufficiently 
stable to be considered part of a hard corona, and to persist following removal to alternate 
solution conditions with dramatically lower protein concentration. In order for protein 
adsorption to be useful as a surface modification technique, the protein coating must be 
long-lived under physiological conditions, and not dissociate from the CPN. These data 
indicate that BSA and lysozyme adsorption to PFBT CPNs meets these conditions. 
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Table 3. Comparison of CPN size and spectral properties. Unless otherwise specified, 
all CPN protein coats were formed by incubation of unmodified CPNs in relevant protein 
solutions and unbound protein was removed by size exclusion chromatography; all 
spectral properties are measured in water. 
 
CPN optical properties are not hampered by protein adsorption. To examine the 
effects of a protein corona on CPN optical characteristics, we compared the absorbance 
and emission maxima and quantum yields of bare and BSA-coated PFBT CPNs. 
Quantum yields for bare and protein-coated PFBT CPNs are shown in Table 3; data for 
PEG-Lipid modified PFBT particles are also included for reference. While bare PFBT 
 
Z-average 
hydrodynamic 
diameter (nm) 
Quantum 
Yield (%) 
λmax 
absorption(nm) 
λmax 
emission 
(nm) 
Unmodified PFBT CPN 
55±2 
(PDI 0.16) 
13.6±0.8 462 537 
BSA-CPNs (coat 
formed by incubation 
with BSA) 
76±2 
(PDI 0.16) 
16.2±0.8 458 535 
lysozyme-CPNs  
71±1 
(PDI 0.15) 
14.2±0.6 460 536 
FBS- CPNs 
75± 1 
(PDI 0.18) 
ND ND ND 
PEG Lipidmethoxy2000-
CPNs 
58±1 
(PDI 0.14) 
21±1 459 535 
BSA-CPNs (coat 
formed via 
reprecipitation into 
BSA) 
78±2 
(PDI 0.18) 
15.5±0.8 458 535 
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CPNs in water have a quantum yield of 13.6 ± 0.8 %, the same particles incubated in 
BSA have a slightly higher quantum yield (16.2 ± 0.8%). These data show that protein 
adsorption does not impede, and in fact can improve CPN brightness.  
We have previously observed higher quantum yields for PEG Lipid-modified 
PFBT CPNs than for bare CPNs, and have attributed this increase in quantum yield to 
insertion of lipid between polymer chains in the CPN core, consistent with a small blue 
shift in absorbance maximum relative to unmodified particles [8]. In this case, insertion 
between polymer chains presumably disrupts the intrachain quenching observed for 
tightly collapsed conjugated polymer [44] and results in somewhat higher observed 
quantum yields. To determine whether insertion of hydrophobic moieties into the PFBT 
core could be responsible for the increased quantum yields for protein-coated CPNs, we 
compared the absorption spectra of bare and BSA-coated particles (Figure S7). A small 
blue shift of 4 nm is observed for BSA-coated PFBT CPNs compared to unmodified 
particles. Hence, the increased quantum yield may result from small disruptions in PFBT 
intra-chain interaction caused by insertion of hydrophobic protein groups (presumably 
hydrophobic side chains) between segments of PFBT chain(s) in the CPN core. 
We note that we have previously reported a slightly higher quantum yield for bare 
PFBT CPNs (18 ± 1 % versus 13.6 ± 0.8 %,). These previously described PFBT CPNs 
were synthesized from a different manufacturer’s lot of PFBT, and differences in optical 
properties presumably reflect differences in the PFBT starting material. Optical data 
reported here was the average of three consecutive independent syntheses of PFBT 
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CPNs, and show that for a given lot of PFBT, the reprecipitation method gives highly 
reproducible optical characteristics for each surface modification/coating. 
Protein-modified CPNs can be prepared either by incubation in, or polymer 
dilution into protein solutions. Data shown above demonstrate that bare (unmodified) 
CPNs prepared by reprecipitation into water can be subsequently incubated in BSA 
solutions to produce BSA-modified CPNs. We have previously prepared CPNs with a 
PEG-lipid surface by reprecipitation in water containing PEG lipid. We asked whether 
BSA-modified CPNs could be prepared similarly prepared (i.e. by reprecipitation into 
BSA containing solutions). In this case, BSA would partition into the hydrophobic phase 
(i.e. the PFBT) during conjugated polymer precipitation. To test the efficacy of this 
alternate method of BSA-modified CPNs, we prepared PFBT nanoparticles via 
reprecipitation of PFBT into water containing BSA. Resulting nanoparticles had a DLS 
size that was indistinguishable from that obtained by incubation of unmodified particles 
in BSA solutions (78 ± 2nm versus 76 ± 2), and did not change when observed over 5 
days Fluorescence quantum yield was indistinguishable from that for BSA-coated CPNs 
obtained via incubation of bare CPNs in BSA (Table 2). The dependence of CPN 
hydrodynamic size on PFBT: BSA ratio was also indistinguishable from that obtained for 
incubation of bare CPNs in BSA (Table S2). These observations indicate that 
reprecipitation in the presence of BSA or incubation with BSA after reprecipitation into 
water is equally efficient methods for generation of BSA-coated PFBT CPNs. We note 
that dilution of conjugated polymer (in THF) into BSA solutions exposes the BSA to 
THF, which does not favor native protein structure. Incubation of bare particles with 
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protein solutions may therefore be the desired protein adsorption protocol if preservation 
of native protein folding is crucial. However, since studies of the conformation of 
proteins adsorbed on many different nanoparticles types demonstrate that protein-
nanoparticle interactions can themselves induce local protein unfolding [26, 38, 39], any 
negative impact of possible THF-promoted protein unfolding is likely insignificant.  
Protein adsorption can be used to modify CPNs for molecular recognition. To 
further establish that protein adsorption to CPNs results in a coating on the CPN surface, 
and to determine whether that protein coating could be used for bioconjugation, we 
performed pulldown experiments using biotin-BSA coated PFBT CPNs and streptavidin 
magnetic beads. Biotin is useful as a tether to attach additional recognition moieties via 
the high affinity biotin-streptavidin interaction. We prepared BSA-biotin coated PFBT 
CPNs by adsorption of bare CPNs with BSA-biotin, using protocols similar to those 
established for BSA adsorption. Excess BSA-biotin was removed from the CPN solution 
using size exclusion chromatography. Streptavidin magnetic beads were then incubated 
with a suspension of biotin-BSA CPNs to allow biotin-streptavidin binding. The 
magnetic beads were then removed from solution, washed, and resuspended in additional 
buffer. As shown in Figure 5, a fluorescence scan of the suspended magnetic beads shows 
substantial PFBT fluorescence, indicating capture of biotin-BSA by streptavidin. No 
PFBT fluorescence was observed when the same experiment was performed with either 
PEG Lipid-coated CPNs or BSA coated CPNs which lack the biotin recognition moiety. 
These controls indicate that CPN fluorescence observed for capture of biotin-BSA-
modified PFBT CPNs reflects specific binding of biotin-BSA by the streptavidin beads. 
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Together, these data indicate that surface functionalization of CPNs by protein adsorption 
can be used for conjugation of relevant recognition moieties to the CPN surface; protein 
surface modification of CPNs not only provides solution stability but also a handle for 
bioconjugation. 
 
 
Fig. 5 Streptavidin-magnetic beads capture biotin-BSA modified CPNs. Fluorescence 
emission reflects the presence of BSA-biotin coated CPNs in the solution. Streptavidin 
magnetic beads were exposed to a solution containing biotin-BSA-coated CPNs, 
followed by magnetic bead removal, washing, suspension of beads in fresh buffer, and 
scanning of fluorescence emission associated with magnetic beads. Significant CPN 
fluorescence is associated with beads incubated with biotin–BSA coated PFBT CPNs 
(solid line), while beads incubated with either PEG lipid-coated PFBT CPNs (dotted line) 
or BSA-coated CPNs (dashed line) show no detectable conjugated polymer fluorescence. 
 
 
Protein adsorption substantially increases uptake efficiency. To determine the 
biological impact of a protein corona on CPN uptake in mammalian cells, we used flow 
cytometry to measure the uptake of PFBT CPNs with several different protein coronas 
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(BSA, lysozyme, and serum proteins). To compare these data with our previous uptake 
experiments, we also observed uptake of PFBT CPNs modified with PEG-Lipid. Since 
we have demonstrated that these PEGylated particles do not change size in the presence 
of BSA (Figure S4), PEG-Lipid PFBT CPN uptake represents uptake in the absence of a 
protein corona and serves as a negative control. Cells were incubated with the different 
nanoparticles in protein-free media to allow uptake, followed by washing of cells to 
remove any nanoparticles associated with cells, and the fluorescence associated with each 
cell was counted by flow cytometry. As shown in Figure 6, more than twelve-fold higher 
fluorescence was observed for cells treated with BSA-coated CPNs than cells treated with 
PEG-lipid modified CPNs. Increased cell-associated fluorescence was also observed for 
lysozyme- and serum coated CPNs relative to PEG Lipid particles. Since total 
fluorescence associated with flow cytometry measurements cannot distinguish between 
CPNs taken into cells and those simply localized at the cell surface, we also performed 
uptake experiments in which BSA-coated PFBT CPNs were incubated with cells on ice. 
At these low temperatures, energy dependent cellular uptake (i.e. endocytosis) does not 
occur, and any CPN fluorescence associated with the cell must reflect adsorption to the 
cell membrane, and/or (less likely) diffusion through cellular membranes. Hence, the 
difference between cell-associated fluorescence at physiological conditions and on ice 
reflects cellular uptake via endocytosis. As shown in Figure 6, little cell-associated 
fluorescence is observed for cells incubated with BSA-coated PFBT CPNs on ice, 
indicating that the majority of cell-associated fluorescence reflects energy-dependent 
uptake of the CPNs into the interior of the cell. Taken together, these data demonstrate 
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that the presence of a protein corona substantially increases cellular uptake. The 
efficiency of uptake is reflects both the presence and composition of the protein corona, 
since the uptake efficiency varies both between protein-coated and PEG Lipid-coated 
CPNs, and between CPNs coated with different proteins. 
 
 
Fig. 6 Cellular uptake. Cells in serum free media were incubated with (left to right) 
unmodified PFBT CPNs; PEG-lipid PFBT CPNs, BSA-coated PFBT CPNs, lysozyme-
coated PFBT CPNs at 37⁰ C or with BSA-coated PFBT CPNs on ice (right hand bar). 
Following incubation, cells were exchanged into CPN-free Ringer’s buffer and allowed 
to incubate for an additional 2 h before total CPN fluorescence associated with the cells 
was determined by flow cytometry. Error bars represent the standard deviation of the 
mean fluorescence at 488 nm excitation. 10,000 cells were counted in each measurement. 
 
 
We also examined the uptake of bare CPNs incubated in protein-free media. 
Interestingly, these unmodified particles also showed higher uptake than that observed for 
PEG-Lipid CPNs (Figure 6). In addition, although unmodified particles would be 
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expected to aggregate under the high ionic strength solution conditions found in media 
(similar to those observed in PBS), we observed no signs of CPN aggregation or 
precipitation in the solution conditions of the cellular uptake experiments. Indeed, while 
bare CPNs in PBS aggregate and precipitate in less than two hours, as observed by 
fluorescence intensity changes, bare CPNs in DMEM show no difference in fluorescence 
intensity for at least six hours, although precipitation was observed at a 24 h time point. 
These data suggest that in the absence of proteins, CPNs in media interact with DMEM 
components in ways that increase CPN stability to aggregation and improve cellular 
uptake, albeit with substantially less impact on colloidal stability than offered by whole 
protein adsorption. We examined the components of DMEM for the presence of 
hydrophobic or amphiphilic components that could be interacting with the bare CPNs 
under these conditions. DMEM contains a significant concentration of hydrophobic 
vitamins and amino acids, including those with hydrophobic side chains. We speculate 
that hydrophobic adsorption of these amphiphilic molecules to CPNs is responsible for 
the improved colloidal stability and higher uptake than would be otherwise expected. 
 
4.3.1 DISCUSSION 
Protein adsorption can be a surface modification strategy. Data included here 
demonstrates that while bare CPNs precipitate under physiological salt conditions, CPNs 
modified with a layer of adsorbed protein are stable for long periods. Stable protein-
modified CPNs coated with a protein layer can be generated either by incubation of bare 
CPNs with protein solutions, or by reprecipitation of conjugated polymers into protein-
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containing solutions; we demonstrated protein adsorption of CPNs with BSA, lysozyme, 
and serum proteins present in fetal bovine serum. Together, these data show that proteins 
form a stable corona at the CPN surface that persists even after long incubation in 
protein-free solutions. This result, although not previously documented for CPNs, is not 
unexpected, given the high hydrophobicity of CPNs and the well-documented 
interactions of proteins with other hydrophobic nanoparticle types [15]. Our data 
demonstrate that for CPNs, protein adsorption provides substantial long-term increases in 
colloidal stability. The observed increase in CPN stability with protein adsorption is 
different than the behavior of nanoparticles whose formation and stability results from 
electrostatic interactions, such as DNA lipoplexes, which can be destabilized in protein 
solutions [45].  
Competing methods for protecting CPNs against aggregation under physiological 
conditions chiefly involve incorporation of PEG, PEG-like compounds, or other 
amphiphiles into the nanoparticle surface during CPN formation [11, 12, 46, 47]. For 
example, we have previously demonstrated that extremely stable PFBT CPNs coated with 
PEG can be synthesized by rapid dilution of conjugated polymers into PEG-lipid 
solutions. These PEG coated CPNs resist hydrophobic aggregation over long periods, 
even at high concentrations [8]. However, attempts to stabilize CPNs with a PEG coating 
are not universally successful; Mark Green’s laboratory uses the miniemulsion method to 
produce PEG coated MEH-PPV CPNs that still show signs of aggregation in PBS [13]. 
Similarly, Daniel Chiu’s laboratory has produced PEGylated CPNs, obtained via 
entrapment of polystyrene functionalized with PEG during CPN synthesis, are reported to 
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require an additional BSA passivation step to prevent protein adsorption [11], an 
observation that suggests that PEG moieties do not completely occlude hydrophobic 
surface area in these particles. Data shown here indicates that protein adsorption to CPNs 
can be used instead of PEGylation as straightforward approach to promote long term 
colloidal stability.  
Our data indicate that protein interaction with bare CPNs likely occurs via 
hydrophobic adsorption. Hydrophobic adsorption as a CPN surface modification method 
has been disparaged in a recent review [2], where the authors argue that surface coatings 
created by hydrophobic adsorption can dissociate under extended incubation and are 
therefore undesirable. This argument is somewhat surprising, given the accepted use of 
hydrophobic adsorption as a method for quantum dot surface modification [48] and the 
centrality of hydrophobic adsorption as the driving force for CPN formation. Data 
included here demonstrate that PFBT CPNs coated with protein via hydrophobic 
adsorption can be exchanged into protein-free solutions without dissociation of the 
protein coating, even after extended incubation. Hence, hydrophobic adsorption of 
proteins to CPNs produces highly stable surface modification that does not readily 
dissociate. This observation is similar to studies of protein encapsulated polystyrene 
nanoparticles, in which protein adsorption to the hydrophobic polystyrene surface has 
been described as “essentially irreversible” [17] and studies of interaction of conjugated 
polymer films with BSA which demonstrated that adsorbed protein was retained even in 
the presence of SDS [49]. We conclude that hydrophobic adsorption is highly suitable for 
CPN modification. Notably, since we have demonstrated that protein rapidly adsorbs to 
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CPN surfaces during incubation, we speculate that at least some of the previous reports of 
covalent protein attachment to CPNs may in fact reflect non-covalent interactions. Data 
shown here indicate that significant controls would be required to distinguish between 
covalent attachment and stable protein adsorption, particularly for conjugation protocols 
which incubate protein with CPNs prior to addition of conjugation reagents. 
The Chiu group has incubated CPNs with the amphiphilic polymers poly (styrene 
sulfonate) and poly (sodium methacrylate) as a method to both increase colloidal stability 
of CPNs and allow bioconjugation [12]. After incubation, the CPNs were reported to be 
coated with a shallow (2 nm) layer of polymeric polyelectrolyte, presumably tethered to 
the PFBT surface primarily by hydrophobic adsorption. The resulting coated PFBT 
particles were highly stable in salt solutions, including PBS, a result which corroborates 
the viability of adsorption of polymeric amphiphiles (including proteins) as method for 
increasing CPN colloidal stability. The authors then used the adsorbed coating as the 
foundation for covalent conjugation to protein that was finally utilized, in an additional 
step, for molecular recognition. As an alternative, we have used BSA-biotin as a CPN 
coating material that both increases colloidal stability and can be used to tether 
streptavidin. Together with other results included in this paper, these data demonstrate 
that protein adsorbed on the CPN surface (1) can be substituted for the amphiphilic 
polymers used by Chiu to increase colloidal stability; (2) remains tethered to the CPN 
surface without requirement for covalent attachment; (3) is available for molecular 
recognition, and (4) can be included on the CPN surface during reprecipitation. Hence, 
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we are able to generate stable protein-coated CPNs suitable for molecular recognition 
processes, including bioconjugation, in a single step.  
 
4.4.1 IMPLICATIONS OF PROTEIN CORONAS ON CPNs FOR BIOLOGICAL 
APPLICATIONS 
Our data demonstrate that in biological protein-containing solutions such as serum 
or plasma, bare CPNs do not maintain their conjugated polymer surface, but are coated 
with a stable layer of protein. Hence, the CPN presented to the cell for uptake in 
biological media does not resemble a bare particle. First, the nanoparticle is substantially 
larger than sizes reported for bare particles; while bare PFBT CPNs have an AFM size of 
18 nm and a DLS intensity averaged size of 55 nm [7] in water, they measure 75 nm in 
the fetal bovine serum solutions typically used for cellular uptake and imaging studies. 
Repeated claims have been made about the necessity of small particles for efficient 
uptake, with a focus on nanoparticles smaller than 30 nm [2]. Our data suggest that a 
protein coat is likely to add 18 to 25 nm to DLS intensity-averaged hydrodynamic size, 
and substantially more to sizes reported by TEM diameter or AFM particle height. 
Hence, few (if any) unmodified CPN particles prepared are likely to be smaller than 30 
nm in physiological protein solutions such as serum or plasma. Larger sizes are not a 
barrier to cellular uptake via endocytic processes, as we have demonstrated, but are likely 
to prevent passive diffusion through (ca. 9 nm ) [51] nuclear pores and the (ca. 4 nm) 
[52] tight epithelial junctions between cells. 
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Our data demonstrate that it is the adsorbed protein corona that determines 
cellular uptake, not the conjugated polymer core characteristics. PFBT CPNs coated with 
protein have more than an order of magnitude higher cellular uptake than observed for 
PFBT CPNs lacking a corona (i.e. PEG Lipid-modified PFBT CPNs). Hence, the protein 
coat presented to the cell determines uptake efficiency. The observed impact of a protein 
corona on CPN uptake has implications for the intracellular brightness of CPNs 
compared to competing labels. We have previously used direct comparisons of the 
intracellular brightness of PEG Lipid-modified PFBT CPNs, Q-dots, and dextran-linked 
fluorescent dyes to conclude that CPNs are 37 times brighter than Q dots and 600 times 
brighter than fluorescent dyes when used at equivalent concentrations as intracellular 
fluid phase labels. However, since intracellular brightness is partly a function of uptake 
efficiency, and protein-coated CPNs are taken into cells with at least an order magnitude 
higher efficiency than the PEG-Lipid PFBT CPNs, we can correct these brightness 
estimates to include the impact of increased uptake in the presence of a protein corona. 
Notably, these modified intracellular brightness estimates suggest that in the presence of 
a protein corona, the relative intracellular brightness of protein-coated CPNs is ca. 400 
times higher than that of a representative quantum dot, and at least 6000 times higher 
than dextran-linked fluorescent dyes. 
Formation of protein corona surrounding CPNs in biological solutions has 
additional implications for cellular targeting strategies. In particular, recognition moieties 
tethered to the CPN core can be occluded by formation of a protein coat in serum, as has 
been observed for transferrin-functionalized silica nanoparticles [53]. Hence, formation 
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of a possible protein corona must be considered when designing CPNs for biological 
applications, particularly for strategies that involve conjugation of small targeting groups, 
such as a peptides, or small tethering agents, like biotin. While our PEG Lipid modified 
PFBT CPNs [8] do not measurably adsorb protein(s) and would behave well under these 
circumstances, protein adsorption could be a potential complication for other CPNs, 
including those with a PEG-like surface. For example, an alternative PEG-Polystyrene 
comb-coated PFBT CPN was reported to bind “nonspecifically” to streptavidin (i.e. 
without the presence of biotin) unless incubated in BSA [11]; in other words, this 
nanoparticle type adsorbs protein(s) in solution that could occlude small targeting 
moieties such as peptides.  
One way to bypass complications from protein interference with molecular 
recognition strategies is to use the protein corona itself as the foundation for 
bioconjugation. We have demonstrated that adsorption of biotinylated BSA to PFBT 
CPNs allows capture of the nanoparticles by streptavidin beads. Hence, moieties 
associated with adsorbed protein are accessible for molecular recognition. Protein 
adsorption thus creates an easy and convenient platform for CPN functionalization. For 
example, CPNs adsorbed with BSA-biotin could be linked to any avidin or streptavidin-
linked surface. Similarly, adsorption of streptavidin could be used to functionalize with 
biotin-linked nucleic acid or peptide moieties, while IgG-adsorbed CPNs could be 
utilized for detection in immunoassays. 
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4.4 CONCLUSION 
Taken together, data included here clearly demonstrates that the presence or 
absence of a protein corona surrounding CPNs in solution has important implications 
both for colloidal stability and for the behavior CPNs in biological applications, 
consistent with what has been reported for other nanoparticle types [15, 28]. In the 
absence of strategies to inhibit protein interaction with unmodified CPNs, the surface 
presented to cells is defined by the protein corona, with corresponding impact(s) on 
cellular uptake. Hence, no discussion of the biological applications of CPNs can be 
carried out independently of discussions of protein adsorption. However, if the protein 
coating is defined by deliberate formation of protein-modified CPNs, as demonstrated 
here, then a protein corona may be used as a flexible tool for bioconjugation, rather than 
an experimental complication.  
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4.6 SUPPLEMENTAL FIGURES 
 
Fig. S3. Histogram of size distribution of measured PFBT-BSA CPNs diameter. 
Image was analyzed using Image J software. Gaussian fit to histogram shows the average 
diameter to be 30 ± 2 nm (mean ±SD). 
 
Fig. S4. Hydrodynamic Diameter of unmodified PFBT particles in water over time.  
Size was determined by Z-average cumulant analysis of DLS data. CPN concentration 
was ca. 3 nM. Error bars represent standard deviation of three independent 
measurements. One way ANOVA indicates that there is no statistically significant 
difference between measured sizes over time (P = 0.236).   
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Fig. S5 Monomodal and bimodal light scattering of suspensions of BSA-CPNs. (A) 
DLS trace at 3.0 nM CPN: 250 nM BSA in water. (B) DLS trace at 3.0 nM CPN: 500 nM 
BSA in water. 
 
Fig. S6.  PEG Lipid-PFBT CPNs in presence of BSA. Bar plot shows hydrodynamic 
size determined by DLS Z- average cumulant analysis over a period of one week.  Black 
bars: 5 nM PEG lipid –PFBT CPNs incubated in PBS alone; Gray bars: 5 nM PEG Lipid-
PFBT CPNs in PBS with addition of 250 nM BSA. One way ANOVA  analysis indicates 
that there is no statistically difference in size for PEG Lipid-PFBT CPNs in PBS and in 
PBS with BSA (P=0.262) 
 
BA
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Fig. S7.  Coating PFBT with BSA results in blue shift. Absorbance spectra of bare 
PFBT CPNs (dotted line) with absorbance maximum at 462 nm and BSA-coated PFBT 
CPNs(solid line) with absorbance maximum at 458 nm in water.  BSA- coated CPNs 
were formed by incubation of 3 nM CPNs with 250 nM BSA, followed by size exclusion 
into water to remove non bound BSA. 
 
Fig. S8.  Size Exclusion separation of BSA-CPNs from excess BSA. Solid line shows 
PFBT-BSA normalized absorbance at 460 nm; dotted line shows normalized BSA 
absorbance at 280 nm. Retention time for BSA-coated PFBT CPNs is 15 ± 3 minutes 
(FWHM), and for BSA alone is 21±2 minutes (FWHM). 
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CHAPTER FIVE 
 
FUNCTIONALIZED CONJUGATED POLYMER NANOPARTICLES BY PROTEIN 
ENCAPSULATION AS DETECTION REAGENTS IN SOLID PHASE 
IMMUNOASSAY 
 
5.1 INTRODUCTION 
 
Conjugated polymer nanoparticles (CPNs) are formed by condensation of 
hydrophobic conjugated polymers with ultra-bright fluorescence. The resulting 
nanoparticles have among the brightest fluorescence per unit size of all characterized 
nanoparticles [1], with no observable cytotoxicity [2-4]. Comparisons of the intracellular 
brightness of CPNs with quantum dots and small molecule fluorescent dyes estimate that 
these nanoparticles are (30-40)–fold and 600–fold brighter, respectively, than equimolar 
amounts of either competing label when taken into cells, depending on the individual 
CPN and cell type [5,6]. As a result, these nanoparticles have excited much interest as 
fluorescent labels for cellular imaging, flow cytometry [7], and highly sensitive 
diagnostics. We have demonstrated that both bare and PEG Lipid-coated CPNs are 
efficiently taken into macrophage cells by macropinocytosis and trafficked to the 
lysosome [2,3]. Importantly, lysosomal trafficking enables use of CPNs as ultra-bright 
fluid-phase labels [5]. 
If CPNs are to be used beyond fluid phase labeling, however, the CPN surface 
must be modified with relevant biorecognition moeities. For example, CPNs used as 
labels for nucleic acid hybridization assays must be linked to a specific nucleic acid 
 150 
oligomer; CPNs used for highly sensitive immunodiagnostic detection must be linked to 
specific antibodies. In addition, CPNs could also be applied as bright labels for individual 
cellular locations in live cell imaging if they were bioconjugated to targeting moieties, 
including peptide signal sequences that promote trafficking to specific intracellular 
organelle types, antibodies or proteins that interact with specific cell-surface receptors to 
promote trafficking via known endocytic mechanisms [8-10], or known cell penetrating 
peptides[ 11-13]. Hence, surface modification of CPNs is a prerequisite for effective and 
widespread bioanalytical application. Unfortunately, unmodified CPNs that contain only 
conjugated polymer are not readily amenable to chemical modification, which makes 
direct attachment of targeting moieties problematic. In addition, the highly hydrophobic 
surface of bare CPNs leads to aggregation under physiological salt conditions [14-15] , 
which impedes their application in diagnostics that require physiological buffers. Hence, 
much effort has been expended to generate methods for CPN surface modification as a 
path to both bioconjugation and improved colloidal stability [3, 6, 7, 15-23]. 
Initial surface modifications strategies focused on inclusion of PEG on the CPN 
surface to promote colloidal stability and allow covalent attachment of additional 
functional groups via the reactive endgroup. For example, we have demonstrated that the 
biotin endgroup of PEG on the surface of reprecipitated PEG Lipid-CPNs can be used to 
for tethering of streptavidin–linked antibodies, and have used that interaction for specific 
labeling of cell-surface receptors [3]. Similarly, Howes et al and others have reported 
covalent linkage of a protein to carboxy endgroups present on the PEG Lipid functional 
group of CPNs synthesized by miniemulsion [17, 22]. Instead of using PEG-Lipid, Koner 
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et al incorporated PS-PEG capped with hydroxyl-groups into PFBT CPNs, and then used 
the surface hydroxyl groups to conjugate the surface PEG to streptavidin [20]. A recent 
report uses PEG coupled to DSPE as the encapsulation matrix in miniemulsion CPN 
syntheses, and again takes advantage of PEG endgroups for covalent attachment (in this 
case, to targeting TAT peptide) [18]. 
Other efforts have focused on incorporation of additional (non-PEG) amphiphilic 
polymers into the CPN core during reprecipitation. Wu et al incorporated polystyrene 
“decorated” with PEG-like moieties into CPNs and covalently linked the carboxy 
endgroup to streptavidin, which was subsequently used to tether biotin-linked antibodies 
for cell-surface receptor labeling [6]. The same group also incorporated poly(styrene-co-
maleic anhydride) (PSMA) into reprecipitated CPNs, and then hydrolyzed the maleic 
anhydride endgroups into carboxy moieties to allow covalent linkage via click chemistry 
[16]. In theory, incorporation of amphiphiles should increase colloidal stability by 
reducing surface hydrophobicity. In practice, however, CPNs incorporating amphiphiles 
may still aggregate in biological buffers and/or require additional surface modification to 
ensure stability, depending on the choice of synthesis method and amphiphile, as well as 
the surface amphiphiole density. For example, some CPNs incorporating styrene-based 
amphiphiles were reported to possess long-term stability only after additional protein 
passivation [6], or require additional polyelectrolyte coating to prevent aggregation in 
physiological buffer [15]. Hence, while incorporation of amphiphilic molecules allows 
bioconjugation, it is not a universally effective strategy to generate CPNs that are stable 
under biological or near-biological conditions. In addition, the majority of methods for 
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incorporation of designed amphiphilic polymers into the CPN core require in-house 
polymer synthesis, which makes this strategy unlikely to be generally applied. 
In an alternate approach, the surface of otherwise bare CPNs can be coated with 
molecules that are tethered to the surface by noncovalent interactions. Liu et al. used a 
folate-conjugated cationic triblock copolymer as an adsorbed coating for polyfluorene 
CPNs [24]; the polyelectrolyte coating both increased colloidal stability in physiological 
salt and incorporated folate into the CPN surface to promote cellular uptake via the folate 
receptor. Similarly, Jin et al demonstrated that CPNs prepared by reprecipitation can be 
coated with polyelectrolytes containing interspersed regions of hydrophobicity and 
charge to impede aggregation in physiological buffer and allow bioconjugation [15]. 
Together, these results demonstrate the effectiveness of adsorbed CPN coatings as a path 
to colloidal stability and bioconjugation. 
We have recently demonstrated that unmodified reprecipitated CPNs are coated 
by protein when incubated in protein solutions, including serum. Proteins are, by 
definition, amphiphilic polymers and contain functional groups available for covalent 
attachment. Adsorbed protein can thus serve the same function(s) as the adsorbed 
polyelectrolyte or copolymer coatings used by other researchers to improve stability and 
facilitation bioconjugation. We have demonstrated that a protein corona surrounding 
PFBT CPNs results in higher colloidal stability and cellular uptake than observed for 
CPNs without a protein coat. This protein corona is highly stable and does not dissociate 
from the CPN surface even after removal of excess (solution-phase) protein. In addition, 
using a surface coating of biotinylated BSA, we have demonstrated that protein-coated 
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CPNs can be utilized for biorecognition processes. These observations indicate that 
surface characteristics of protein-coated CPNs are dictated by the protein corona, not the 
CPN core, consistent with what has been observed for silica, polystyrene, iron oxide, 
quantum-dot, and other nanoparticles that also acquire a protein-coat in protein solutions 
[25, 26]. We have also demonstrated that protein-coated CPNs can be formed either by 
incubation of preformed CPNs with protein solutions or more directly, by incorporation 
of protein into the CPNs during reprecipitation. Notably, including protein into the 
aqueous phase during reprecipitation allows straightforward synthesis of protein-
functionalized CPNs in a single step. Here we expand this work to demonstrate that 
incorporation of protein into the NP surface is a flexible and straightforward strategy to 
create CPNs modified with a series of useful biomolecular recognition reagents, 
including neutravidin, biotin, immunoglobulin (IgG), and protein-A. We further 
demonstrate use of these protein-modified CPNs in a series of useful analytical assays. 
 
5.2 MATERIALS AND METHODS 
5.2.1 REAGENTS 
All chemicals and reagents used were commercially available. Each of 
polyfluorene conjugated polymer PFBT (poly[9,9-dioctylfluorenyl-2,7-diyl)- co-(1,4-
benzo-{2,1’,3}-thiadiazole)], (Mw 48,000, polydispersity 2.7.) (American Dye Source), 
neutravidin (Thermo Scientific), polyclonal goat anti-rabbit IgG (GenScript), polyclonal 
anti rabbit (goat) IgG and biotin conjugated anti rabbit IgG (goat) (Rockland antibodies), 
bovine albumin serum (BSA) fraction V, (Omnipur), protein-A (Weed Scientific 
 154 
laboratory), sulfo-NHS -biotin (Thermo scientific) were used without further purification. 
BSA-biotin was prepared by labeling of biotin following pierce protocol for labeling of 
proteins. All water used was Barnstead Nanopure deionized water (18.2 MΩ) that had 
been further filtered through 20 nm PVDF filter (Whatman). 
 
5.2.2 NANOPARTICLE SYNTHESIS 
Protein-modified PFBT CPNs were prepared by reprecipitation, as previously 
described. Briefly, PFBT polymer stock solution was dissolved in tetrahydrofuran (THF) 
to make a 250 ppm solution that was then rapidly diluted 1:10 in 10 mL phosphate 
buffered saline (PBS: 140 mM NaCl, 2.7 mM KCl, 10m M Na2HPO4, 1.8 mM KH2PO4 at 
pH 7.4) containing 250 nM protein, under continuous sonication with a micro-tip 
equipped sonicator (Branson; 45% power, corresponding to 67.5 W). Sonication was 
continued after dilution, to make a total of 2 minutes sonication. The nanoparticle 
suspension was filtered through a 220 nm PVDF membrane syringe filter, and 
nanoparticles were separated from excess protein and THF using size exclusion 
chromatography using Sephacryal S 200 stationary phase as the stationary phase and 
phosphate buffered saline as the mobile phase. The molar concentration of 25 ppm PFBT 
was calculated to be 4.0 nM based on the mass of the conjugated polymer diluted in 
water during reprecipitation, and the size of the CPN core as measured for PBFT-BSA by 
TEM. IgG-functionalized PFBT CPNs with a surface coating of IgG were prepared by 
incubation of Protein-A functionalized CPNs with 250 nM goat IgG in PBS for a period 
of 24 h, followed by removal of excess IgG by size exclusion chromatography, as above.  
 155 
5.2.3 NANOPARTICLE SIZE MEASUREMENT 
The hydrodynamic size of the CPNs were measured by Photon Correlation 
Spectroscopy (PCS), also called Dynamic Light Scattering (DLS), using a Malvern 
Zetasizer (ZS90). DLS experiments were performed in the backscattering mode 
(scattering angle of 173⁰) at 25⁰C using 1x PBS as dispersant. Refractive index of PFBT 
in THF at 25 ppm was 1.40 as measured using refractometer (Abbe refractometer, model 
2WAJ). Prior to each measurement, CPN samples were sonicated for 20 seconds in a bath 
sonicator to remove bubbles and minimize possible transitory/unstable aggregates. The 
Z-average mean hydrodynamic size and polydispersity index were determined and 
analyzed in terms of intensity weighted distributions using cumulant analysis. 
Measurements were performed on each of three separate preparations; the mean and 
standard deviation were calculated for these triplicate data. 
 
5.2.4 SPECTROPHOTOMETRIC MEASUREMENTS 
Fluorescence signal was obtained from emission spectra obtained with a steady 
state spectrofluorometer (Photon Technology International, PTI, Quantmaster), using 460 
nm excitation (2 nm band pass) and emission scanned from 480nm- 650nm (1 nm step: 2 
nm band pass). Fluorescence associated with the CPNs was quantified by integrating the 
emission spectra from 500 nm to 600nm. Absorbance spectra were acquired using 10 
ppm CPNs in PBS with UV-VIS recording spectrophotometer (UV-2501PC, Shimadzu) 
in water. Spectra were collected from 350 nm to 600 nm. 
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5.2.5 SOLID PHASE IMMUNOASSAY 
Antigen (rabbit IgG) was coated on 96 well micro plate surface at various 
concentrations (0.1nM to 200 nM) in phosphate buffer saline (PBS) at pH 7.4 and 
incubated for two hours at room temperature. After removal of non-adsorbed rabbit IgG 
and washing 3 times with washing buffer (PBS/0.05% Tween 20), the well surfaces were 
blocked with 4% non-fat dry milk in PBS/0.05% Tween 2, followed by three washes with 
washing buffer. For immunoassays using detection with neutravidin-functionalized 
CPNs, biotinylated goat anti-rabbit IgG (1:100,000 dilution 4mg/ml stock) (200 µL) was 
added at this point and incubated for two hours in room temperature, followed by three 
buffer washes; other immunoassays proceeded directly to addition of CPN detection 
reagent. The detection agent, CPNs coated with relevant protein (goat anti-rabbit IgG, 
protein-A coupled to goat anti-rabbit IgG, or neutravidin) was added to the final 
concentration of 0.02 nM in 200 µL PBS and incubated overnight at 4°C, followed by 
washing 3 times with washing buffer and addition of 200 µL PBS. Fluorescence intensity 
of CPNs bound to antigen was measured by reading fluorescence in microplate reader 
(Tecan, GENios) using 485 nm excitation and 535 nm emission ( gain 90, and integration 
time 20 µs). Fluorescence intensity was corrected for background (fluorescence of 
antigen wells in the absence of CPNs) and converted to binding plots assuming 1:1 
binding of nanoparticle to antigen. Data were fit to a single site binding isotherm using 
nonlinear least squares analysis in SigmaPlot. 
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5.3 RESULTS AND DISCUSSION 
 
Protein-functionalized CPNs can be prepared in single- step. We previously 
introduced a straightforward reprecipitation method for synthesis of PEG-lipid coated 
CPNs, in which conjugated polymer in a small amount of organic solvent is diluted into 
an aqueous solution of PEG lipid under continuous sonication [3]. As the conjugated 
polymer precipitates, the lipid portion of the PEG-lipid inserts between portions of the 
conjugated polymer chain, while the polar PEG extends out into solution. The result is a 
nanoparticle composed of a conjugated polymer core surrounded by surface corona of 
PEG. We recently demonstrated that direct substitution of protein for the PEG-Lipid 
results in CPNs modified with a surface layer of protein. In this case, hydrophobic 
patches on the protein presumably interact with the hydrophobic conjugated polymer 
during synthesis and are incorporated into the CPN surface during particle formation, 
leaving hydrophilic regions on the protein free to extend out into solution. Given the 
importance of protein-modification for bioconjugation of protein, we asked whether this 
one-step reprecipitation protocol could be used to prepare CPNs coated with protein 
moieties useful for bioanalytical or diagnostic assays. We chose test proteins with high 
utility in a variety of molecular recognition strategies: neutravidin (which can be used to 
tether commercially available biotin-linked recognition moieties such as nucleic acids, 
peptides, and antibodies), a representative polyclonal IgG (in this case, goat anti-rabbit 
IgG); and protein-A (which specifically binds the constant region (Fc) of IgG molecules 
and can therefore be used as a foundation for tethering any IgG). We also included 
biotinylated BSA as a test protein; we have previously demonstrated that biotinylated 
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BSA adsorbed to the CPN surface serves to effectively present biotin for streptavidin 
recognition but had not previously incorporated biotinylated BSA into CPNs directly 
during reprecipitation, as carried out here. Our goal was to create a toolbox of protein-
coated CPNs that could be used in a wide variety of molecular recognition and detection 
applications. 
To prepare the protein-coated CPNs, PFBT dissolved in a small volume of THF 
was diluted ten-fold into a solution of the relevant protein in water, under brief (2 min) 
sonication, as previously described. A recent study of protein corona formation around a 
variety of nanoparticle types indicates that protein corona formation can be rapid (less 
than 30 s) [27, 28] and a stable corona is likely to coat the CPN completely during 
sonication. CPNs formed were immediately removed from both THF and excess 
(unincorporated) protein was removed via size exclusion chromatography into either PBS 
or water, depending on the desired application. The result was a suspension of protein-
coated CPNs, created in a single step. Notably, this direct method takes dramatically less 
time than other protocols for synthesis of CPNs adsorbed with amphiphiles, since it 
requires neither an overnight evaporation to remove THF nor an extended incubation 
with polyelectrolyte or amphiphiles.  
Following CPN synthesis, we used dynamic light scattering to verify nanoparticle 
production and to determine the respective hydrodynamic diameters of protein-coated 
particles. Comparison of the size of CPNs prepared using this protocol to that for 
unmodified (bare) CPNs prepared in the absence of added protein shows significantly 
increased hydrodynamic radius (Table 1) reflecting the presence of a protein layer 
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surrounding the CPN core. Bare (unmodified) PFBT CPNs in water have a hydrodynamic 
diameter of 55 nm. However, the hydrodynamic diameters for PFBT CPNS prepared by 
dilution into protein solutions ranged from 80 nm (BSA-biotin coated CPNs) to 146 nm 
for anti-rabbit IgG-coated CPNs. The relative sizes of the different CPNs are consistent 
with the size of the different proteins incorporated at the CPN surface and roughly follow 
the relative protein sizes; the largest hydrodynamic diameter is obtained for CPNs coated 
with IgG (MW 150 000 kDa) while the smallest hydrodynamic diameter is obtained for 
CPNs coated with BSA (MW 66.5 kDa). Size increases do not strictly mirror the sizes of 
the free proteins (i.e. increases in CPN diameter are not exactly twice the solution-phase 
diameter of the incorporated proteins). A number of studies have suggested that protein 
unfolding can occur upon binding to hydrophobic nanoparticles [29-31], presumably to 
allow interaction of hydrophobic residues in the protein interior with the nanoparticle 
surface. Hence, the diameter of a monolayer of proteins at the CPN surface is expected to 
be somewhat different than the diameter of the same proteins in solution. 
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Table 1. Size Characteristics of Protein-coated PFBT CPNs. Hydrodynamic diameters 
CPNs were obtained by Z-average cumulant analysis of Light Scattering; measurements 
of protein-encapsulated CPNs were in PBS); bare particle data were obtained in water to 
avoid aggregation. Low Polydispersity Indices reflect uniform coating of PFBT Nps; the 
PFBT polymer itself has some polydispersity, which contributes to observed 
polydispersity indices. Bare PFBT CPNs prepared under similar conditions have a zeta 
potential of -36.7 ± 0.9 mV.  
 
 
 
CPN composition 
 
Hydrodynamic radius 
(Z-avg) in buffer (nm) 
 
Polydispersity 
index 
 
Zeta potential 
(mV) 
Neutravidin-PFBT 114 ± 2 0.12 -28.0 ± 0.9 
Anti-rabbit IgG-
PFBT 146 ± 3 0.11 -22.4 ± 0 .9 
Protein A-PFBT 106 ±1 0.16 -14.2±0.9 
Biotin-BSA-PFBT 80 ± 2 0.12 -26 ± 1 
 
We also measured the zeta potential of both bare and protein-coated CPNs. We 
have previously reported that bare PFBT Nps have a significantly negative zeta potential, 
and that a protein corona surrounding CPNs results in less negative zeta potentials 
(Ackroyd and Kandel, submitted manuscript), consistent with occlusion of conjugated 
polymer oxidative defects[32,33] by less negatively-charged protein molecules at the 
CPN surface. As shown in Table 1, direct incorporation of protein at the CPN surface 
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during reprecipitation reduces the observed zeta potential in a similar and protein-specific 
fashion. While our uncoated PFBT CPNs have a zeta potential of -36.7 ± 0.9 mV, zeta 
potentials for protein-coated CPNs ranged from -28 to -12 mV. In addition, the zeta 
potential measured for PFBT NPs with a surface coating of biotinylated BSA (-26 ± 1) is 
indistinguishable from the value previously measured for BSA-coated CPNs (-26.0 ± 0.5 
mV) (Ackroyd and Kandel, submitted manuscript). Together, the size and zeta potential 
measurements confirm formation of a protein coat surrounding PFBT CPNs upon 
precipitation into protein solution.  
 
5.3.1 COLLOIDAL STABILITY OF PROTEIN COATED CPNs 
Protein-coated PFBT CPNs shows colloidal stability in buffer solution. Our CPN 
reprecipitation protocol results in protein-coated CPNs in water or buffer, without 
solution-phase protein. As shown in previous work, the size exclusion chromatography 
step results in removal of essentially all excess (non-adsorbed) protein. Hence, removal 
of unbound proteins could favor protein dissociation over time. However, in the case that 
protein-CPN affinity is very high, and/or multi-site interaction results in high avidity, the 
half-life of bound protein can be sufficiently high that essentially no protein dissociation 
will be observable, as has been reported for other nanoparticle types [34]. To evaluate 
whether adsorbed protein was retained on the CPN surface over time, we evaluated the 
hydrodynamic diameter of the different protein-coated CPNs over a period of 7 days. 
Figure 1 shows a representative DLS diameter time course over time. For CPNs adsorbed 
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with IgG, protein-A, or biotinylated BSA, no size change was observed over time (Figure 
1), clearly reflecting stable adsorption of these proteins to the CPN surface. 
Neutravidin coated particles had stable measured sizes for at least three days 
(Figure 1). However, measurements at 7 days show approximately two-fold increases in 
measured size. We conclude that while neutravidin-coated particles are stable for several 
days, they are best used soon after synthesis. In principle, observed neutravidin-CPN size 
changes after time could reflect protein dissociation from the CPN surface over time.  
 
Fig. 1. Colloidal stability of protein-encapsulated CPNs in physiological salt.  Data 
reflects intensity-weighted Z-average mean hydrodynamic size of PFBT CPNs 
functionalized with biotinylated BSA (closed circles), Protein-A (closed triangles), IgG 
(open circles), and neutravidin (open squares).  CPNs were stored and analyzed in PBS.  
Error bars (largely occluded by symbols) reflect standard deviation of triplicate data. 
  
 163 
Alternatively, since neutravidin exists as a tetramer, slow exchange between neutravidin 
monomers on different nanoparticles could result in gradual aggregation. To determine 
whether neutravidin dissociation from the CPN surface is occurring, we observed the 
DLS size of neutravidin-coated particles stored in water rather than PBS. Since bare 
particles do not aggregate in water over this time period, any dissociation of neutravidin 
from the CPN surface would be observable as a measured decrease in observed DLS size. 
We note that the hydrophobic driving force for protein adsorption is higher in salt 
solutions than in water, so that any protein dissociation from the CPN would be more 
pronounced in water than in buffer. We observe no change in the DLS size of 
neutravidin-coated CPNs in water after 7 day incubation (data not shown). We conclude 
that appreciable neutravidin dissociation from the CPN surface does not occur, and that 
change in the size of neutravidin-coated CPNs in buffer at 7 days likely reflects 
neutravidin-neutravidin interaction(s) rather than protein dissociation from the CPN 
surface. 
Together, these DLS time-course data indicate that adsorption of each of IgG, 
protein-A, biotinylated BSA or neutravidin to the PFBT core is highly stable; protein 
adsorption under these conditions is “essentially irreversible” [34] and protein adsorption 
to the CPN core can be considered part of a highly stable “hard corona”. Stable protein 
adsorption is perhaps not surprising, given the high surface hydrophobicity of PFBT 
CPNs. Other studies of protein interaction with nanoparticles have demonstrated that 
protein adsorption increases as the surface hydrophobicity increases [35, 36] and that 
 164 
protein affinity for hydrophobic nanoparticles is greater than protein affinity for 
hydrophilic nanoparticles [37]. 
Table 2. Spectral properties of protein-coated CPNs. For comparison with bare CPNs, 
which aggregate in PBS, all data were obtained in water using fluorescein as the 
reference fluorophore. Emission maxima of protein-functionalized PFBT CPNs were 
indistinguishable from bare.  
 
CPN composition ABSORBANCE MAXIMUM (nm) 
QUANTUM YIELD 
(%) 
PFBT in water 460.0 13.7± 0.1 
Neutravidin-PFBT 459 13.2± 0.1 
Anti-rabbit IgG-PFBT 459.4 15.1± 0.1 
Protein A-PFBT 461.6 14.7 ± 0.1 
Biotin-BSA-PFBT 459.2 15.3 ± 0.1 
 
5.3.2 SPECTRAL PROPERTIES OF PROTEIN- COATED PFBT CPNs  
If protein-functionalized CPNs are to be effectively used as detection reagents for 
biorecognition, the protein coating must not substantially diminish CPN fluorescent 
brightness. We investigated the quantum yield of each of protein-A, IgG, and BSA-biotin 
encapsulated CPNs, and compared them to bare particles. As shown in Table 2, these 
protein-encapsulated CPNs largely retain the spectral properties of unmodified CPNs, 
consistent with our previous observations of CPNs with other protein coronas. We have 
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previously observed that PEG-Lipid coated CPNs show significant increases in quantum 
yield relative bare CPNs, and have interpreted that observation as reflecting insertion of 
lipid in between polymer chains in the CPN core, a process that alleviates fluorescent 
quenching caused by tight chromophore packing [3]. Data in Table 2 suggests that 
insertion of hydrophobic residues into the CPN core may be occurring; however, any 
impact on observed quantum yield or absorbance maxima is small and protein-dependent. 
 
5.3.3 PROTEIN-A CPNs AS SCAFFOLDS FOR CPN LINKAGE TO IgG  
We have prepared PFBT CPNs coated with protein-A as a general scaffold for 
bioconjugation to a series of IgG molecules. Protein-A binds the constant region of IgG 
molecules, well away from the antigen binding site, and should therefore capture IgG 
molecules and present them in an orientation that allows efficient antigen binding. As 
proof of principle for IgG attachment to protein-functionalized CPNs, we incubated 
protein-coated CPNs with polyclonal IgG (in this case, goat anti-rabbit IgG). While the 
DLS diameter of protein-A PFBT CPNs was 106 ± 1 nm, the same CPNs incubated with 
IgG had a DLS diameter of 158 ± 3 nm, reflecting tethering of a layer of IgG to the 
protein-A CPN surface. Similarly, when protein-A coated CPNs were incubated with 
IgG, their zeta potential changed from -14.7 ± 0.1 to -12.0 ± 0.4 mV, consistent with 
significant alteration of the CPN surface. No size increases were observed when protein-
A coated CPNs were incubated with BSA. We conclude that protein A adsorbed on the 
CPN surface specifically binds IgG.  
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To demonstrate the utility of the resulting IgG-linked Protein-A CPNs for 
application(s) in immunoassays, we carried out a solid phase sandwich immunoassay in 
which various concentrations of antigen (polyclonal rabbit polyclonal IgG, in this case) 
were adsorbed on 96-well plates and detected using IgG tethered to protein-A CPNs, as 
described above. Representative data are shown in Figure 2. Consistent with antigen-
antibody interaction, bound CPN fluorescence changes as a function of antigen 
concentration, and the resulting data can be fit by a single site binding isotherm to yield a 
Kd of 5.4 ± 0.7 nM. Plate immunoassays generally require enzyme-linked amplification 
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to allow readout. In this case, very high CPN fluorescence brightness allows detection of 
antigen over a large concentration range without any requirement for signal 
amplification. 
We designed the assay in Figure 2 to reflect antibody-antigen interactions (i.e. 
goat anti-rabbit IgG binding to antigen), and not protein-A interaction with antigen rabbit 
IgG. However, since both partners of the antibody-antigen pair we have chosen are IgG 
in this case, it is theoretically possible that observed CPN fluorescence in the 
 
Fig. 2 Solid phase immunoassay with detection by Protein-A functionalized CPNs.  
Antigen (rabbit IgG) adsorbed to 96-well plates was detected by goat anti-rabbit IgG 
tethered to protein-A coated PFBT CPNs.  Resulting CPN fluorescence data were fit to 
the single site binding isotherm.  
free antigen concentration (M)
1e-11 1e-10 1e-9 1e-8 1e-7 1e-6
%
 to
ta
l f
lu
or
es
ce
nc
e
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
 168 
immunoassay could reflect protein-A interaction with antigen IgG rather than primary 
IgG interaction with antigen IgG. Relatively large (52 nm) increases in the size of 
Protein-A coated CPNs upon exposure to IgG suggests that any uncapped Protein-A is 
likely hidden behind a surface layer of IgG, and is sterically inaccessible to antigen. In 
addition, we observe close agreement between Kd values in immunoassays that use a 
PFBT- protein-A-IgG sandwich and those using PFBT directly adsorbed with IgG (see 
below), consistent with binding of antigen rabbit IgG by anti-rabbit IgG, rather than 
protein-A.  
 
5.3.4 IgG ADSORBED CPNs AS DETECTION AGENT IN IMMUNOASSAY(S)  
While we have demonstrated that protein-A CPNs can be used to tether IgG for 
immunoassays, it would be advantageous to use IgG-coated CPNs without requirement 
for a mediating protein-A layer, since the resulting particles could be formed in a single 
synthetic step. However, direct IgG adsorption has the potential to occlude antigen-
binding region of the antibodies if the IgG complementarity determining region interacts 
with the CPN surface. The result could be an IgG-coated CPN that, while stable, would 
not appreciably bind antigen. To investigate the antigen-binding effectiveness of IgG-
coated CPNs prepared by reprecipitation of PFBT into IgG solutions, we incubated CPNs 
modified with goat anti-rabbit IgG with antigen (in this case, rabbit IgG). The DLS 
diameter of the IgG-coated PFBT CPNs was 146 ± 2nm, while the diameter after 
incubation with antigen was 163 ± 2 nm, reflecting antigen binding by IgG on the CPN 
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surface. Hence, even after adsorption/incorporation into the CPN surface, the IgG 
molecules retain the ability to bind antigen. We cannot rule out the possibility that some 
of the adsorbed IgG is positioned on the CPN surface in a way that impedes antigen 
binding, since a variety of antibody orientations (and conformations) on the CPN surface 
are possible. However, the DLS and solid-phase immunoassay demonstrate that a 
sufficient quantity of IgG on the CPN surface is oriented to allow stable antigen binding. 
To further demonstrate that IgG-coated CPNs bind target antigen, and can be used 
as a specific detection reagent in bioanalytical assays, we carried out additional solid 
phase immunoassays. As for the previous assay, different concentrations of antigen 
 
Fig. 3.  Solid phase immunoassay with detection by IgG-adsorbed CPNs.  
Antigen (rabbit IgG) adsorbed to 96-well plates was detected by PFBT CPNs 
functionalized with anti-rabbit IgG. Resulting CPN fluorescence data were fit to the 
single site binding isotherm.  
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(rabbit IgG) were adsorbed onto 96-well plates using IgG-coated CPNs. In this case, 
bound antigen was detected with PFBT CPNs coated with goat anti-rabbit IgG. The 
resulting sigmoidal binding curve is shown in Figure 3. A fit of the single site binding 
isotherm to this data yields an apparent antibody-antigen Kd of 5.5 ± 0.8 nM, a value 
indistinguishable from that obtained in Figure 1, which used IgG tethered to protein A –
coated CPNs as the detection reagent. Agreement between Kd values obtained from these 
different methods of coating CPNs with IgG suggests that IgG directly adsorbed to the 
nanoparticle surface binds antigen as effectively as IgG tethered to CPNs via protein-A.  
Neutravidin-coated CPNs serve as a scaffold for bioconjugation to biotin-linked 
recognition moieties. In principle, neutravidin-coated CPNs can serve as a scaffold for 
attachment of any biotin-linked recognition moiety. Since biotin-linked nucleic acids, 
peptides, and antibodies are commonly available, neutravidin PFBT CPNs can readily 
serve as highly bright labels for any diagnostic or cellular imaging sandwich assay that 
uses these recognition moieties. To demonstrate that a neutravidin corona on PFBT CPNs 
can be used to tether biotinylated reagents, we incubated neutravidin-coated PFBT CPNs 
prepared by reprecipitation together with biotinylated goat anti-rabbit antibody. As a 
control, we also incubated the neutravidin-PFBT CPNs with BSA. The DLS 
hydrodynamic diameter of the neutravidin antibodies increased when incubated in 
biotinylated antibody from 114 ± 2 nm to 162 ± 2 nm, reflecting a surface antibody layer 
mediated via the biotin-streptavidin interaction; no size increase was observed for the 
same nanoparticles incubated in BSA (111 ± 2 nm versus 114 ± 2 nm in the presence of 
BSA).  
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As a demonstration of the utility of these neutravidin-coated CPNs as a highly 
bright detection label, we carried out a sandwich immunoassay in which antigen binding 
by biotinylated antibody was detected using freshly synthesized neutravidin-PFBT CPNs. 
Various concentration of a primary antibody (rabbit IgG) were adsorbed to a 96-well 
plate. A complementary biotinylated secondary antibody (biotinylated goat anti-rabbit 
IgG) was used to bind adsorbed primary antibody, and then detected via fluorescence 
associated with the neutravidin CPNs. The resulting sigmoidal binding curve (Figure 4) 
fits a single site binding isotherm, yielding IgG-antigen Kd of 4.5 ± 0.7 nM, a value 
indistinguishable from that obtained from previous plate assays using the same antigen-
antibody pair, but detected using CPNs with different protein coats. 
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Adsorbed protein layer is retained under serum conditions. Vroman described a 
picture of protein interaction with manmade materials in which an initial protein layer is 
defined by binding kinetics and populated with proteins with high on-rates, although not 
necessarily high equilibrium affinities [38]. This initial layer would then change over 
time as low affinity proteins with high on-rates were displaced by higher affinity proteins 
with slower on-rates [28, 39]. A similar process could operate for nanoparticles; a protein 
coat surrounding a nanoparticle could be altered by the presence of competing proteins in 
solution, with the result that any functionalization offered by a protein corona would be 
undermined in serum or intracellular solutions [26]. To determine whether CPNs 
 
Fig. 4.  Solid phase immunoassay with detection by neutravidin-adsorbed CPNs.  
Antigen (rabbit IgG) adsorbed to 96-well plates was detected by a sandwich of 
biotinylated goat anti-rabbit IgG and neutravidin-functionalized PFBT CPNs.  Resulting 
CPN fluorescence data were fit to the single site binding isotherm.  
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functionalized with proteins would be compromised by the competition with serum 
proteins, we compared plate immunoassays carried out in the presence of fetal bovine 
serum. Using a protocol analogous to that used to obtain Figure 2, various concentrations 
of antigen (rabbit IgG) were detected by measurement of CPN fluorescence after 
overnight incubation with IgG-functionalized CPNs in 10% fetal bovine serum. Under 
these conditions, CPN would bind antigen only in the case that the relevant protein 
corona was not displaced by serum proteins. As shown in Figure 5, IgG-functionalized 
CPNs bind target antigen even after overnight incubation with competing serum proteins. 
Analysis of the resulting binding curve yields an IgG-antigen dissociation constant of 2.1 
± 0.5 nM. We conclude that protein corona-functionalization of CPNs is sufficiently long 
lived to allow biorecognition in the presence of competing proteins. 
 
Fig. 5. Solid phase immunoassay with CPN detection in the presence of serum.  
Antigen (rabbit IgG) adsorbed to 96-well plates was detected by goat anti-rabbit IgG 
tethered to protein-A coated PFBT CPNs in the presence of 10% FBS.  Resulting CPN 
fluorescence data were fit to the single site binding isotherm.  
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5.3.5 DISCUSSION 
Data provided here demonstrates that direct protein adsorption during synthesis 
allows straightforward protein encapsulation of CPNs. If the CPNs are formed by 
reprecipitation into protein solutions and excess protein and residual solvent are 
immediately removed by size exclusion, as performed here, then protein-functionalized 
CPNs can be synthesized quickly, in a few hours, without requirement for overnight THF 
removal or extended incubation in protein solutions. This protein coating both improves 
colloidal stability under physiological salt conditions and allows CPNs to be 
functionalized with proteins of biological interest. We demonstrate modification of PFBT 
CPNs with relevant recognition proteins, including protein-A, immunoglobulin, 
neutravidin, and biotinylated BSA. Together, this collection of CPN surface modification 
should allow easy adaptation of ultrabright CPNs as detection reagents for a range of 
useful bioassays. Hydrophobic CPNs have not, in general, been utilized as detection 
reagents for in vitro diagnostic assays, with limited proof of principle exceptions [7, 40, 
41]. However, this easy protein functionalization has the potential to greatly expand CPN 
utility, provided that the protein corona is both stable and available for biorecognition.  
Since the protein coronas formed here are not covalently linked to the CPN 
surface, one potential criticism is that the protein corona could dissociate from the CPN 
surface over time. The result would be loss of both functionality and colloidal stability in 
buffer, with resulting loss of overall utility. Our observations of DLS size after extended 
incubation in protein-free solutions indicate that dissociation of the tested coronas does 
not occur at an observable rate, either because the hydrophobic adsorption is sufficiently 
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stable, or because multisite interaction (avidity) ensures that single-site dissociation is 
followed rapidly by re-association. Hence, the relevant protein coronas are not readily 
removed from the CPN core; protein functionalization via adsorption is highly stable.  
Several protein corona studies have indicated that protein adsorption can result in 
partial protein unfolding and/or denaturation [29-31, 42]. Hence, a stable adsorbed 
protein coat may not be able to perform its relevant endogenous function, since 
adsorption could alter conformation sufficiently to preclude biomolecular recognition. 
We have not carried out a systematic study of the degree of protein unfolding caused by 
CPN binding. However, our investigations of the binding activity of CPNs functionalized 
with IgG, protein-A, and neutravidin indicates that when directly adsorbed to PFBT 
CPNs, these proteins form stable complexes with their relevant binding partners. While 
protein adsorption to CPNs could involve a variety of protein orientation and 
conformations, some of which could be sterically or conformationally inappropriate for 
molecular recognition, our DLS and immunoassay data shows that a substantial portion 
of the protein corona is both accessible and sufficiently folded for binding. Indeed, 
apparent Kds obtained from IgGs tethered to CPNs via protein-A was identical to that 
from IgGs directly adsorbed to the CPN surface. In this case at least, direct adsorption 
has no apparent impact on binding affinity.  
An additional potential concern is that relevant protein functionalization could be 
displaced by competing proteins present in biological solutions (e.g. in serum or under 
intracellular or intra-organellar conditions) [26, 43]. In that case, formation of a stable 
corona in protein-free solutions does not imply stable protein functionalization under 
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individual assay- or cellular imaging conditions. To investigate whether a preformed 
protein corona can survive in the presence of competing proteins, we compared results of 
plate immunoassays in the presence and absence of serum. We obtained sigmoidal 
binding curves under both conditions, with mildly higher affinity binding in the presence 
of serum presumably reflecting tighter binding under increased osmotic stress. While we 
cannot rule out the possibility that serum proteins could have displaced some portion of 
the protein-A corona during the course of the overnight incubation with serum, it is clear 
that sufficient protein functionalization remains for biorecognition; these protein- 
encapsulated CPN can be used as detection reagents in the presence of competing 
protein(s), such as those present in serum or inside cells.  
Recent modeling of nanoparticle protein corona formation argues that in mixed 
protein solutions, an initial metastable corona of a specific composition will change over 
time to a more stable composition [28, 39]. Since we have chosen our protein coronas for 
practical utility rather than known highest equilibrium affinity for the CPN surface, this 
model suggests that displacement of the preformed corona by higher affinity plasma or 
serum proteins could be a significant experimental complication, particularly for 
experiments requiring long incubations. However, our protein corona functionalization 
varies from the model in that the functionalized CPNs start with a preformed and stable 
protein corona (a “hard corona”) before exposure to the mixed protein solution. Studies 
of the protein composition of the corona surrounding different nanoparticle types over 
time in complex protein mixtures indicates that while the percentage composition of 
corona proteins can change over time [43], so does the density of proteins in the 
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corona[34,39,44,45]. Importantly, after a relatively dense protein monolayer is achieved, 
few overall changes in protein composition occur [34]. While the concurrence of a dense 
associated protein layer and minimal changes in composition has typically been 
interpreted as reflecting binding of proteins with the highest equilibrium binding affinity 
[26], an alternate explanation is that a dense existing protein coat causes competing 
solution-phase proteins to be largely excluded from proximity to the CPN surface, much 
as a high density large MW PEG coat excludes competing proteins. Hence, in the 
presence of a dense protein layer, the avidity of protein adsorption could cause re-
association of a given protein with the CPN surface before any solution phase proteins 
could approach closely enough to exchange into the hard corona, regardless of the 
relative affinities of the different proteins. We hypothesize that incorporation of protein 
into the CPN core during formation (i.e. a performed hard corona formed during CPN 
synthesis) promotes a sufficiently high protein density that solution phase proteins are 
excluded from the CPN surface, with the result that displacement by competing proteins 
is minimized. Other groups have reported that for individual nanoparticle types, a 
preformed corona was not displaced by serum proteins [27, 46], and that a preformed 
corona was protective against competing protein adsorption [47]. 
 
5.4 CONCLUSION 
The easy methodology for production of highly stable protein-functionalized 
CPNs reported here allows flexible application of CPNs as detection reagents for 
virtually any in vitro molecular recognition assay. For example, IgG-functionalized CPNs 
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(formed either by direct IgG adsorption or tethered to Protein-A adsorbed on the CPN 
surface) can be used as detection reagents in a range of immunoassays, as demonstrated 
here. Depending on the choice of IgG, these functionalized CPNs could also be used as 
specific labels in western blotting, fixed cell imaging, or diagnostic assays. Neutravidin-
functionalized CPNs are a flexible foundation for tethering the range of available 
biotinylated reagents to the CPN surface. In all of these applications, the high inherent 
brightness of the CPNs would be a huge advantage. It is our expectation that 
straightforward and relevant protein functionalization, as demonstrated here, will greatly 
increase the widespread use of CPNs as fluorescent labels for sensitive detection in 
bioassays.  
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CHAPTER SIX 
GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
 
The impetus for studying conjugated polymer nanoparticles (CPNs) comes from 
their high fluorescence brightness and reasonable photostability. As such, CPNs find 
applications in cell labeling, sensing, and long term imaging. However, such applications 
are hindered by the inertness of the CPN surface as well as the limited colloidal stability 
of CPNs in biological media. The research presented in this thesis developed and 
characterized several methods of surface passivation to functionalize CPN surface and 
maintain colloidal stability in high ionic strength solution. 
Here, we prepared extremely bright, functionalized and stable conjugated polymer 
nanoparticles by the inclusion of end group functionalized PEG-Lipids. We demonstrated 
that functionalized nanoparticles exhibit improved optical properties, long term solution 
stability and can be used for targeted cellular labeling of cell surface markers. In another 
study, we compared the fluorescence brightness of cells loaded with PEG-Lipid modified 
CPNs to cells loaded with quantum dots (Qdots) and dextran linked small molecule 
organic dye of similar sizes. Our results showed that CPNs are 175x brighter than Q dots 
and 1400x brighter than Alexa fluor when evaluated in flow cytometry. Our data suggests 
that extreme brightness of CPNs allow the use of extremely low loading concentration 
indicating CPNs are appropriate and attractive candidates as fluid phase markers.  
In a subsequent chapter, we characterized and tested methods of protein 
adsorption on the CPN surface to provide colloidal stability and to allow bioconjugation. 
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Unmodified hydrophobic CPNs tend to aggregate in saline solution and biological media 
with high salt concentration. We found that incubation of CPNs with proteins such as 
bovine albumin serum, lysozyme, and fetal bovine serum created a strongly associated 
CPN surface coating. Such a coating not only provides colloidal stability in high ionic 
strength solution over a wide pH range, but also functionality for bioconjugation. 
Similarly, we demonstrated that a formation of stable PFBT CPN corona occurred with 
immunoglobulin, protein-A and neutravidin. We then utilized the protein functionalized 
CPNs as detection reagents in solid phase immunoassays. Taken together, we conclude 
that surface passivation of CPN with functional phospholipid and protein offers a 
straightforward functionalization method for CPNs. This in turn enables CPNs to be 
widespread fluorescent label in biological imaging and sensitive detection in bioassays. 
However, to realize the widespread use of CPNs in biological applications, some 
issues remain. A consistent theme in this thesis was on the study of the methods to 
introduce functionality on the CPNs surface by incorporation of functional polymers and 
proteins. Surface decoration of CPN with different proteins and targeting ligands results 
in multifunctional nanoparticles which has great potential for imaging and delivery of 
biologically relevant molecules simultaneously. So, nanoparticle formulation and surface 
decoration with various proteins and targeting ligands comprise future work. As shown in 
chapter 3, PEG lipid modified CPNs can be used as bright fluid phase markers in 
macrophage cells. Targeted intracellular labeling improves sensitivity and limit of 
detection. Further studies examining the mechanism of cellular uptake and intracellular 
distribution of functionalized CPNs are required to gain insights about efficiency of 
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intracellular labeling. In addition, future work includes the stability and efficacy of 
decorated CPNs in intracellular environment. This work presented in this thesis provides 
the basis on which the proposed studies can be built. Altogether, these studies will 
provide important information concerning the formulation of CPN for biological imaging 
sensing and detection.  
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